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Two fundamental objectives of bioprocess engineering are to increase productivity and 
improve product quality. Glycosylation is a critical and variable factor in the quality of several 
therapeutic proteins, particularly those with immune-system interactions such as monoclonal 
antibodies (mAbs). In this thesis, supplementation of nutrients to growth medium of CHO
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camelid antibodies. Targeted profiling via 1D-
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differences between glycan sites of expressed proteins; the fermentation and sampling timeline; 
glutamine levels; finally, no standardized metrics for reporting shifts in glycan distributions with 






I would like to express thanks to the University of Waterloo and the Department of Chemical 
Engineering for the opportunity to pursue graduate studies and complete my doctoral program. I 
would also like to thank the Government of Canada by way of NSERC and the MAbNet 
antibody research network for supporting my research. A major thank-you to my co-authors, as 
well as the Butler Lab, the McConkey Lab, the Durocher Lab, and members of MAbNet for their 
collaboration, help, and above all friendship. I feel privileged to be counted among these 
colleagues. I would further like to express my thanks to Andrew and Margaret Stevens for their 
scholarship to the chemical engineering department that supported me financially during my 
research. 
An enormous thank you to my supervisor Professor Marc Aucoin for taking a chance on me 
to join his research group, remaining patient, and not giving up on me. Thank you for your 
guidance and support and always doing your best to help me. Thanks also to all my colleagues in 
the Aucoin Lab, Steve, Stan, Andreas, Steffen, Sandi, Megan, Jian, Zen-Zen, Altamash, and Jann 
– thanks for putting up with me.  
Thank you to my PhD committee members Dr. Maud Gorbet, Dr Hector Budman, Dr. Brian 
Dixon, and Dr. Mario Jolicoeur for evaluating my thesis, and my suitability to receive a doctoral 
degree.  
Thank you to Dr. Brendan MacDonald, Dr. Thorsten Dieckmann, Dr. Bo Cui, Dr. Bernie 
Dunker, for all your help, support, and encouragement; I wouldn’t be here without it. I would 
also like to thank Dr. Marc Gibson, Dr. John Dick, and Dr. Morteza Ahmadi for commiserating 





Thank you to Velocity, Dean Pearl Sullivan, Jay Shah, Larry Smith, Mike Kirkup and the 
Faculty of Engineering for encouraging me to reach beyond my grasp. Thanks as well to Y 
Combinator, and my group partners Geoff Ralston and Tim Brady for encouraging me to grasp 
further still. 
Thank you to my partner Jen for sticking with me and supporting my dreams; Mom, Dad, 
and my brothers for all their support and love. Thank you to all my friends who have suffered 
through years of pretending to listen to what my research is about.  
Thanks to Moufeed, my best friend and partner on the wild adventure of the past 4 years. 
Thanks also to Christian, and the rest of the ExVivo gang. 
Also, thank you to Jan Venne and the UWaterloo NMR Facility, as well as the administrative 
and support staff at the Department of Chemical Engineering: Judy, Rose, Liz, Ingrid, Bert, Tom, 







To whomever should read this, I may no longer even be living, but I invite you to join me in 
a great conversation that was started before I got here, and will continue long after both of us 
have left. 






Table of Contents 
Examining Committee Membership ............................................................................................... ii 
Author’s Declaration ...................................................................................................................... iii 
Statement of Contributions ............................................................................................................ iv 
Abstract   ................................................................................................................................. vi 
Acknowledgements ....................................................................................................................... vii 
Dedication   ................................................................................................................................. ix 
Table of Contents ............................................................................................................................ x 
List of Figures ............................................................................................................................... xv 
List of Tables ............................................................................................................................... xix 
List of Abbreviations ................................................................................................................. xxiii 
Chapter 1 Introduction ............................................................................................................... 1 
1.1 Objective of Research........................................................................................................... 4 
1.2 Hypothesis of Research ........................................................................................................ 5 
Chapter 2 Literature Review...................................................................................................... 6 
2.1 Antibodies in vivo ................................................................................................................. 6 
2.2 Antigen Binding ................................................................................................................... 8 
2.2.1 Monoclonal Antibodies (mAbs) ........................................................................................... 9 
2.2.2 Antibody Fragments and Fusion Proteins .......................................................................... 10 
2.3 Glycosylation ...................................................................................................................... 11 
2.3.1 Eukaryotic Glycosylation ................................................................................................... 12 
2.3.2 N-linked Glycosylation ...................................................................................................... 13 





2.3.4 N-Glycoform & Immune Effector Function ....................................................................... 19 
2.3.5 O-linked Glycosylation ...................................................................................................... 19 
2.4 Glycan Analysis ................................................................................................................. 20 
2.5 Cell Culture Platforms and Glycoengineering .................................................................... 21 
2.5.1 Mammalian ......................................................................................................................... 22 
2.5.2 Prokaryotes ......................................................................................................................... 24 
2.5.3 Yeast ................................................................................................................................... 25 
2.5.4 Insect .................................................................................................................................. 26 
2.6 Omics Methods towards Enhancing Bioprocesses ............................................................. 27 
2.6.1 Proteomics .......................................................................................................................... 29 
2.6.2 Metabolomics ..................................................................................................................... 31 
2.6.3 Applications of Omics to Cell Culture ............................................................................... 37 
2.6.4 Quenching & Extraction ..................................................................................................... 43 
Chapter 3 An omics approach to rational feed: Enhancing growth in CHO cultures with NMR 
metabolomics and 2D-DIGE proteomics ............................................................... 46 
3.1 Overview ............................................................................................................................ 46 
3.2 Introduction ........................................................................................................................ 47 
3.3 Materials & Methods .......................................................................................................... 49 
3.3.1 Cell Line ............................................................................................................................. 49 
3.3.2 2D-DIGE Proteomics Experiments .................................................................................... 50 
3.3.3 NMR Metabolomics Experiments ...................................................................................... 55 
3.4 Results ................................................................................................................................ 56 
3.4.1 2D DIGE Proteomics Analysis ........................................................................................... 57 





3.4.3 1D-1H-NMR Metabolomics Analysis ................................................................................ 61 
3.5 Discussion .......................................................................................................................... 68 
3.5.1 Omics Methods as Tools for Rational Feed Design ........................................................... 68 
3.5.2 Anaplerotic TCA Metabolism Limitations ......................................................................... 68 
3.5.3 Tetrahydrofolate Conversions and NADPH Regeneration................................................. 71 
3.5.4 Limitations to Lipid Synthesis ............................................................................................ 72 
3.5.5 Redox Modulation .............................................................................................................. 73 
3.6 Conclusions ........................................................................................................................ 74 
Chapter 4 Tuning a MAb glycan profile in cell culture: Supplementing N-acetylglucosamine 
to favour G0 glycans without compromising productivity and cell growth ........... 76 
4.1 Overview ............................................................................................................................ 76 
4.2 Introduction ........................................................................................................................ 78 
4.3 Materials & Methods .......................................................................................................... 80 
4.3.1 Cell Culture ........................................................................................................................ 80 
4.3.2 Growth Medium & Supplemented Nutrients ...................................................................... 81 
4.3.3 Glycan Analysis ................................................................................................................. 81 
4.3.4 mAb Quantification ............................................................................................................ 82 
4.3.5 Extracellular Metabolite Profiling ...................................................................................... 82 
4.3.6 Intracellular Nucleotide and Nucleotide-Sugar Analysis ................................................... 82 
4.4 Results ................................................................................................................................ 83 
4.4.1 Growth Effects GlcN vs. GlcNAc ...................................................................................... 86 
4.4.2 Glycosylation Effects GlcN vs. GlcNAc ............................................................................ 87 
4.4.3 Glycosylation Effects GlcNAc ........................................................................................... 88 





4.4.5 Intracellular Nucleotides and Nucleotide-Sugar Pools ....................................................... 92 
4.5 Discussion .......................................................................................................................... 93 
4.5.1 Simple Method for Affecting Glycan Distributions ........................................................... 93 
4.5.2 Diversity of Reported Glycan Effects from Glucosamine .................................................. 94 
4.5.3 Growth Limitations from Glucosamine .............................................................................. 95 
4.6 Conclusions ........................................................................................................................ 97 
Chapter 5 Supplementing Growth and Glycoform .................................................................. 99 
Chapter 6 Supplementing Glycosylation: A Review of Applying Nucleotide-Sugar Precursors 
to Growth Medium to Affect Therapeutic Recombinant Protein Glycoform 
Distributions ......................................................................................................... 101 
6.1 Overview .......................................................................................................................... 101 
6.2 Introduction ...................................................................................................................... 103 
6.3 Glycosylation .................................................................................................................... 105 
6.3.1 Nucleotide-Sugar Metabolism .......................................................................................... 105 
6.3.2 N-Linked Glycosylation ................................................................................................... 108 
6.3.3 Microheterogeneity........................................................................................................... 109 
6.4 Controlling Glycosylation by Supplementation ............................................................... 109 
6.4.1 Key Factors Impacting Supplementation Results ............................................................. 111 
6.4.2 Glycoform Distribution Indexes ....................................................................................... 115 
6.4.3 Supplementation of Nucleotide-Sugar Precursors ............................................................ 117 
6.5 Glycoforms: Bioefficacy and Functionality ..................................................................... 133 
6.5.1 Immune Effector Functions for Antibodies ...................................................................... 134 
6.5.2 Glycoforms and Antibody Immune Effector Functions ................................................... 135 





6.6 Conclusions ...................................................................................................................... 142 
Conclusions & Recommendations .............................................................................................. 144 
References   .............................................................................................................................. 148 
Appendix A – Chapter 3 Supplementary Data ........................................................................... 163 
Appendix B – Chapter 4 Supplementary Data ............................................................................ 168 






List of Figures 
Figure 1 – Basic immunoglobulin (Ig) structure............................................................................. 7 
Figure 2 – Antibodies activating two common immune effector functions to destroy an EGFR 
presenting cancer cell; antibody dependent cell cytotoxicity (ADCC), and 
complement dependent cytotoxicity (CDC). ............................................................. 8 
Figure 3 – Eukaryotic 14 sugar N-linked precursor oligosaccharide ........................................... 13 
Figure 4 – Eukaryotic N-glycosylation in mammalian cells ........................................................ 15 
Figure 5 – Examples of diversity of potential glycoforms ........................................................... 16 
Figure 6 – Most common human N-glycoforms for IgG1&2 in blood serum according to Flynn 
et al. (2010) .............................................................................................................. 16 
Figure 7 – Normal phase HPLC elution profile of glycans cleaved from mAb EG2-hFc ............ 21 
Figure 8 – Immunogenic N-glycan moieties Neu5Gc and α-gal, from rodent-derived cells ....... 23 
Figure 9 – Prokaryote N-glycosylation from glycoengineered E. coli ......................................... 25 
Figure 10 – Hyper-mannosylated yeast N-glycosylation.............................................................. 26 
Figure 11 – Paucimannosidic N-glycosylation in insect cells ...................................................... 27 
Figure 12 – Convoluted Spectral Peaks 1D-
1
H-NMR .................................................................. 35 
Figure 13 – Targeted Profiling of Convoluted 1D-
1
H-NMR Spectra by Chenomx Software ...... 35 
Figure 14 – Quantification by Metabolites by Chenomx Software .............................................. 36 
Figure 15 – Representative monochrome image of a 2D-DIGE Gel. CHO
BRI
-1 labeled with Cy5 
and CHO
BRI
-1A7-1 labeled with Cy3. ..................................................................... 58 
Figure 16 – Anaplerotic TCA and mitochondrial shuttle metabolism, which contribute to 
replenishing cytosolic acetyl-CoA, NAD+, and NADPH. ...................................... 63 
Figure 17 – Tetrohydrofolate (THF) C1 cofactors replenishing NADPH from serine, while 
producing glycine and formate, by cycling the THF intermediates between different 





Figure 18 – Lipid synthesis requires nutrients such as choline and several precursors observed in 
this work to be excreted, including phosphocholine, cytidine, glycerol and ethanol.
.................................................................................................................................. 65 
Figure 19 – Fully depleted nutrients under normal culture conditions (solid lines) and following 
additional supplementation (dashed lines) at 0 hrs (circle) and at 50 hrs (triangle) as 
per Table 11. ............................................................................................................ 67 
Figure 20 – Culture growth profile of CHOBRI-1A7 cells in bioreactor and flask-scale 
cultivations. .............................................................................................................. 67 
Figure 21 – Intracellular nucleotide sugar metabolic pathways utilizing glucose or supplemented 
GlcN or GlcNAc. ..................................................................................................... 85 
Figure 22 – Growth and viability of CHO cells severely impacted during supplementation of 7.5 
mM glucosamine (GlcN), compared to only marginal impacts to growth and 
viability during supplementation of 7.5 mM N-acetylglucosamine (GlcNAc). 
Duplicate lines represent duplicate flasks. ............................................................... 87 
Figure 23 – A similar shift to less complex glycoforms is observed from supplementing either 
glucosamine (GlcN) or N-acetylglucosamine (GlcNAc). ........................................ 88 
Figure 24 – Increasing the concentration of N-acetylglucosamine (GlcNAc) increases the glycan 
shift towards G0 glycoforms. ................................................................................... 89 
Figure 25 – Increasing the concentration of N-acetyleglucosamine (GlcNAc) supplemented to 
cultures reduces late-exponential cell growth with marginal impact to viability. 
Duplicate lines represent duplicate flasks. ............................................................... 90 
Figure 26 – A) Final protein titers of EG2-hFc from cultures supplemented with GlcNAc. B) 
Final acetate concentrations from cultures supplemented with GlcNAc. Error bars 
represent the standard deviation between duplicate flasks. ..................................... 91 
Figure 27 – Nucleotide and nucleotide-sugar ‘per-cell’ intracellular concentrations from 
quenched cell samples taken at 72hrs from cultures supplemented with GlcNAc. 
Error bars represent the standard deviation between duplicate flasks. .................... 92 
Figure 28 – Glycoform distribution for EG2-hFc harvested from a bioreactor fermentation of 
CHO
BRI
-1A7 grown in BioGro-CHO medium supplemented with the cocktail of 





Figure 29 – Duplicate flasks of CHO
BRI
-1A7 cultured with a cocktail of supplements to improve 
growth, detailed in Chapter 3, as well as supplements of GlcNAc, which affect 
glycoform distribution, detailed in Chapter 4. ....................................................... 100 
Figure 30 – Metabolic pathways for the synthesis and transport of intracellular nucleotide sugars 
utilizing glucose (Glc), galactose (Gal), glucosamine (GlcN), acetylglucosamine 
(GlcNAc), and acetylmannosamine (ManNAc), towards N-glycosylation in 
mammalian cells. This includes the assembly of dolichol-14-sugar oligosaccharide 
and co-translational binding for N-glycosylation of proteins beginning in the 
cytosol and occurring in ER, followed by the sculpting of further monosaccharide 
modifications in the Golgi by pH-dependent heteromeric glycosyltransferases. .. 108 
Figure 31 – A monoclonal antibody glycan distribution segmented to demonstrate the 
glycosylation index formulae. In each case the proportion of the glycan distribution 
with a particular moiety (i.e. sialic acid, terminal galactose, etc.) is divided by the 
proportion that could have received that particular moiety, with respect to the 
sequence of glycosyltransferase enzymes acting on the protein undergoing 
glycosylation. ......................................................................................................... 117 
Figure 32 – Comparison of glycoform shifts reported for experiments employing the 
supplementation of glucosamine (GlcN), its acetylated form acetyl-glucosamine 
(GlcNAc), and the nucleoside uridine (Urd), to affect N-linked glycoforms of 
recombinant glycoproteins produced in mammalian cell cultures. ....................... 121 
Figure 33 – Comparison of glycoform shifts reported for experiments employing the 
supplementation of glucosamine (GlcN), its acetylated form acetyl-glucosamine 
(GlcNAc), and the nucleoside uridine (Urd), to affect N-linked glycoforms of 
recombinant glycoproteins produced in mammalian cell cultures. ....................... 126 
Figure 34 – Comparison of glycoform shifts reported for experiments employing the 
supplementation of acetyl-mannosamine (ManNAc), and the nucleoside cytidine 
(Cyt), to affect N-linked glycoforms of recombinant glycoproteins produced in 
mammalian cell cultures. ....................................................................................... 131 
Figure 35 – Complete set of nutrients and metabolites tracked by 1D-1H-NMR under normal 
culture conditions (solid lines) and following additional supplementation (dashed 
lines) in batch (circle) and fed-batch (triangle)...................................................... 167 
Figure 36 – Time course imaging of cell growth under GlcN and GlcNAc supplementation 





Figure 37 – Growth rate comparison of CHO-K1-CC1-61 cells supplemented with 7.5 mM GlcN 
& GlcNAc, demonstrating that the negative growth effect of glucosamine 
supplementation, as well as the lack of negative growth effect from GlcNAc 
supplementation, is independent of the CHO
BRI






List of Tables 
Table 1 – N-Glycan distribution of IgG1&2 in human blood serum according to Flynn et al. 
(2010) .......................................................................................................................... 17 
Table 2 – Elution time, glucose units, and major glycan structures of Figure 6 .......................... 21 
Table 3 – Examples of omics cellular domains ............................................................................ 28 
Table 4 – Differentially expressed proteins after transfection of CHO
BRI
 cells to stably express 
EG2-hFc heavy-chain mAb, as identified by LC-MS/MS.......................................... 59 
Table 5 – Functional annotation analysis in DAVID enriched functionally related gene groups, 
associated with differentially expressed proteins. An enrichment score was 
determined by a geometric mean of all the enrichment p-values of each annotation 
term in the group followed by a minus log transformation applied on the averaged p-
values. The enrichment score is a relative score used to rank overall importance of 
annotation term groups. .............................................................................................. 61 
Table 6 – Nutrients supplemented to production growth medium with respect to their 
approximate initial concentrations (% increase). ........................................................ 66 
Table 7 – Comparison of glycoform shifts and differences between reported experiments for the 
supplementation of glucosamine (GlcN), its acetylated form acetyl-glucosamine 
(GlcNAc), and the nucleoside uridine (Urd), towards expanding intracellular 
nucleotide-sugar pools of UDP-GlcNAC in cultured mammalian cells to affect N-
linked glycoforms of recombinant glycoproteins. Experimental differences reported 
include: Supplementation cocktails and concentrations with multiple bullet-points 
representing separate flask or bioreactor conditions; The cell line utilized and the 
lineage of that cell line where reported; The protein being expressed and whether it is 
a mutant variant or fusion; The bioprocess scale, time of supplementation, and time of 
harvest; The amount of glutamine (Gln) utilized in the growth medium. ................ 118 
Table 8 – Comparison of glycoform shifts and differences between reported experiments for the 
supplementation of galactose (Gal), the nucleoside uridine (Urd), and the enzyme 
cofactor manganese (Mn2+), towards expanding intracellular nucleotide-sugar pools 
of UDP-galactose in cultured mammalian cells and affecting N-linked glycoforms of 
recombinant glycoproteins. Experimental differences reported include: 
Supplementation cocktails and concentrations with multiple bullet-points representing 
separate flask or bioreactor conditions; The cell line utilized and the lineage of that 
cell line where reported; The protein being expressed and whether it is a mutant 
variant or fusion; The bioprocess scale, time of supplementation, and time of harvest; 





Table 9 – Comparison of glycoform shifts and differences between reported experiments for the 
supplementation of the acetylated amine sugar N-acetylmannosamine (ManNAc), and 
the nucleoside cytidine (Cyt), towards expanding intracellular nucleotide-sugar pools 
of CMP-NeuAc in cultured mammalian cells and affecting N-linked glycoforms of 
recombinant glycoproteins. Experimental differences reported include: 
Supplementation cocktails and concentrations with multiple bullet-points representing 
separate flask or bioreactor conditions; The cell line utilized and the lineage of that 
cell line where reported; The protein being expressed and whether it is a mutant 
variant or fusion; The bioprocess scale, time of supplementation, and time of harvest; 
The amount of glutamine (Gln) utilized in the growth medium. .............................. 129 
Table 10 – Therapeutic efficacy of monoclonal antibodies (mAbs) and immune effector function 
(IEF) with respect to fucosylation of N-glycans. A biantennary glycan with a circled 
region is provided to indicate the moiety. IEFs include antibody dependent cell 
cytotoxicity (ADCC), complement dependent cell cytotoxicity (CDC), as well as 
binding to the immune antibody receptor FcγRIIIa. ................................................. 136 
Table 11 – Therapeutic efficacy of monoclonal antibodies (mAbs) and immune effector function 
(IEF) with respect to N-glycans possessing the bisecting N-acetylglucosamine 
(GlcNAc) moiety. A biantennary glycan with a circled region is provided to indicate 
the moiety. IEFs include antibody dependent cell cytotoxicity (ADCC). ................ 138 
Table 12 – Therapeutic efficacy of monoclonal antibodies (mAbs) and immune effector function 
(IEF) with respect to galactosylation of N-glycans. A biantennary glycan with circled 
regions is provided to indicate the moieties. IEFs include antibody dependent cell 
cytotoxicity (ADCC), and complement dependent cell cytotoxicity (CDC). ........... 139 
Table 13 – Therapeutic efficacy of monoclonal antibodies (mAbs) and immune effector function 
(IEF) with respect to sialylation of N-glycans. A biantennary glycan with circled 
regions is provided to indicate the moiety. IEFs include antibody dependent cell 
cytotoxicity (ADCC), complement dependent cell cytotoxicity (CDC), anti-
inflammatory properties, as well as protein serum half-life (serum t1/2). ................. 140 
Table 14 – Therapeutic efficacy of monoclonal antibodies (mAbs) and immune effector function 
(IEF) with respect to high-mannose N-glycans. Two N-glycans are provided to 
describe this glycoform. IEFs include binding to the immune antibody receptor 
FcγRI, complement dependent cell cytotoxicity (CDC), and protein serum half-life 
(serum t1/2). ................................................................................................................ 141 





Table 16 – Comparison of glycoform shifts and differences between reported experiments for the 
supplementation of glucosamine (GlcN), its acetylated form acetyl-glucosamine 
(GlcNAc), and the nucleoside uridine (Urd), towards expanding intracellular 
nucleotide-sugar pools of UDP-GlcNAC in cultured mammalian cells to affect N-
linked glycoforms of recombinant glycoproteins. N-linked glycoforms of 
recombinant glycoproteins. Glycoform shifts are reported as %-shifts in indices of 
mannosylation (MI), antennarity (AI), fucosylation (FI), galactosylation (GI), and 
sialylation (SI) (as per Equations 1-5, Figure 28) relative to reported control culture 
glycoforms. Experimental differences reported include: Supplementation cocktails 
and concentrations with multiple bullet-points representing separate flask or 
bioreactor conditions; The cell line utilized and the lineage of that cell line where 
reported; The protein being expressed and whether it is a mutant variant or fusion; 
The bioprocess scale, time of supplementation, and time of harvest; The amount of 
glutamine (Gln) utilized in the growth medium. ...................................................... 172 
Table 17 – Comparison of glycoform shifts and differences between reported experiments for the 
supplementation of galactose (Gal), the nucleoside uridine (Urd), and the enzyme 
cofactor manganese (Mn2+), towards expanding intracellular nucleotide-sugar pools 
of UDP-galactose in cultured mammalian cells and affecting. Glycoform shifts are 
reported as %-shifts in indices of mannosylation (MI), antennarity (AI), fucosylation 
(FI), galactosylation (GI), and sialylation (SI) (as per Equations 1-5, Figure 28) 
relative to reported control culture glycoforms. Experimental differences reported 
include: Supplementation cocktails and concentrations with multiple bullet-points 
representing separate flask or bioreactor conditions; The cell line utilized and the 
lineage of that cell line where reported; The protein being expressed and whether it is 
a mutant variant or fusion; The bioprocess scale, time of supplementation, and time of 
harvest; The amount of glutamine (Gln) utilized in the growth medium. ................ 175 
Table 18 – Comparison of glycoform shifts and differences between reported experiments for the 
supplementation of the acetylated amine sugar acetyl-mannosamine (ManNAc), and 
the nucleoside cytidine (Cyt), towards expanding intracellular nucleotide-sugar pools 
of CMP-NeuAc in cultured mammalian cells and affecting N-linked glycoforms of 
recombinant glycoproteins. N-linked glycoforms of recombinant glycoproteins. 
Glycoform shifts are reported as %-shifts in indices of mannosylation (MI), 
antennarity (AI), fucosylation (FI), galactosylation (GI), and sialylation (SI) (as per 
Equations 1-5, Figure 28) relative to reported control culture glycoforms. 
Experimental differences reported include: Supplementation cocktails and 
concentrations with multiple bullet-points representing separate flask or bioreactor 
conditions; The cell line utilized and the lineage of that cell line where reported; The 





scale, time of supplementation, and time of harvest; The amount of glutamine (Gln) 







List of Abbreviations 
 1H-NMR – nuclear magnetic resonance spectroscopy of hydrogen nuclei 
 2AB – 2-aminobenzmide  
 A – glycan antennarity  
 ADCC – antibody dependent cell cytotoxicity 
 ADP – adenosine diphosphate 
 AMS – aspartate malate shuttle 
 Asn - asparagine 
 ATP - adenosine triphosphate 
 BHK – baby hamster kidney (cell line) 
 BRI – Biotechnology Research Institute of Canada 
 CDC – complement dependent cytotoxicity  
 CDR – complementary determining region 
 CHO – Chinese hamster ovary (cells) 
 CMP – cytosine monophosphate 
 CQA – critical quality attribute 
 CSI – chemical shape indicator 
 DIGE – differential in-gel electrophoresis 
 DO – dissolved oxygen 
 DHFR – dihydrofolate reductase selection/amplification marker 
 DSS – 2,2-Dimethyl-2-silapentane-5-sulfonate (internal NMR standard) 
 EG2-hFc – single domain camelid antibody specific to EGFR fused to a human Fc region 
 EGFR – epidermal growth factor receptor 
 ER – endoplasmic reticulum 
 F – glycan fucosylation 
 Fc – crystallisable fragment (antibody) 
 FID – free induction decay (NMR) 
 Fv – variable fragment (antibody) 
 Fab – antigen binding fragment (antibody) 





 G – glycan galactosylation 
 Gal – galactose 
 GalNAc – N-acetylgalactosamine 
 Glc – glucose 
 GlcN - glucosamine 
 GlcNAc – N-acetylglucosamine 
 GnT-III – N-acetylglucosaminyltransferase III  
 GPI – glycophosphatidylinositol 
 GS – glutamine synthase selection/amplification marker 
 HAMA – human anti-murine antibody 
 HAT – hypoxanthine-aminopterin-thymidine 
 HEK293 – human embryonic kidney (cell line) 
 hMT-IIA – human metallothionein IIA induced promoter 
 HPLC – high performance liquid chromatography  
 Ig – immunoglobulin (antibody) 
 M – glycan mannose 
 mAbs – monoclonal antibodies 
 MAbNet – strategic NSERC monoclonal antibody research network 
 Man – mannose 
 ManNAc – N-acetylemannosamine 
 NADH – nicotinamide adenine dinucleotide 
 Neu5Ac – N-acetylneuraminic acid (sialic acid) 
 Neu5Gc – N-glycolylneuraminic acid 
 NK – natural killer (cells) 
 NMR – nuclear magnetic resonance (spectroscopy) 
 NS0 – mouse myeloma (cell line) 
 NSERC – Natural Science and Engineering Research Council of Canada 
 PER.C6 – human cell line derived from embryonic retinal cells 
 S – glycan sialylation 





 scFv – single chain antibody fragment 
 SCLC – small cell lung cancer 
 Ser - serine 
 Sp2/0 – mouse hybridoma (cell line) 
 TCA – tricarboxylic acid (cycle) 
 Thr – threonine  
 TNF – tumour necrosis factor 
 UDP – uridine diphosphate 
 Xyl - xylose 






Chapter 1 Introduction 
The production of recombinant therapeutic biologics in cell culture is a rapidly growing 
industry, creating many opportunities for bioprocess engineering research and development. 
Leading the products within this market are monoclonal antibodies (mAbs). Elvin et al. 
estimated in 2011, that global annual sales of therapeutic mAbs were approaching $50 billion 
USD – over a third of all biologics – from only twenty-eight approved drugs (Elvin et al., 2011). 
By the end of 2014, the number of approvals had increased to forty-seven, with sales eclipsing 
$75 billion USD the previous year (Ecker et al., 2015). Given the number of new products in the 
pipeline and the emergence of follow-on biosimilars and biobetters, i.e. nonoriginal biologics 
(NOBs), the size of this market is expected to nearly double by 2020 (Albrecht et al., 2014; 
Ecker et al., 2015). Today, biologics make up nine of the top ten global selling pharmaceutical 
products, and approximately 20% of all global pharmaceutical sales (Lindsley, 2017). 
To meet this increasing demand for recombinant therapeutic biologics, bioprocess engineers 
have conventionally been tasked with the primary goal of increasing the yield of bioprocesses, 
either by increasing maximum cell densities of cultures, or improving their productivity. 
Applying emerging methods, such as metabolomics and proteomics analysis towards this 
primary goal is examined in Chapter 3. Compared to small-molecule pharmaceuticals, 
therapeutic biologics like mAbs also possess molecule-to-molecule heterogeneity directly 
impacting their therapeutic efficacy. Therefore a further goal of bioprocess engineers has 
emerged to improve the quality of therapeutic biologics. The strategy of supplementing 
nucleotide-sugar precursors and related components to cell cultures to affect product quality by 




Regarding omics methods, these technologies are producing an unprecedented amount of 
information for interpreting the state of bioprocesses at various scopes (Section 2.6). Measuring 
the differential expression of all cellular proteins, referred to as ‘proteomics’, through methods 
such as two-dimensional differential in-gel electrophoresis (2D-DIGE) reveal important details 
of how cells are regulating to overcome stresses imposed by recombinant expression of proteins 
(reviewed by Lalonde and Durocher, 2017). Similarly, ‘metabolomics’, focuses upon identifying 
and quantifying all low molecular weight molecules being consumed and produced in both the 
extracellular supernatant as well as the intracellular metabolite pools; this is referred to as 
metabolite “footprinting” and “fingerprinting” respectively (as reviewed by Kell et al., 2005). 
Omics methods far outstrip conventional metrics for bioprocesses, which limit focus solely to 
conventional metrics such as dissolved oxygen, temperature, pH, carbon substrates, and a 
selection of toxic metabolites (typically lactate and ammonia). Observing the full complement of 
differentially expressed proteins like in proteomics (as reviewed by J. Y. Kim et al., 2012), or the 
small molecular weight compounds (nutrients and excreted waste products) through 
metabolomics, which are the result of all cellular mechanisms during a culture (as reviewed by 
Cuperlović-Culf et al., 2010), offer a powerful means to characterize the phenotype of cultured 
cells. Omics tools and analysis applied to cell culture processes have been leveraged to produce 
higher overall yields, mitigate metabolic bottlenecks, and detect scaling problems (Chong et al., 
2010b; Dietmair et al., 2012; Schaub et al., 2012; Sellick et al., 2011a; Zang et al., 2011). Tools 
such as these are demonstrated in Chapter 3 for a 75% increase in maximum cell density of CHO 
cultures; and to identify a metabolic bottleneck in Chapter 4 leading to growth restriction while 




Biotherapeutics, such as monoclonal antibodies (mAbs), require advanced cellular processes, 
such as glycosylation, to become biologically active (Dordal et al., 1985; Nose and Wigzell, 
1983). As such, mAbs and other ‘glycoprotein’ biologics are typically manufactured using 
higher-order eukaryotic platforms such as mammalian cell cultures, with a significant majority 
by Chinese Hamster Ovary (CHO) cells, which have grown to become an industry standard 
(Ghaderi et al., 2012). Mammalian cells, such as CHO, are more challenging to culture compared 
to bacteria and yeast, and have reduced productivity, but are capable of a wide range of human-
like post-translational modifications to proteins. These modifications include glycosylation, 
which is acknowledged in FDA guidances for industry to be a major critical quality attribute 
(CQA) of mAbs and other biologics (FDA, 2015). Glycosylation affects a host of drug factors 
including immunogenicity (Bosques et al., 2010; Padler-Karavani et al., 2008), secretion by cells 
(Hickman and Kornfeld, 1978), drug clearance-rate (Morell et al., 1968), protein stability 
(Mimura et al., 2001) and solubility (Leavitt et al., 1977), as well as effector function for mAbs 
for required recognition by the immune-system (Chapter 6). As such, on the subject of improving 
cell culture productivity, this research has focused on CHO-based mammalian cell cultures, and 
on the subject of product quality, this research has focused specifically on affecting 
glycosylation. 
Glycan heterogeneity occurs naturally, but is influenced by numerous factors such as 
perturbations in culture conditions, including temperature, pH and dissolved oxygen, which have 
been widely reviewed (Butler, 2006; del Val et al., 2010; Eon-Duval et al., 2012; Hossler, 2012; 
Spearman et al., 2011). More directly, this heterogeneity is driven by up/down shifts in the 
expression of cellular enzymes and transporter proteins (Chen and Harcum, 2006; N. S. C. Wong 




et al., 1999; Pels Rijcken et al., 1995b). With respect to commercial bioprocesses, heterogeneity 
implies drugs of inconsistent quality (molecule to molecule) and batch to batch variability. 
Tools, like emerging omics methods demonstrated in Chapter 3 & Chapter 4, empower 
bioprocess engineers to observe these domains directly and affect necessary actions. 
Strategies to affect and control glycosylation can be grouped into three categories: 1) 
glycoengineering of cell platforms to alter expression of enzymes and Golgi transporters; 2) in 
vitro remodeling of glycans as a downstream process; 3) supplementation of nucleotide-sugar 
precursors and related components to culture medium to affect the metabolism of glycosylation. 
This 3
rd
 strategy of supplementation of metabolic precursors of glycosylation to growth medium 
is the focus of this research (detailed in Chapter 4 & Chapter 6), and touches upon both 
bioprocess goals of culture growth and product quality due to its effects on cell growth (detailed 
in Chapter 4), as well as effects to the glycan distribution on product glycoproteins (i.e. product 
quality; Chapter 4 & Chapter 6). The particular problem regarding inconsistency of reported 
effects of glycosylation precursor supplementation strategies is analyzed and addressed in 
Chapter 6. 
1.1 Objective of Research 
The purpose of this research is to demonstrate supplementation strategies to both enhance 
cell growth of CHO mammalian cell cultures, and tune glycosylation to improve mAb product 
quality with the aid of omics methods. Towards these objectives, omics methods are applied to 
elucidate factors at the scale of the metabolome and proteome, to create a nutrient cocktail to 
enhance culture growth as investigated in Chapter 3. Subsequently, strategies for tuning 
glycosylation by supplementing nucleotide sugar precursors to affect the intracellular metabolite 




nature of growth effects to CHO cultures of nucleotide-sugar precursor supplementation in 
Chapter 4. 
1.2 Hypothesis of Research 
Omics analysis of CHO
BRI
-1A7 cells expressing EG2-hFc heavy-chain chimeric camelid 
antibodies can be utilized to identify cell stresses and resource limitations. In turn, 
supplementation strategies can be designed to alleviate these stresses providing additional 
resources to metabolic systems to improve growth. Additionally, supplementation of precursors 
to intracellular nucleotide-sugars can be employed to alter the glycosylation profile of 
monoclonal antibodies produced in CHO
BRI
-1A7 cells. This shift in the glycoform is an effect 
caused by increase intracellular nucleotide-sugar pools. Metabolomic analysis of cells following 
supplementation will elucidate relationships between elevated levels of these intracellular pools 
and protein glycosylation, to overcome negative growth effects. This will allow for improved 
feeding strategies and process controls for affecting glycosylation and product quality of 






Chapter 2  Literature Review 
2.1 Antibodies in vivo 
Antibodies, referred to formally as immunoglobulins (Ig), are a diverse class glycoproteins 
secreted by B-cells, which form a fundamental part of the immune system (as reviewed by 
Jefferis, 2012). Five known types of human antibodies exist in vivo, characterized by differences 
in their constant-region “heavy chains”, and are classified as: IgA, IgM, IgD, IgE, and IgG, with 
Immunoglobulin G and A antibodies subdivided into four and two subtypes respectively and 
classified numerically (IgG1-4 and IgA1-2) (as reviewed by Jefferis, 2012). IgG1&2 are the 
most commercially exploited antibody types (Elvin et al., 2011), and IgG1 predominates in 
human blood (reviewed by Jefferis, 2009). Commonly described as having a “Y-shaped” 
structure, antibodies possesses two sites for binding to a particular epitope of a target antigen 
with high specificity (reviewed by Ahmad et al., 2012). 
The two antigen binding arms of the structure, Fab fragments, contain the variable binding 
portion (Fv), possessing the complementary determining regions (CDRs) specific to antigen 
epitopes (as reviewed by Schroeder and Cavacini, 2010). The portion of antibodies responsible 
for immune effector function is called the crystallisable fragment (Fc) (as reviewed by Spearman 
et al., 2011). Human IgG antibodies in vivo are heterodimer proteins assembled from two heavy 
chains and two light chains joined at various locations by disulfide bonds (as reviewed by 





Figure 1 – Basic immunoglobulin (Ig) structure  
The glycosylated effector region of the constant heavy-chain, shown in Figure 1, binds to Fcγ 
receptors of natural killer (NK) and monocyte cells of the immune system, which can trigger 
antibody dependent cell cytotoxicity (ADCC) for clearing pathogens (reviewed by Schroeder and 
Cavacini, 2010). Antibody effector regions also play a part in stimulating the complement 
system, triggering Complement dependent cytotoxicity (CDC) (reviewed by Jefferis, 2009). 
These immune effector activations are demonstrated in Figure 2, while a comprehensive review 
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Figure 2 – Antibodies activating two common immune effector functions to destroy an EGFR presenting cancer cell; 
antibody dependent cell cytotoxicity (ADCC), and complement dependent cytotoxicity (CDC). 
2.2 Antigen Binding  
Antibodies bind particular epitopes of target molecules, referred to as antigens, with high 
specificity (as reviewed by Jefferis, 2012). This quality makes antibodies powerful tools for 
therapeutic applications, where antibodies can neutralize a target like a cytokine, or activate the 
immune system against cancerous cells, or be conjugated with a drug for targeted delivery in the 
body (as reviewed by Ecker et al., 2015). Similarly, an antibody’s high specificity for antigen 
binding also makes it a valuable tool for diagnostic applications, such as detection of an analyte 
with a high degree of specificity – for instance, the home pregnancy test (as reviewed by 
Yamada et al., 2017).  
Whole monoclonal antibodies (mAbs) have been favoured as an antigen-binding technology 
in industry, but alternatives such as antibody fragments and numerous fusion proteins have 





2.2.1 Monoclonal Antibodies (mAbs) 
The ready availability of antibodies with high specificity to any desired target are built upon 
the 1975 publication of Kohler and Milstein’s process to create monoclonal antibodies (mAbs) in 
vitro, i.e. functionally identical immunoglobulins that bind exclusively to one epitope of a target 
antigen (Köhler and Milstein, 1975). The first mAbs were produced by fusing primary murine B 
lymphocytes producing antibodies (primary cells recovered directly from the spleen of a mouse), 
to a continuous strain of myeloma cells by using inactivated Sendai virus (Köhler and Milstein, 
1975). Selection for fused ‘hybridoma’ cells was achieved by employing myeloma cells lacking 
an enzyme present in B-cells to metabolize hypoxanthine-aminopterin-thymidine (HAT) for 
purine nucleotide synthesis (Köhler and Milstein, 1975). HAT-medium eliminated unfused 
myeloma cells, while unfused B-cells died from poor adaptability to suspension culture (Köhler 
and Milstein, 1975). Single clones were then plated and observed to maintain their phenotype, 
thus achieving cultures producing monoclonal antibodies (Köhler and Milstein, 1975). 
The first commercially approved therapeutic mAb generated from hybridoma technology was 
muromonab-CD3 (Orthoclone OKT3), a fully murine-derived antibody for preventing rejection 
of renal transplants (reviewed by Chatenoud et al., 1988). While possessing some effectiveness 
as an immunosuppressant for organ transplant, administration of the OKT3 and other murine-
antibodies often precipitated severe flu-like symptoms in patients due to ‘cytokine release 
syndrome’(Chatenoud et al., 1988). The non-human origins of murine-therapeutics were detected 
by the human immune system in vivo causing patients to generate human anti-murine antibodies 
(HAMAs) causing rapid clearance of the drugs and significantly reducing their long-term 




The next generation of commercial mAbs was referred to as ‘chimeric’, possessing murine 
variable regions and human constant regions (Morrison et al., 1984).  Chimeric mAbs were 
succeeded by ‘humanized’ mAbs, which possessed grafted complementary determining regions 
(CDRs, as shown in Figure 1) (Jones et al., 1986). While humanized mAbs demonstrated 
improved effector function, slower clearance rates, and reduced immunogenicity – chimeric and 
humanized antibodies possessing ~25% and ~10% murine content respectively, still elicited 
HAMA responses (reviewed by Spearman et al., 2011).  
The latest generation of mAbs are fully human, with no murine content (reviewed by Elvin et 
al., 2011); however, the funnel of mAbs in clinical trials still contains humanized, chimeric, and 
even murine mAbs, but these are becoming fewer and fewer as the industry continues to grow 
rapidly (Reichert, 2017). Fully human monoclonal antibodies are actually still produced in mice; 
however, as this is achieved by bioengineering transgenic mice to produce human heavy and 
light chains from yeast artificial chromosomes (YACs) introduced to the mouse germline, and 
subsequently breeding them for immunodeficiency (Green et al., 1994). Similar research was 
simultaneously published in 1994 with an alternative method by Lonberg et al. creating a 
transgenic strain of mice capable of producing fully human immunoglobulins for commercial 
therapeutics (Lonberg et al., 1994). 
2.2.2 Antibody Fragments and Fusion Proteins 
While a glycosylated Fc region of an antibody is essential for immune effector functions like 
ADCC and CDC, the treatment of several disorders rely simply on binding and neutralizing 
target antigens like cytokines (Ecker et al., 2015). As such, these treatments can be manufactured 




restrictions. Similarly, radioactive and toxic drug deliveries can be accomplished by fusion to 
antibody fragments in place of an Fc component (reviewed by Ahmad et al., 2012). 
There are also fusion antigen-binding proteins that continue to possess immune effector 
function, such as chimeric single domain heavy-chain only camelid antibodies (HCAbs), 
possessing enhanced tumour penetration by their reduced molecular weight and size (Zhang et 
al., 2009). An example of these heavy-chain mAbs is the ~80kD EG2-hFc, single domain 
camelid chimeric antibody produced by CHO
BRI
-1A7 cells utilized in this research, which binds 
to epidermal growth factor receptors (EGFR) towards therapeutic treatments against forms of 
cancer overexpressing this receptor (Agrawal et al., 2012; Bell et al., 2010; Zhang et al., 2009). 
2.3 Glycosylation 
Glycosylation is acknowledged in several reviews of the FDAs quality by design (QbD) 
program to be a major critical quality attribute (CQA) of MAbs and other biotherapeutics (del 
Val et al., 2010; Eon-Duval et al., 2012; Glassey et al., 2011). Unlike other cellular processes 
like transcription and translation of DNA and RNA, which follow a semi-consistent coded 
template, glycosylation is not coded; and as reviewed by many researchers, is influenced by 
numerous factors such as perturbations in culture conditions (Butler, 2006; del Val et al., 2010; 
Eon-Duval et al., 2012; Hossler, 2012; Spearman et al., 2011)), bottlenecks in the substrate 
supply chain (Nyberg et al., 1999; Pels Rijcken et al., 1995b), and the regulation of cellular 
processes, i.e. the up/down regulation of cellular enzymes and transporter proteins (Chen and 
Harcum, 2006; N. S. C. Wong et al., 2010). These factors in commercial bioprocesses contribute 
to variable products with direct implications to its final effectiveness for treatment. Furthermore, 




and inferior therapeutic qualities and as such certain glycoforms are more sought after than 
others (Jefferis, 2012). 
A comprehensive discussion of glycosylation, its metabolism, impact on the efficacy of 
therapeutic glycoproteins (particularly mAbs), as well as supplementation strategies utilizing 
nucleotide sugar precursors and related components to affect resulting glycoforms, is available in 
Chapter 6.  
2.3.1 Eukaryotic Glycosylation 
There are two main forms of glycosylation, N-linked and O-linked, which are designated by 
the functional group of the amino-acids where the glycans are bound; these processes have been 
reviewed by numerous researchers (Butler, 2006; Ghaderi et al., 2012; Hossler et al., 2009; Roy 
Jefferis, 2009; Moremen et al., 2012; Spearman et al., 2011; Spiro, 2002). N-glycans are bound 
via amide-linkages to asparagine residues, and are typically larger oligosaccharides compared to 
O-glycans, which are bound to serine or threonine by glycosidic bonds. O-linked glycosylation 
can also occur on hydroxylysine or tyrosine in the case of collagen and glycogenin respectively 
(reviewed by Moremen et al., 2012). Further, there are two lesser known forms of glycosylation: 
C-mannosylation, where mannose is affixed by carbon-carbon covalent bonds to the C2 position 
of tryptophan, and glypiation, where glycophosphatidylinositol (GPI) anchors are formed 
between mannose, phosphoethanolamine, and the terminal carboxyl-group of a protein, which 
are common in cell surface proteins of eukaryotes (reviewed by Spiro, 2002). 
With respect to mAbs, N-linked glycosylation of the Fc region receives the most attention in 
literature, as it is a major factor in effector function and binding to Fcγ receptors of the immune 




2.3.2 N-linked Glycosylation 
N-linked glycosylation begins in the cytoplasm with the assembly of a seven sugar 
oligosaccharide onto a dolichol phosphate ancho, (as reviewed by Burda and Aebi, 1999). Once 
assembled, this oligosaccharide is flipped into the endoplasmic reticulum (ER) where dolichol 
phosphate linked mannose and glucose species donate the remaining four mannose residues and 
three glucose residues to complete the N-glycosylation oligosaccharide precursor (as reviewed 
by Spearman et al., 2011). This fourteen sugar lipid-linked oligosaccharide is then detached from 
its dolichol phosphate anchor and bound to an asparagine amino acid of a protein undergoing 
translation by the oligosaccharyltransferase (OST) enzyme complex (as reviewed by Spearman 
et al., 2011). 
 
Figure 3 – Eukaryotic 14 sugar N-linked precursor oligosaccharide 
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The resulting precursor to N-linked glycosylation, shown in Figure 3, is bound to the protein 
at a site referred to as a ‘sequon’ via oligosaccharide transferase (OST) (as reviewed by 
Spearman et al., 2011). Failure of the oligosaccharide to attach to a sequon causes product 
variation referred to as macroheterogeneity for glycoprotein therapeutics, which can lead to 
problems of bioactivity (Dordal et al., 1985; Nose and Wigzell, 1983). The most common sequon 
for N-glycosylation, called the consensus sequon, is identified by a three amino-acid pattern of 
‘asparagine-(variable)-serine/threonine’ where the variable residue must not be proline (as 
reviewed by Moremen et al., 2012). Non-consensus sequons have been identified, where 
serine/threonine are replaced with cysteine, glycine or valine; however, these are observed rarely 
(less than 4% cumulatively) (Zielinska et al., 2010). Once bound to its sequon, in step with 
protein folding, glycotransferase enzymes of the ER act upon the oligosaccharide precursor 
glycan shown in Figure 3, removing the three terminal glucose moieties as well as the central 





Figure 4 – Eukaryotic N-glycosylation in mammalian cells  
Glycosylation continues into the Golgi with the removal of three more terminal mannose 
moieties, as per Figure 4, where an example of a possible sequence of glycosyltransferases yields 
a ‘complex’ glycan that is biantennary, fully galactosylated, fully sialylated, and with a core α1-6 
fucose moiety.  This glycan can be represented by an abbreviated nomenclature, “FA2G2S2” for 
its structure, following the Oxford Glycobiology Institute convention (reviewed by Gornik et al., 
2007). In this case, the ‘F’ refers to fucose bound by an α1-6 bond, the ‘A’ to the degree of 
antennarity (in this case, biantennary), ‘G’ to the degree of galactosylation, and the ‘S’ for 
sialylation. Instead of just one glycan resulting from this process, as shown in Figure 3, 
glycosylation typically yields a distribution of several glycans based on partial completion or 
further processing beyond steps shown in Figure 3. This variation is referred to as 
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Figure 5 – Examples of diversity of potential glycoforms  
Regarding in vivo human N-glycoforms for antibodies, in an examination of the prevalent 
glycans of IgG1&2 found in human blood serum of five healthy patients reported by Flynn and 
colleagues (2010), the most prevalent five glycoforms cover over 90% of the distribution; these 
glycans are as shown in Figure 6; their relative proportions are detailed in Table 1. An important 
characteristic of antibody glycoforms in vivo, noted by reviewer Jefferis, is their tendency to shift 
in response to illnesses, as such the optimal distribution of glycans on antibodies for treating a 
particular disorder may vary from the distribution reported by Flynn et al. (Flynn et al., 2010; 
Jefferis, 2012). 
 


























Further reported by Flynn et al. for IgG1 and IgG2, as noted in Table 1, the resulting 
bisecting forms of IgG1&2 are approximately 12% and 9.3%, respectively (Flynn et al., 2010). 
This is most notable, because these glycans in particular cannot be produced in CHO mammalian 
cell cultures, which do not express the glycosyltransferase enzyme GnT-III (Xu et al., 2011). 
Table 1 – N-Glycan distribution of IgG1&2 in human blood serum according to Flynn et al. (2010) 
N-Glycan Structure IgG Type 1 (%) IgG Type 2 (%) 
Aglycosylated 0.19 ± 0.11 0.18 ± 0.04 
Hybrid 0.681 ± 0.23 1.74 ± 1.10 
Bisecting 12.054 ± 2.99 9.31 ± 2.41 
Afucosylated 3.66 ± 0.97 2.31 ± 0.96 
Sialylated 10.533 ± 1.73 10.12 ± 2.22 
Most Common Glycoforms in vivo: 
FA2G0 12.5 ± 2.7 25.1 ± 5.7 
FA2G1 42.3 ± 2.4 35.6 ± 3.0 
FA2G2 21.7 ± 3.7 16.1 ± 3.8 
FA2BG1 7.2 ± 1.6 4.1 ± 1.1 
FA2G2S1 8.6 ± 1.19 6.2 ± 1.6 
 
2.3.3 Antibody Fc & Immune Effector Function 
While the Fab region of antibodies allow them bind with high specificity to their target 
antigens, it is their glycosylated Fc regions that interact with the immune system. IgGs possess 
paired glycosylation sequons at ‘asparagine 297’ (Asn297) on the heavy chain CH2 domain of 
their Fc region, and depending on the resulting glycoform, produce varying immune response 
activation capability in vivo (as reviewed by Jefferis, 2012). N-glycosylation of the Fc region has 




functions (Nose and Wigzell, 1983). As noted previously, the glycosylation of antibodies also 
affect a host of other drug factors including immunogenicity (Bosques et al., 2010; Padler-
Karavani et al., 2008), secretion by cells (Hickman and Kornfeld, 1978), drug clearance-rate 
(Morell et al., 1968), protein stability (Mimura et al., 2001), and solubility (Leavitt et al., 1977). 
Therefore, this shifting in the therapeutic effect and major drug characteristics of MAbs with 
glycosylation forms much of the reasoning behind its status as a ‘critical quality attribute’ 
(CQA).  
The Fc regions of antibodies interact with the immune system by binding to numerous 
different Fc receptors on the surfaces of white blood cells, as well as complexing with C1q of the 
Complement system (as reviewed by Jefferis, 2012). Fc receptors can be separated into two 
categories, neo-natal Fc receptors (FcRN) and Fcγ receptors (FcγR). FcRN are active in adults 
and play important roles in immunoglobulin serum half-life as well as transport of antibodies 
across epithelial membranes (as reviewed by Jefferis, 2012). FcγR possess six established 
isotypes: FcγRI (CD64), FcγRIIa/b/c (CD32) and FcγRIIIa/b (CD16), and are found in varying 
proportions on a myriad of leukocytes including macrophages, dendritic cells, neutrophils, and 
natural killer cells (NK) (as reviewed by Jefferis, 2012). 
The interaction of FcγR with an antibody-antigen complex mediates a host of immune 
effector functions including antibody-dependent cell phagocytosis (ADCP), cytolysis or 
cytotoxicity (ADCC), and the release of cytokines and chemokines spurring further cascades of 
immune responses within the highly regulated immune system (as reviewed by Lazar and 
Desjarlais, 2009). 
MAb glycoforms are often characterized depending on how well they can recruit immune 




ADCC, typically present only FcγRIIIa, which upon interaction with the glycosylated Fc region 
of an IgG, kill antibody-targeted cells either by lytic granule release leading to cytolysis, or 
induction of apoptosis by secretion of tumor necrosis factor (TNF) family (as reviewed by Lazar 
and Desjarlais, 2009). Complement-dependent cell cytotoxicity (CDC) is activated by the C1q 
component, which binds to an antibody-antigen complex, spurring on the Complement cascade, 
to lyse cells and also produce cytokines to recruit macrophages (as reviewed by Jefferis, 2012). 
2.3.4 N-Glycoform & Immune Effector Function 
While different binding sites for C1q, FcRN and FcγR are employed on the Fc region of 
antibodies, all occur near the CH2 domain and therefore observe interaction with the major 
paired N-glycosylation sites at Asn297 (as reviewed by Lazar and Desjarlais, 2009). As such, 
different glycoforms yield different binding affinities and therefore significant final effects from 
these three immune system triggers. A detailed discussion of this topic is available in Chapter 6, 
and examines the current understanding of how changes in N-glycoforms of antibody Fc regions 
affect their immune effector functionality. 
2.3.5 O-linked Glycosylation 
O-linked glycosylation occurs in the Golgi, and while some consensus binding sites have 
been identified, most remain unknown (as reviewed by Moremen et al., 2012). However, as 
reviewed by Van den Steen and colleagues, O-glycans tend to occur in locations on the protein 
with a higher propensity of serine, threonine and proline (Van den Steen et al., 1998). The most 
common form is the ‘mucin’ form, where a core N-acetylgalactosamine (GalNAc) is bound to 
the OH- functional group of either serine or threonine; these proteins occur ubiquitously in vivo 




is not yet recognized as notably consequential to effector functions or bioefficacy; however, it 
will affect some basic efficacy characteristics like protein stability (Wang et al., 1996). 
2.4 Glycan Analysis 
Methods for measuring the distribution of glycans on glycoconjugates is a burgeoning 
research area with a diversity of proposed techniques. The most established methods, as 
reviewed by Spearman and colleagues, rely on glycan isolation and fluorescent labeling, 
followed by quantification by various options such as chromatography, capillary electrophoresis, 
and mass spectroscopy (MS) (Spearman et al., 2011). Glycan isolation is achieved by cleaving 
glycans from proteins, using an enzyme such as N-PNGase-F, after which they are labeled with a 
fluorescent compound such as 2-aminobenzamide (2AB) (reviewed by Butler, 2004a). HPLC 
separation (normal phase) of fluorescent tagged N-glycans is compared to a reference dextran 
ladder creating a metric of “glucose units”, with corrections for different monosaccharides (Guile 
et al., 1996). Glucose units may be subsequently crosschecked against online databases such as 
GlycoBase, which possesses more than 350 2AB-labelled N-glycans including 117 identified in 
the human serum (Campbell et al., 2008). An elution profile where glucose units have been used 
to identify oligosaccharides cleaved from EG2-hFc chimeric heavy-chain mAb is shown in 
Figure 7, the retention times, glucose units, and glycan type are shown in the accompanying 





Figure 7 – Normal phase HPLC elution profile of glycans cleaved from mAb EG2-hFc 






33.379 5.85 FA2G0 
36.215 6.60 FA2G1 isomer 
36.631 6.72 FA2G1 isomer 
39.139 7.48 FA2G2 
40.688 7.99 FA2G2S1 
42.154 8.51 FA2G2S2 
 
2.5 Cell Culture Platforms and Glycoengineering 
Therapeutic protein biopharmaceuticals on the market today can be characterized along a 
gradient of complexity with respect to the cellular processing required for biological activity. 
Several biologics, such as mAbs and erythropoietin (EPO), require complex-type glycosylation 
for effector function (Dordal et al., 1985; Nose and Wigzell, 1983) and are manufactured using 




proteins are not glycosylated and can be prepared in simpler prokaryote platforms such as 
Escherichia coli (Goeddel et al., 1979). Compared to other platforms, mammalian cell culture 
systems are limited by comparatively slow growth and lower product yields. Furthermore, 
several established rodent-derived cell lines such as NS0 and CHO form glycosylation structures 
immunogenic in humans (Bosques et al., 2010; Padler-Karavani et al., 2008). CHO cells, the de 
facto industry standard, are also incapable of forming structures like bisecting GlcNAc (Xu et al., 
2011), which form ~10% of human antibody glycans in vivo (Flynn et al., 2010), or α2-6 
sialylation, which is present on 40% of endogenous EPO (Takeuchi et al., 1988) and the main 
contributor to anti-inflammatory properties of sialylated IgGs (Anthony et al., 2008). As such, 
fully human cell lines like HEK293 and Per.C6 have grown more popular and attempts have 
been made with some success to “glycoengineer” human-like glycosylation in alternative 
production platforms of bacteria, yeast, insect cells and improve mammalian platforms currently 
in use (as reviewed by Lalonde and Durocher, 2017). 
2.5.1 Mammalian 
Complex therapeutic glycoproteins derived from recombinant technology, such as mAbs, are 
often manufactured in continuous rodent cell lines like Chinese hamster ovary (CHO), mouse 
myeloma and hybridoma (NS0 and Sp2/0), as well as baby hamster kidney (BHK) (as reviewed 
by del Val et al., 2010; Ghaderi et al., 2012; Hossler et al., 2009). Of these platforms, the most 
widely used are CHO cells, as they are the best characterized and most widely approved, making 
them effectively an industry standard (as reviewed by Butler and Meneses-Acosta, 2012). 
Although production capacity with these platforms continues to grow year by year, often 





The strength of mammalian cell cultures, as a production platform for biotherapeutics lies in 
their capacity for human-like glycosylation structures. However, it has been determined that 
rodent-derived cell lines can generate non-human glycoforms with implications towards 
immunogenicity (Bosques et al., 2010; Ghaderi et al., 2010). Shown in Figure 7, these 
immunogenic glycan residues include terminal glycolneuraminic acid (Neu5Gc) (Ghaderi et al., 
2010) and terminal α-linked galactose residues (α-gal) (Bosques et al., 2010). 
 
Figure 8 – Immunogenic N-glycan moieties Neu5Gc and α-gal, from rodent-derived cells  
The ability to add a terminal Neu5Gc moiety to glycans was lost by a mutation to the CMAH 
gene in hominids approximately three million years ago and the human immune system 
constitutively produces antibodies against this glycoform as well as α-gal (as reviewed by 
Ghaderi et al., 2012). 
Given the immunogenic glycoforms associated with rodent-originating mammalian cell lines, 
as well as the fact their glycosylation structures, while human-like, do not achieve the level of 
complexity as de novo human glycoforms, more attention is being directed towards fully human 
cell lines, such as PER.C6 derived from human embryonic retinal cells and HEK293 from human 
embryonic kidney cells (Butler and Meneses-Acosta, 2012; Lalonde and Durocher, 2017). 
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Glycoengineering of mammalian cells is seeing increasing success for altering glycan 
profiles, particularly as modeling of underlying glycosylation mechanics and regulation 
improves (McDonald et al., 2016; Spahn et al., 2016). Some common efforts by researchers 
include goals of increasing sialylation, and reducing immunogenic Neu5Gc. This has been 
accomplished by over-expression of the sialyltransferase α2-6-sialT in CHO (Raymond et al., 
2015; Weikert et al., 1999; Zhang et al., 1998) and BHK (Schlenke et al., 1999). It has also been 
accomplished using silencing RNA in CHO cells, preventing expression of sialic acid-removing 
‘sialidase’ enzymes (Ferrari et al., 1998). Preventing immunogenic N-glycolylneuraminic acid 
moieties has been accomplished with silencing RNA to block expression of CMP-Neu5Gc 
forming enzymes (Chenu et al., 2003). Increasing sialylation has further be improved through 
over-expression of transporter proteins in CHO, such as ‘CMP-SAT’ to improve sialic acid 
transfer into the Golgi (Wong et al., 2006). Similar strategies have been employed by other 
groups in CHO cells to improve galactosylation (Weikert et al., 1999), introduce the capacity for 
bisecting GlcNAc glycoforms to IgG (Umaña et al., 1999), and reduce fucosylation (Mori et al., 
2004). Several additional examples are discussed further in Chapter 6. 
2.5.2 Prokaryotes 
Bacteria originally were thought to lack the ability to perform complex post-translational 
modifications like glycosylation, until the discovery that ε-proteobacterium Campylobacter 
jejuni were capable of a simplified form of protein glycosylation (Szymanski et al., 1999). This 
glycosylation infrastructure was subsequently transferred to Escherichia coli as a means to use 
prokaryotes to produce recombinant glycoproteins (Wacker et al., 2002). This form of 
glycosylation is a single step transfer of a lipid-linked heptasaccharide onto the asparagine 




analogous to the dolichol lipid-linked oligosaccharide attachment to proteins co-translationally in 
the endoplasmic reticulum by eukaryotes discussed in Section 2.3.2 as well as Chapter 6. While 
this bacterial glycosylation is not human-like, one advantage to its simplicity is that all 
glycosylated proteins receive identical glycans (Lizak et al., 2011), of the form as shown in 
Figure 8. 
 
Figure 9 – Prokaryote N-glycosylation from glycoengineered E. coli  
2.5.3 Yeast 
Conventionally, yeasts are an attractive option for recombinant protein production and 
bioprocesses in general for numerous reasons: yeasts possess rapid growth rates, reach high cell 
densities, adapt well to suspension culture in chemically defined media, and are well-
characterized for scale-up to industrial-scale production (as reviewed by Ghaderi et al., 2012). 
Furthermore, yeasts are eukaryotes, capable of post-translational modifications necessary for 
bioactivity of therapeutic proteins.  
The normal glycosylation structures of yeasts, however, are very different from those found 
in mammals. Wild-type yeasts produce ‘hyper-mannosylated’ glycoproteins, sometimes with 
hundreds of mannose residues, as shown in Figure 10 (as reviewed by Gemmill and Trimble, 
1999). These glycoforms tend to be immunogenic in humans with rapid clearance rates, 






Figure 10 – Hyper-mannosylated yeast N-glycosylation 
To overcome this drawback glycoengineering has been employed to create strains of Pichia 
pastoris capable of producing human-like glycosylation with upwards of 90% terminal 
sialylation (Hamilton et al., 2006) and removal of core fucose for enhanced ADCC (as reviewed 
by Lalonde and Durocher, 2017). However, no commercial examples of this technology are 
approved to-date. 
2.5.4 Insect 
Insect cells offer efficient high production of protein, but yield shorter “paucimannosidic” N-
glycoforms that may contain immunogenic core α1-3 fucose residues, as shown in Figure 11 
(reviewed by Ghaderi et al., 2012).  
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Figure 11 – Paucimannosidic N-glycosylation in insect cells  
While a popular lab-scale production platform, insect cells have not historically been utilised 
for therapeutic protein production. However, this has changed with the approval of Cervarix™, a 
vaccine against forms of the human papilloma virus (HPV) from GlaxoSmithKline (GSK) (as 
reviewed by Palmberger et al., 2012). A major difference between insect cell platforms and 
others is the fact that recombinant protein production is achieved through a transient process 
using the baculovirus expression vector system (BEVS), rather than integrating amplified genes 
stably into the chromosomes of the cell line. Baculoviruses do not replicate in mammals, a safety 
feature for applications of BEVS towards production of therapeutics (as reviewed by Sokolenko 
et al., 2012). 
Glycoengineering of insect cells has been pursued as a means to achieve human-like 
glycosylation with some success (Aumiller et al., 2012), however, no commercial examples of 
therapeutic glycoproteins from glycoengineered insect cells are approved to-date. 
2.6 Omics Methods towards Enhancing Bioprocesses 
Omics methods provide a holistic accounting of species within a particular domain of cellular 
functions, as summarized in Table 3. While genomics and transcriptomics grew out of 
technologies for rapid DNA and RNA sequencing, proteomics and metabolomics have been built 
on more conventional analytical chemistry and biochemistry techniques such as gel-
  




electrophoresis, chromatography, mass spectrometry (MS), and nuclear magnetic resonance 
spectroscopy (NMR).  
Table 3 – Examples of omics cellular domains 
Cellular Function Focus ‘Omics Method 
DNA Replication DNA and Genes Genomics 
Transcription mRNA Transcriptomics 
Translation Proteins Proteomics 
Metabolism Metabolites Metabolomics 
Within the realms of genomics and transcriptomics, numerous hierarchical conflicting 
mechanisms such as epigenetics, gene silencing, and interference produce something of a 
superposition of phenotype, whereas the realms of proteomics and metabolomics represent a 
more defined phenotype representation for characterizing cell culture bioprocesses. However, the 
fidelity of the sampling and analysis methodologies remain a challenge for both proteomic and 
metabolomic techniques. In proteomics, protocols for quenching and extraction of intracellular 
proteins are relatively simple to execute. However, the actual analytical protocols selected can 
create trade-offs for the quality of results when utilizing either a bottom-up shotgun-style 
proteomics method where samples are digested together without prior separation and results are 
dependent on mass-based labeling (e.g. isobaric tags), or a top-down method such as a gel-based 
separation of intact proteins prior to digestion and analysis (reviewed by Westermeier, 2016). In 
metabolomics on the other hand, while extracellular ‘footprinting’ of supernatant metabolites is 
simple to execute with just a single centrifugation step to pellet cells, intracellular 
‘fingerprinting’ requires challenging quenching and extraction protocols, of which there is a 
limited consensus in the field for the best methods to follow (Sellick et al., 2011b). Therefore, 




phenotype has been achieved. Stolfa and colleagues provide a thorough accounting for the 
various omics methods and how they have been employed, particularly towards CHO cell 
bioprocesses (Stolfa et al., 2017). For the purposes of this thesis the following sections focus on 
proteomics and metabolomics in bioprocesses.  
2.6.1 Proteomics 
Proteomics is the application of analytical biochemistry methods to identify and quantify the 
global range of proteins and peptides at the cellular level, referred to collectively as the 
‘proteome’. Experiments are conducted as a quantitative detection of differential expression of 
species in the proteome, observing induced shifts in cellular phenotype, as well as changes 
regarding isoforms of proteins and differences in post-translational modifications depending on 
the method employed (reviewed by Westermeier, 2016).  
Proteomic methodologies can be described broadly as following either a top-down, or 
bottom-up approach to the quantitation of sample peptides depending on the point at which 
trypsin digest step is implemented. For top-down methods, intact proteins are initially separated, 
such as in 2D-gels, by size and isoelectric focusing (IEF), after which individual spots are 
excised from the gel, trypsin digested and analyzed by mass spectrometry (demonstrated in 
Chapter 3). In the latter, or bottom-up approach, which includes methods often referred to as 
“shotgun” proteomics, the sample is first labelled via methods such as isobaric tagging, and then 
digested en masse without further discrimination, before analysis by mass spectrometry or by 
various forms of chromatography (reviewed by Westermeier, 2016). Shortcomings of gel-based 
top-down techniques include the loss of species that are very basic, hydrophobic, very large, or 
in very small concentrations (reviewed by Westermeier, 2016). Bottom-up techniques suffer 




identical peptide sequences between different proteins, and loss of information on post-
translational modifications and isoforms of species (reviewed by Westermeier, 2016). A 
particular advantage of bottom-up methods is that they can be fully automated, while top-down 
methods require the technical finesse of a trained scientist; however, top-down techniques are 
also generally regarded to be more reliable. Broadly, like other omics methods, hybrids or 
parallel analytical methods following these two approaches can minimize the limitations of one 
another. 
2.6.1.1 2D Differential In-Gel Electrophoresis (DIGE) 
Two dimensional differential in-gel electrophoresis (2D-DIGE) is a top-down gel-based 
proteomics method where proteins and peptides are pre-labeled fluorescently and then separated 
in a sodium dodecyl sulfate polyacrylamide gel via electrophoresis (SDS-PAGE) in two 
directions (this method is detailed in Chapter 3). Sample proteins are first separated by 
isoelectric focusing (IEF) by immobilized pH gradient (IPG) strips embedded in the gel, with 
proteins travelling to the location in the gel where they have a neutral charge. Subsequently, like 
a typical SDS-PAGE, the proteins are separated by molecular weight, with smaller proteins and 
peptides travelling faster through the polyacrylamide gel. The proteins in the gel, visible from 
their fluorescent tags can be identified and quantified with respect to their location on the gel, 
with respect to their molecular weight and isoelectric point. In a single gel, two samples are 
labeled with separate fluorescent dyes and run together so they can be directly compared to 
determine levels of differential expression (Meleady, 2018). 
2.6.1.2 Peptide Tagging Proteomics 
Bottom up proteomics methods function on the basis of chemically labelling peptides or 




digestion and subsequently mass spectrometry, the resulting spectra can be analyzed to identify 
and quantify the distribution of species in the proteome. Methods include stable isotope labeling 
with amino acids in cell culture (SILAC) utilizing light and heavy versions of amino acids; 
isobaric tags for relative and absolute quantitation (iTRAQ); and tandem mass tags (TMT). In 
these methods, the abundance of peptides (and by extension their respective proteins) from 
different experimental samples can be directly compared to one another for analysis of 
differential expression (Zhang and Elias, 2017). 
2.6.2 Metabolomics 
Metabolomics is the application of analytical chemistry methods to identify and quantify (i.e. 
‘profile’) the global range of small molecular weight compounds at the cellular level, referred to 
collectively as the ‘metabolome’. Observed as the cumulative result of all regulatory interactions 
from cellular functions, the profiled metabolome provides a time-point characterization of the 
cellular metabolic phenotype for a culture (reviewed by Stolfa et al., 2017) 
A distinction is drawn in metabolomics between profiling the intracellular and extracellular 
environments, the endo and exometabolome respectively, referred to as ‘footprinting’(Allen et 
al., 2003) and ‘fingerprinting’(Fiehn, 2002). The distinction between these two analyses is 
important, for two fundamental reasons. First, differences in concentration across the cellular 
membrane are often characteristic of transport and regulatory actions, which may lead to deficits 
and bottlenecks for nutrients in the intracellular substrate supply chain of cellular functions. A 
clear example of this is the observed steep concentration gradient observed for glucose between 
the extracellular and intracellular environments reported by Ma and colleagues, where the 
intracellular concentration of glucose was two orders of magnitude below that of the growth 




dramatically increased difficulty of profiling the intracellular metabolite pools, or 
endometabolome, compared to those of the supernatant. Fingerprinting requires chemical 
treatments to denature enzymes and halt metabolic activity in an instant, which is referred to as 
“quenching”, and serves to halt enzymatic activity and preserve short-lived metabolites 
(Dietmair et al., 2010; Sellick et al., 2009). Quenching is subsequently followed by a chemical 
“extraction” process, which serves to lyse cells for recovery of metabolites (Dietmair et al., 
2010; Sellick et al., 2010). Different procedures and chemical agents have been proposed for 
both quenching and metabolite extraction of polar and non-polar metabolites by different 
research groups, and are discussed in Section 2.6.4. 
Metabolomics possesses several key advantages over other ‘omics platforms for elucidating 
bioprocess information. For instance, the capability for high throughput sample processing 
makes metabolomics a strong candidate for on-line process analysis. Furthermore, metabolomics 
requires less specialized equipment and techniques compared to other ‘omics methods, primarily 
utilizing conventional analytical chemistry techniques such as mass spectrometry and NMR. This 
also makes it the most economical omics technology for commercial applications. 
A distinction is currently drawn in research between the similar fields of metabonomics and 
metabolomics, the latter focuses on global profiling of metabolites at the cellular level i.e. 
extending from cell-level regulation activities. Conversely, metabonomics has a more 
macroscopic focus of full biological systems, finding applications in drug pharmacokinetics and 
diagnostic pathology (reviewed by Chrysanthopoulos et al., 2010). The term ‘metabonomics’ 
was coined by Nicholson and colleagues, with a scope for observing “dynamic multiparametric 
metabolic responses from living systems”(Nicholson et al., 1999). Samples are typically drawn 




of disease-states and drug toxicity (reviewed by Khoo and Al-Rubeai, 2007). Therefore, the 
scope of metabonomics is making observations at a fundamentally larger scale (full body) 
compared to metabolomics (cell-level). However, given the practical similarities that these 
research fields both refer to quantitative metabolite analysis in biological systems, these terms 
are often used interchangeably. 
Metabolomics is predated by several metabolic engineering tools, such as dynamic kinetic 
metabolic models, pathway analysis, metabolic flux analysis (MFA), and flux balance analysis 
(FBA). Metabolomics possesses a distinct and sometimes complementary scope to these other 
methods, which feature the application of predictive computational models. Since metabolic 
fluxes are not necessarily linearly dependent on metabolite concentrations, metabolomics does 
not provide direct information regarding reaction rates or fluxes through metabolic pathways 
(reviewed by Chrysanthopoulos et al., 2010). Rather, it provides a “snap-shot” of supernatant 
and intracellular pool concentrations, information which can be utilized without detailed 
metabolic network modeling. Computational models of intracellular metabolic networks can 
however be supported by data from metabolomics, as has been demonstrated (Fernandes et al., 
2016; Goudar et al., 2010; Selvarasu et al., 2012) and is discussed further in Section 2.6.3.2. 
2.6.2.1 NMR Spectroscopy Targeted Profiling 
Numerous methods fall under the umbrella of nuclear magnetic resonance spectroscopy 
(NMR), and several of these are applicable for metabolic research, particularly when utilizing 




N incorporated into certain nutrients to observe their incorporation 
into cellular metabolism (Goudar et al., 2010). For the purposes of this thesis, discussion has 
been limited to simple ‘pulse-acquire’ single dimension hydrogen nuclear magnetic resonance 
spectroscopy (1D-
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H-NMR experiment, the free induction decay (FID) signal is Fourier-transformed, 
producing a spectrum of hydrogen peaks unique to the mixture of metabolites in the sample. This 
spectrum is normalized against an internal standard, 2,2-Dimethyl-2-silapentane-5-sulfonate 
(DSS), added to the sample prior to analysis, and the area beneath the resulting peaks 
corresponds proportionately to the total number hydrogen nuclei sharing a particular position in a 
metabolite’s chemical structure, and by extension the concentration of that metabolite of interest. 
With the aid of software and a human ‘profiler’, a process of “targeted profiling” can be 
employed to first identify metabolites by the peaks in a spectrum, and then quantify them by 




H-NMR possesses advantages over other metabolomics methods including a non-
destructive analysis, and a capability for observing volatile organic acid metabolites, such as 
formate and acetate, which are difficult to observe with some HPLC and MS methods (discussed 





Figure 12 – Convoluted Spectral Peaks 1D-1H-NMR 
Initially, an FID spectrum will possess areas of overlapping peaks, representing hydrogen 
atoms bonded to particular metabolites as shown in Figure 12. These ‘convoluted’ spectral 
patterns can be disentangled relatively easily by a software-assisted human profiler, as shown in 
Figure 13, where lysine, acetate and arginine are detected in the cluster. 
 









Quantification is achieved by nullifying the ‘subtraction line’ as shown in Figure 14, which 
represents area-difference between the ‘profile’ and the original spectrum. 
 
Figure 14 – Quantification by Metabolites by Chenomx Software 
2.6.2.2 Mass Spectrometry (MS) 
Mass spectrometry (MS) in metabolomics, much like NMR, relies on an established library 
for deconvolution of species within a sample spectra for identification and quantification (as 
reviewed by Yi et al., 2016). MS methods generally observe a greater number of total 
metabolites compared to NMR; however the methods are often considered complementary and 
can be used together synergistically (Blondeel et al., 2015; Goudar et al., 2010). Various 
chromatography based MS methods have been employed by different research groups for 
analysis of metabolomics in mammalian cell cultures, including HPLC (Blondeel et al., 2015; 
Chong et al., 2009, 2010b; Dietmair et al., 2012), liquid chromatography MS (LC-MS) (Chong et 
al., 2012, 2010a; Goudar et al., 2010; Ma et al., 2009; Selvarasu et al., 2012; Zang et al., 2011), 
and gas chromatography MS (GC MS) (Chrysanthopoulos et al., 2010; Dietmair et al., 2012; Ma 
et al., 2009; Schaub et al., 2012; Sellick et al., 2011a).  
Human profiler matches 
pure-compound spectra 





Mass spectrometry metabolomics methods rely on various systems to ionize species, separate 
by mass, and subsequently analyze. Given the broad range of metabolites in any given cell 
culture system (i.e. aqueous, hydrophobic, volatile, etc.), different ionization and analysis 
schemes are necessary to observe different groups. Emwas provides a thorough comparison of 
different MS methods applied towards metabolomics, and compares their strengths and 
weaknesses against available NMR methods (Emwas, 2015). 
2.6.3 Applications of Omics to Cell Culture 
2.6.3.1 Growth Medium and Feeding Regimes 
One fundamental application of omics for mammalian cell culture is the optimization of 
growth medium, and post-inoculation nutrient feeding in the case of fed-batch processes. The 
majority of ingredients in media are detectable nutrients, and their patterns for uptake and 
consumption can reveal growth-limiting factors and accumulation of excreted toxic waste 
metabolites.  
A challenge in recent decades for design of growth medium for mammalian cell culture is 
avoiding the practice of using ‘complex’ ingredients derived from animals or other biological 
systems (e.g. yeast cultures). Unlike ‘defined’ media components, complex supplements possess 
unquantifiable characteristics and create challenges for maintaining batch to batch consistency. 
Furthermore, in the case of supplements derived from animal products, there are contamination 
concerns from prions and viruses (as reviewed by Butler, 2004a). Despite reservations, the use of 
complex components in growth medium has persisted, because fully chemically defined media 
have historically underperformed in comparison. However, as noted in the work of Ma and 
colleagues, a limitation associated with complex supplements is that their digestion yields 




Therefore, as media designs improve, chemically defined options that are optimized for cultured 
cells will ultimately achieve better results. Ma and colleagues achieved this with metabolomics 
methods, creating a chemically defined medium for GS-amplified CHO and NS0 bioprocesses 
previously growing in non-animal derived hydrolysate-containing complex medium (Ma et al., 
2009). The chemically defined medium achieved better growth and increases in protein titers of 
80% and 115% for CHO and NS0 processes respectively. At the same time in applications where 
hydrolysates and complex components cannot be avoided, methods such as proteomics can 
provide a clear perspective on how these components shift phenotype (Kim et al., 2011). Such 
insights can provide further leads for ways to improve the growth and productivity of cultures, as 
well as engineer better platforms.  
Another fundamental advantage of using omics methods for media design and optimization 
identified by Ma and colleagues was that rather than taking a conventional approach of starting 
at a basal medium and gradually adding nutrients, the researchers were able to perform a top-
down approach. The medium design began with 90+ components, which were simultaneously 
monitored by metabolomics methods. Components were systematically removed until less than 
40 components remained (Ma et al., 2009). Therefore, the final medium formulation was on par 
in terms of number of ingredients with several published basal mammalian growth media, such 
as modified Eagle’s medium (DMEM, IMEM) (Eagle, 1955) and RPMI 1640 (Moore et al., 
1967), while demonstrating fewer ingredients than other formulations such as Ham’s F-12 (Ham, 
1965) and 199 (Morgan et al., 1950) – as an aside, Morton provides an excellent accounting of 
recipes developed throughout the 20
th
 century for defined culture medium (Morton, 1970). Ma 
and colleagues’ 40 ingredient recipe is an important result, because the cost of growth medium is 




dedicated to complex ingredients (reviewed by Butler, 2004b). Furthermore, each additional 
component to a growth medium represents a possible source of vulnerability to the batch to batch 
consistency of commercial bioprocesses; the fewer components, the better.  
A further key area for applying omics to design of media and nutrient feeds is identifying 
crucial growth or productivity-limiting factors. With advanced multivariate data analysis 
(MVDA) methods, experiments can take one very large data set to achieve significant advances 
in productivity (Schaub et al., 2012). Schaub and colleagues increased product titres from 5 to 
8g/L in CHO cultures by applying knowledge from multivariate transcriptomics to metabolic 
models (Schaub et al., 2012). 
Growth limiting nutrients can often be identified by observing which metabolites are 
depleted from the supernatant (as demonstrated in Chapter 3) or intracellular metabolite pools at 
major time points in the culture, such as when the cells are transitioning between exponential 
growth and stationary phase. Sellick and colleagues reported aspartate, asparagine and glutamate 
catabolism via truncated TCA interactions for a CHO culture producing IgG (Sellick et al., 
2011a). By compensating for these depleting nutrients with a modified nutrient feed strategy, the 
system achieved an increase in biomass of 35% and more than doubled antibody titers. Culturing 
similar mammalian bioprocesses, Bradley and colleagues detected growth-limitations from 
histidine depletion (Bradley et al., 2010); Chong and colleagues detected depleted tryptophan 
and choline (Chong et al., 2009); and Dietmair and colleagues detected depleted CTP and UDP-
glucoronic acid (Dietmair et al., 2012). While all four researchers were working with CHO cells 
– and, with the exception of Dietmair and colleagues, were producing an IgG protein product – 
the diversity of these results can be attributed to several factors, which commonly vary across 




different proprietary media, separate subtypes of CHO cell lines (i.e. K1, DG44, Dukx), different 
selection markers and amplification strategies (i.e. DHFR, GS, hMT-IIA), and different 
bioreactor scales. Determining these differences can be difficult in some cases as many 
publications, particularly those originating from industry research groups, routinely fail to 
disclose information about their expression system and cell-line origins beyond the fact that the 
cells are “CHO”. However, this ultimately illustrates the strength of multiple omics methods, 
such as metabolomics and proteomics, for optimizing cell culture bioprocesses and growth 
medium, because it remains capable of detecting bottlenecks in cellular infrastructure across 
varied production platforms. 
2.6.3.2 Flux Modeling 
Omics methods can provide complementary tools towards flux modeling. This was well 
illustrated by Fernandes and colleagues, who utilized isotopic labeled 
13
C glutamine and 
metabolomics methods to observe a fed-batch process, developing a dynamic model of CHO 
major metabolic pathways (Fernandes et al., 2016). Similarly, Selvarasu and colleagues 
employed both footprinting and fingerprinting metabolomics data to achieve greater model 
complexity and better identifying growth limiting pathways linked to glutathione, and 
glycerophospholipid synthesis (Selvarasu et al., 2012). Given limitations to intracellular 
metabolomic profiling (i.e. ‘fingerprinting’), flux modeling can offer an alternative means of 
characterizing intracellular metabolism and potential bottlenecks. This is typified by Schaub and 
colleagues’ use of ‘footprinting’ for extracellular metabolomic analysis, coupled with 
transcriptomics and an intracellular flux model as a process-control strategy (Schaub et al., 
2012). In this particular instance, flux modeling reached similar conclusions to the fingerprinting 




metabolism to the citrate cycle” (Sellick et al., 2011a). With these and similar realizations on 
CHO metabolism, Schaub and colleagues increased their titers from 4.9 to 7.9 g/L (Schaub et al., 
2012). 
2.6.3.3 Phenotype Consistency 
Of major concern in bioprocess engineering is maintaining phenotype consistency of cultured 
cells to prevent batch-to-batch variation. Phenotype refers to the observable physical 
characteristics resulting from gene expression and cellular responses to environmental factors. 
Conventionally, measuring cell phenotype was limited to factors such as cell growth, viability, 
productivity, and the consumption/excretion of select metabolites. However, with the advent of 
‘omics methods, measuring variation in the cell phenotype of cultured cells has the potential to 
be extended to include the global metabolic profile and the up/down regulation of proteins (i.e. 
metabolomics, and proteomics). Major areas in bioprocesses vulnerable to shifts in cell 
phenotype producing batch-to-batch variation include: cell aging in perfusion and chemostat 
reactors; scaling up a bioprocess to larger volumes; process alterations; spontaneous loss of 
recombinant genes of interest and silencing in stable expression systems; and spontaneous 
mutations. Regarding batch to batch variation, cell aging and bioprocess scale-up, each of these 
circumstances was investigated by Chrysanthopoulos and colleagues, who successfully 
employed global metabolomics profiling to analyze variation in six perfusion bioreactors 
growing BHK cells (Chrysanthopoulos et al., 2010). Four of the reactors were “lab-scale” and 
two were “manufacturing-scale”, operated over a course of approximately 150 days each. Clear 
shifts in global metabolic phenotype were observed for all three investigated factors by 
observing the metabolic profile data using principle component analysis (PCA) and hierarchical 




Similar observations of metabolomic profile shifts for a fed-batch scale-up of CHO-DG44 
cells from a 7L to 5000L bioreactor process were observed by Aranibar and colleagues, with 
greater reliance on glycolysis in scale-up, as typified by more rapid depletion of glucose and 
galactose, but lower accumulation of TCA intermediates; these shifts were hypothesized to be 
linked to poorer DO transfer at larger scale (Aranibar et al., 2011). Regarding phenotype shifts 
for process changes, Aranibar and colleagues also observed whether metabolism would be 
significantly shifted with the introduction of the anti-apoptotic agent dextran sulfate. The 
researchers reported a significant shift in the metabolism of 28 separate metabolites, including 
amino acids, TCA intermediates and nucleotide precursors (Aranibar et al., 2011). 
Regarding observations of batch-to-batch variation, Schaub and colleagues monitored a total 
of 45 bioreactors (9 process generations of 3 parallel fermentations), profiling the nine highest 
performing amongst them for correlations between productivity, metabolite consumption 
patterns and up/down regulation of genes (Schaub et al., 2012). 
2.6.3.4 Gene Overexpression 
Metabolomic analysis can reveal a lack of uptake of certain nutrients by cells, often 
characteristic of the cells not requiring the nutrient, or excretion and accumulation of waste 
metabolites. In the former case, this can be indicative of a bottleneck either in transport or 
metabolism caused by under-expression of necessary enzymes and transport proteins needed to 
properly digest the nutrient. In the latter case, it may be over-feeding of the nutrient, leading to 
toxic effects like apoptosis (Chong et al., 2009). Similarly to lack of nutrient consumption, it has 
been hypothesized that some of these excretions, particularly those of TCA intermediates such as 
malate, are the result of under-expressed enzymes (Chong et al., 2010a; Dietmair et al., 2012; Ma 




within intracellular metabolite pools of bottlenecked intermediates, often leading to their 
excretion from the cell. Malate is metabolised by several enzymes including malate 
dehydrogenase II (MDH-II) in the mitochondrion as part of the TCA cycle (Chong et al., 2010a), 
and by MDH-I and malic enzyme in the cytosol (as reviewed by Schaub et al., 2012). Malic 
enzyme acts in the cytosol and uses malate as a substrate to regenerate pyruvate, producing 
NADPH in the process. MDH-I&II mediate the conversions between oxaloacetate and malate in 
the cytosol and mitochondria respectively. Chong and colleagues put forward the hypothesis that 
the excretions of malate were due to an accumulation in intracellular pools, caused by under-
regulation of the MDH-II enzyme within the mitochondrion, which results in a bottleneck. By 
over-expressing MDH-II in CHO cultures, Chong and colleagues were able to achieve a 3-fold 
increase in intracellular ATP and NADH levels, a 1.9-fold increase in integral viable cell density, 
a 1.2-fold increase in protein titer, and a 40% reduction in malate and lactate secretions by the 
cells (Chong et al., 2010a). 
While the approach for selection of an enzyme target by Chong et al., is a heuristic one, the 
selection of gene-targets for over-expression can also be achieved more systematically, as 
demonstrated by Schaub and colleagues, where metabolomic and transcriptomic data were 
correlated from high-producing batches to identify 247 deregulated genes linked to culture 
productivity (Schaub et al., 2012). 
2.6.4 Quenching & Extraction 
2.6.4.1 Metabolites 
Metabolomic fingerprinting of the endometabolome possesses numerous challenges to ensure 
consistency and reliability of results. A significant concern for intracellular profiling is the issue 




During sampling, active enzymes in cells will deplete certain intracellular pools, and expand 
others, before removal of supernatant, rinsing, and conventional cell-lysing procedures can be 
enacted. This will result in skewed intracellular profiles with respect to the extracellular 
metabolites quantified from the supernatant at the matching time-point. In order to successfully 
extract intracellular metabolites, it is necessary to introduce a “quenching” procedure to denature 
these enzymes and protect intracellular metabolite pools.  
Several options have been put forward for combinations of chemical and/or heat treatments 
to achieve this goal of reliable intracellular sampling. The two most popular options for 
mammalian cell culture quenching methods are those proposed by Sellick and colleagues, and 
Dietmair and colleagues (Dietmair et al., 2010; Sellick et al., 2009). In the former, the quenching 
protocol utilizes a 60% methanol solution buffered with ammonium bicarbonate (Sellick et al., 
2009); however, a drawback of this method is that some cell-leakage is induced from prolonged 
exposure to the methanol in the solution. Indeed, 100% methanol is their proposed cell-lysing 
and extraction agent (Sellick et al., 2010). The researchers suggest that this can be mitigated by 
procedural efficiency (i.e. working faster). Dietmair and colleagues proposed an alternative 
quenching procedure, claiming less cell leakage, using cold 0.9% w/v NaCl saline solution 
(Dietmair et al., 2010). Sellick and colleagues responded reporting a direct comparison of the 
two methods, suggesting that despite cell-leakage, the actual quenching and denaturing of 
enzymes was better with their approach, citing increases in malate when profiling TCA 
intermediates from saline-quenched cells were due to enzymes remaining active (Sellick et al., 
2011b). One clear advantage between the two procedures is that a methanol solution can be kept 
at far lower temperatures (-40°C) compared to a saline solution (~4°C), which better halts any 




preserve the intracellular metabolite pools of nucleotide sugars, the precursors for glycosylation 
(Braasch et al., 2015). Regarding subsequent metabolite extraction, similarly with quenching, a 
diverse series of procedures have been proposed by the same authors (Dietmair et al., 2010; 
Sellick et al., 2010). To remove the extraction solution, researchers typically apply some 
variation of lyophilisation treatment or evaporation on ice in a nitrogen atmosphere to capture 
aqueous metabolites.  
Of significant concern regarding metabolomics research is a lack of standardized accepted 
practices, particularly with regards to quenching and extraction procedures, though acetonitrile-
based extraction protocols have been demonstrated to be the most reliable of late (Lu et al., 
2017). Several groups have previously employed variations of the procedures discussed in this 
section, some eschewing any quench at all (Aranibar et al., 2011; Goudar et al., 2010), opting 
instead to utilize flux modeling (Schaub et al., 2012), or selecting another omics methods for 
providing an intracellular perspective (demonstrated in Chapter 3).  
2.6.4.2 Proteins 
Unlike the metabolome, or transcriptome, the proteome doesn’t suffer unduly from labile 
species, and halting the processes of enzymes is sufficient to preserve a sample for analysis. As 
such, cells can be centrifuged and pelleted, while a cell lysis and extraction protocol detailed in 





Chapter 3 An omics approach to rational feed: Enhancing 





Expression of recombinant proteins exerts stress on cell culture systems, affecting the 
expression of endogenous proteins, and contributing to the depletion of nutrients and 
accumulation of waste metabolites. In this work, 2D-DIGE proteomics was employed to analyze 
differential expression of proteins following stable transfection of a Chinese Hamster Ovary 
(CHO) cell line to constitutively express a heavy-chain monoclonal antibody. Thirty-four 
proteins of significant differential expression were identified and cross-referenced with cellular 
functions and metabolic pathways to identify points of cell stress. Subsequently, 1D-
1
H-NMR 
metabolomics experiments analyzed cultures to observe nutrient depletion and waste metabolite 
accumulations to further examine these cell stresses and pathways. From among fifty metabolites 
tracked in time-course, eight were observed to be completely depleted from the production 
media, including: glucose, glutamine, proline, serine, cystine, asparagine, choline, and 
hypoxanthine, while twenty-three excreted metabolites were also observed to accumulate. The 
differentially expressed proteins, as well as the nutrient depletion and accumulation of these 
metabolites corresponded with upregulated pathways and cell systems related to anaplerotic 
TCA-replenishment, NADH/NADPH replenishment, tetrahydrofolate cycle C1 cofactor 
conversions, limitations to lipid synthesis, and redox modulation. A nutrient cocktail was 
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assembled to improve the growth medium and alleviate these cell stresses to achieve a ~75% 
improvement to peak cell densities. 
Keywords: CHO cells; 2D-DIGE; Proteomics; NMR; Metabolomics 
 
3.2 Introduction 
The majority of recombinant therapeutic glycosylated biologics are produced in Chinese 
Hamster Ovary (CHO) cell lines (Ghaderi et al., 2012). Expression of these recombinant proteins 
draws energy and resources away from the endogenous cellular systems and infrastructure. 
Strategies to mitigate these stresses and maximize cell growth and productivity include 
optimization of growth medium and nutrient feeding (D. Y. Kim et al., 2012; Kim et al., 2005; 
Kim and Lee, 2009; Lee et al., 1999; Ma et al., 2009; Sellick et al., 2011a; Xing et al., 2011).  
Growth medium, while historically relying on ‘complex’ components with somewhat 
unknown content such as serum and hydrolysates, has trended towards ‘fully chemically defined’ 
formulations. Switching to fully chemically defined growth medium (CDM) was motivated by 
high component costs, batch-to-batch ingredient variation, and most notably the potential for 
contamination from mycoplasma, prions, and viruses from fetal bovine serum (as reviewed by 
Butler, 2013). Non-animal derived complex components, such as hydrolysates derived from soy, 
wheat, gluten and yeast, while removing many of these concerns, remain ‘black boxes’ for 
process optimization. Approximately 450 commercial ‘off the shelf’ serum-free growth media 
are available on the market for various animal cell types (as reviewed by van der Valk et al., 
2010). However, commercial growth medium can be very expensive at production scale, and for 
any given bioprocess, a host of factors including but not limited to: the choice of cell-line and 




expressed, and production scale will impact cellular metabolism and how successful an ‘off the 
shelf’ growth medium will be, necessitating some level of tailored optimization.  
Process and growth medium optimization can often be accomplished empirically in a ‘blind’ 
manner with multivariate methods, or by attempting to utilize simulation. However, omics 
methods such as proteomics and metabolomics provide an exciting opportunity to look under-
the-hood of a bioprocess and make real determinations of cell stresses and system limitations for 
cells expressing recombinant proteins. 
Omics methods have been well utilized to enhance culture growth by investigating a broad 
spectrum of nutrients and excreted metabolites through classical analytical chemistry methods, 
including liquid chromatography mass spectrometry (LC-MS) (Chong et al., 2009, 2010b; Ma et 
al., 2009; Selvarasu et al., 2012) and/or gas chromatography mass spectrometry (GC-MS) 
(Dietmair et al., 2012; Ma et al., 2009; Schaub et al., 2012; Sellick et al., 2011a) as well as 
NMR-based methods (Aranibar et al., 2011; Bradley et al., 2010; Carinhas et al., 2013; Goudar 
et al., 2010; Read et al., 2013; Sokolenko et al., 2014). NMR possesses several advantages such 
as ease of sampling, which is rapid and non-destructive (as reviewed by Sokolenko et al., 2014). 
Further, NMR is useful for detecting volatile organic acid metabolites, which are not observable 
by some conventional HPLC and MS methods, and have only recently been reported in CHO 
cells by metabolomics researchers employing NMR (Aranibar et al., 2011; Bradley et al., 2010; 
Carinhas et al., 2013; Sokolenko et al., 2014). 
In this work, a proteomics analysis by two dimensional in-gel electrophoresis (2D-DIGE) 
was conducted between a parental CHO cell line and a stably transfected derivative cell line 
expressing a single-domain chimeric heavy chain camelid-derived antibody (EG2-hFc) (Agrawal 




metabolomics analysis of cell culture supernatant from cells stably producing EG2-hFc grown in 
CDM, by targeted profiling of 1D-
1
H-NMR spectra, was conducted to measure depleted 
nutrients and the accumulation of excreted metabolites. Together, these omics methods were 
utilized to evaluate the system stresses of the CHO cells and to tailor production growth medium 
to maximize the cell growth of the cultures. The production growth medium was supplemented 
with nutrients corresponding to four reported metabolic systems in CHO cells that were up-
regulated after gaining the ability to produce EG2-hFc. These pathways related to anaplerotic 
TCA-replenishment, NADH/NADPH replenishment, tetrahydrofolate cycle C1 cofactor 
conversions, limitations to lipid synthesis, and redox modulation.  
3.3 Materials & Methods 
3.3.1 Cell Line 
DXB11-derived CHO
BRI
-1A7 cells, negative for dihydrofolate reductase (DHFR-), were 
transfected with pTT44-EG2hFc1 to stably express the 80 kDa single-domain chimeric heavy-
chain monoclonal antibody EG2-hFc (Agrawal et al., 2012). Briefly, EG2-hFc cDNA was cloned 
into pTT44, a modified pTT5 vector (Durocher et al., 2002) containing a puromycin expression 
cassette, under the control of a cytomegalovirus (CMV) promoter. The parental strain of CHO
BRI
 
cells was transfected with the linearized construct pTT44-EG2hFc1 using PEImax in 2 ml of CD 
DG44 media (Invitrogen, ON, Canada), and puromycin selection was applied (10 µg/ml) until 
the pool of resistant transfectants finally reached ~80+% viability. Single cell dilution in 96-well 






3.3.2 2D-DIGE Proteomics Experiments 
3.3.2.1 Cell Culture 
Culture supernatant samples from parental CHO
BRI
 cells and the newly established 
CHO
BRI
-1A7 cell line that constitutively produces EG2-hFc were harvested after 8 days of batch 
cultivation. Six parallel cultures were carried out in 250 mL polycarbonate shaker flasks 
(Corning, NY, USA) for both cell lines with PowerCHO-2CD growth medium (Lonza, NY, 
USA). The shaker flasks, each containing 60 mL, were grown at 37°C with 5% CO2, with an 
agitation speed of 120 rpm for eight days. Both cell lines and their replicates were grown under 
the same culture conditions. On day 8, culture supernatant samples were harvested and filtered 
via 0.45 µm membrane. Cell pellets were collected and kept frozen until analysis. 
3.3.2.2 Cell Lysis & Protein Extraction 
Approximately 2x10
7
 cells were harvested from cultures after 8 days of batch cultivation and 
pelleted at 1000 rpm (~250 rcf) for 5 minutes and stored at -80°C. Cell pellets were subsequently 
resuspended and washed three times with sterile ice cold 1X PBS solution. Following washing, 
cell pellets were resuspended in 500 µL of lysis buffer at 4°C, containing 7M urea, 2M thiourea, 
50mM Tris pH 8.0, and 4% CHAPS (Fisher, ON, Canada). The lysis buffer also included 15µL 
protease inhibitor cocktail (Sigma, ON, Canada). The cells in lysis buffer were subsequently 
vortexed and sonicated twice for 30 seconds using a Microson Ultrasonic Cell Disruptor 
(Misonix, NY, USA) at a power level of 4 at 4°C. Following sonication, the samples were 
incubated on a rotator at 4°C for 3.5 hours to ensure complete lysis. The samples were then 
centrifuged for 30 minutes at 14,000 rpm (22000 rcf) at 4°C to remove insoluble cell debris. 
Supernatant was recovered and any further interfering substances were removed via an 




determined using a Bio-Rad protein assay (Bio-Rad Laboratoris Ltd., ON, Canada) with bovine 
serum albumin (BSA) (Sigma, ON, Canada) utilized as the standard. Protein samples and BSA 
standards were measured in triplicate at an absorbance of 595 nm with a Varian Cary 50 Bio 
UV-Vis Spectrophotometer (Varian, QC, Canada). 
3.3.2.3 2D Differential In-Gel Electrophoresis (2D-DIGE) 
Six biological replicate gels were prepared for comparative proteomic analysis between 
CHO
BRI
-1A7 and parental CHO
BRI





 sample replicate. A dye swap procedure was employed, where gels 1-3 used a Cy5 
label for CHO
BRI
 and a Cy3 label for CHO
BRI
-1A7, and gels 4-6 reversed the Cy3 and Cy5 
labels; CyDye DIGE Fluor minimal dye (GE Healthcare, Uppsala, Sweden). 50 µg of each 
protein sample was labeled with 1µL of 200 pmol/µL CyDye DIGE Fluor minimal dye. 
Following incubation with 10 mM lysine stop solution, samples were combined with rehydration 
buffer containing 7M urea, 2M thiourea, 4% CHAPS, and 20 mM dithiothreitol (DTT) (Fisher, 
ON, Canada), and 0.5% immobilized pH gradient buffer ampholytes (GE Healthcare, Uppsala, 
Sweden). Protein samples in rehydration buffer were applied to Immobiline Drystrips, pH 3-
10NL; 24 cm immobilized pH gradient (IPG) gel strips (GE Healthcare, Uppsala, Sweden) with 
a total volume of 450 µL per strip and incubated overnight.  
Isoelectric focusing (IEF) for first-dimension separation was performed using an Ettan 
IPGphor II system (GE Healthcare, Uppsala, Sweden) at 20
o
C for 24 hours with the following 
voltage program: 100V (1 h), step increase to 500V (2 h), gradient to 1000V (2 h), gradient to 
3000V (3 h), gradient to 8000V (3 h), hold at 8000V (10 h), hold at 500 V prior to second 
dimension separation (~ 3 h). Following completion of IEF, the strips were reduced in 10 mL of 




Canada), and 2% SDS (BioShop Canada Inc., ON, Canada) with 1% w/v DTT (Fisher, ON, 
Canada) for 15 minutes. This was followed by alkylation in 10mL equilibration buffer with 2.5% 
w/v iodoacetamide (IAA) (Sigma, ON, Canada) for 15 minutes. 
The second dimension separation was run on large format 12% SDS-PAGE gels using a 
DALTsix Electrophoresis unit (GE Healthcare, Uppsala, Sweden). IPG strips were placed on top 
of each of six gels with an agarose sealing solution containing 25mM Tris base, 192mM glycine 
(Fisher, ON, Canada), 0.1% SDS, 0.5% agarose (BioShop Canada Inc., ON, Canada), and 
0.002% (w/v) bromophenol blue (Fisher, ON, Canada). The six gel plate sandwiches were placed 
into the cassette carrier. and the electrophoresis unit was filled with 4.5 L of 1X running buffer 
containing 25mM Tris base, 192mM glycine (Fisher, ON, Canada), and 0.1% SDS (BioShop 
Canada Inc., ON, Canada), cooled to 10°C using a MultiTemp III Thermostatic Circulator (GE 
Healthcare, Uppsala, Sweden). The upper buffer chamber was filled with 2X running buffer 
containing 50 mM Tris base, 384mM glycine (Fisher, ON, Canada), and 0.2% (w/v) SDS 
(BioShop Canada Inc., ON, Canada). Electrophoresis was carried out at 1 watt/gel for 30 minutes 
followed by an increase to 18 watts/gel until the dye front reached the bottom of the gel. 
3.3.2.4 Gel Scanning & Analysis 
2D-DIGE gels were scanned under fluorescence acquisition mode using a Typhoon 9400 
scanner (GE Healthcare, Uppsala, Sweden). All the resulting gel images were cropped to the 
same size using PDQuest Advanced 2D Analysis Software v8.0.1 (Bio-Rad Laboratories LTD, 
ON, Canada) and then uploaded into DeCyder v7.0 software (GE Healthcare, Uppsala, Sweden). 
The gel images were first processed in the DeCyder Differential In-Gel Analysis (DIA) module 
by detecting the number of spots per gel image. Gel-to-gel matching was then performed by 




(BVA) module. Only spots that matched across all six replicate gels were considered. In parallel 
with the DIGE labelled gels, matching preparative gels containing approximately 800 µg of 
protein were separated by 2D-SDS-PAGE. Gels were fixed with 50% methanol/10% acetic acid 
for 10 minutes and stained overnight with GelCode® Blue Stain Reagent (Thermo Scientific, 
ON, Canada), followed by destaining for 5 hours in ultrapure water. 
Differences in protein abundance were assessed based on the intensity ratios of the paired 
samples and normalized to remove any dye-bias. Relative spot intensity levels were extracted 
from DeCyder v7.0 and imported into the software package R v2.12.0 for statistical analysis. 
Once adjusted and log-transformed, the relative spot intensity levels were subjected to a paired t-
test and an initial list of p-values was produced. This list was subjected to a False Discovery Rate 
(FDR) test (Benjamini and Hochberg, 1995), where proteins were considered differentially 
expressed based on a p-value cut-off corresponding to a calculated FDR of 10%. Differential 
expression data is shown as fold change, with positive values representing an increase in 
abundance and negative values representing a decrease relative to controls. If more than one spot 
shared a common protein identification (e.g. where multiple isoforms were present), fold change 
results for the most abundant differentially expressed isoform are reported.  
3.3.2.5 Protein Identification by Mass Spectrometry 





-1A7 were excised from coomassie-stained preparative gels using an EXQuest Spot 
Cutter (Bio-Rad Laboratories LTD, ON, Canada). Excised spots were subjected to in-gel tryptic 
digestion followed by LC-MS/MS analysis. The gel pieces were washed twice with 50 mM 
ammonium bicarbonate (NH4HCO3) and destained with 50% acetonitrile (ACN)/25 mM 






by alkylation with 100 mM IAA for 15 minutes in the dark at room temperature. Protein 
digestion was carried out with the addition of 13 ng/µL sequencing grade modified trypsin 
(Promega Corporation, Madison, Wisconsin) in 50 mM NH4HCO3 and incubated overnight at 
37
o
C. The peptides were extracted with 5% formic acid and 100% ACN, evaporated to dryness 
then reconstituted in 5 µL of 0.1% formic acid. The digested peptides were sent to the Hospital 
for Sick Children Mass Spectrometry Facility (ON, Canada) for mass spectrometry (LC-MS/MS) 
analysis. The samples were loaded onto a 150µm ID Magic C18 pre-column (Michrom 
Biosciences, CA, USA) at 4 µl/min and separated over a 75 µm ID analytical column. Using an 
EASY n-LC nano-chromatography pump (Proxeon Biosystems, Odense, Denmark), the peptides 
were eluted over 60 minutes at 300 nL/min in a 0 to 40% acetonitrile gradient in 0.1% formic 
acid (Fisher, ON, Canada). The peptides were eluted into a LTQ linear ion trap mass 
spectrometer (Thermo-Fisher, CA, USA) operated in a data dependent mode. Six MS/MS scans 
were obtained per MS cycle. 
3.3.2.6 Database Protein Identification 
Protein identification was performed using PEAKS Studio v5.3 (Bioinformatics Solutions 
Inc., ON, Canada), which combines auto de novo sequencing with database searching, and the 
results of two search engines: PEAKS DB and X!Tandem. All mass spectra were searched 
against the CHO protein database (Xu et al., 2011). Search results were evaluated on a 
percentage score system, and FDR was also applied and estimated with decoy sequences. Protein 
identification was considered successful when the protein score was ≥ 90% with ≥ 2 unique 
peptides and an FDR below 1%. Additionally, at least 2 unique peptides also needed to be 
identified in the X!Tandem search engine. For some samples, there was more than one confident 




compared with their relative spot locations on the gel to manually confirm and/or reject their 
identification. 
The resulting gene list of differentially expressed proteins was searched against DAVID 
(database for annotation, visualization, and integrated discovery (Huang et al., 2009a, 2009b). 
The Functional Annotation Clustering tool found within DAVID was used to cluster enriched 
related terms for identifying related functions and pathways.  
3.3.3 NMR Metabolomics Experiments 
3.3.3.1 Cell Culture 
Flask experiments were conducted in 125 mL polycarbonate shaker flasks (Corning Inc.), 
while bioreactor experiments were conducted in a 3L bioreactor (Applikon Biotechnology Inc., 
CA, USA). All cultures were grown at 37°C, with an agitation speed of 120rpm. Samples were 
stored at −80°C. Cell density measurements were observed for bioreactor experiments with 
trypan-blue exclusion by haemocytometer and by a Coulter Counter Z2 (Beckman-Coulter, FL, 
USA), while flask experiments were counted exclusively via the Coulter Counter. 
3.3.3.2 Growth Medium & Supplemented Nutrients 
Cells were grown in serum-free BioGro-CHO (BioGro Technologies Inc., MB, Canada). 
Unless noted otherwise, all chemicals were purchased from Sigma-Aldrich (MT, USA). L-
asparagine (Asn), choline chloride (Chol) (Alfa Aesar, Lancashire, England), L-cysteine (Cys), 
L-proline (Pro) and L-serine (Ser) were prepared as 100mM stock solutions. D-glucose (Glc) 
(Life Technologies, Carlsbad, CA, USA) was prepared as a 1M stock solution. All stock 




glutamine (Gln) and 10mM hypoxanthine (Hyp) with 1.6mM thymidine, HT supplement (Life 
Technologies, CA, USA), were purchased as liquid stock solutions. 
3.3.3.3 Metabolite Profiling 
NMR spectra were acquired with a Bruker Avance 600MHz spectrometer with a TXI 600 
probe. Following acquisition, spectra were imported into Chenomx NMR Suite 7.7 (Chenomx 
Inc., AB, Canada) and manually profiled (Sokolenko et al., 2014). All compounds were 
quantified with the software’s built-in 600MHz compound library, with the exception of 
GlutaMAX™, which was added using the Chenomx NMR Suite 7.7’s ‘compound builder’ tool. 
Ammonia measurements were taken using an Orion Star™ Plus ISE Meter (Thermo-Fisher, CA, 
USA). 
3.4 Results 
A combined omics approach was utilized to analyze the system stresses to CHO cells 
transfected to express a recombinant monoclonal antibody. A comparative proteomic analysis 
conducted between the EG2-hFc expressing CHO
BRI
-1A7 cells and the non-producing parental 
strain CHO
BRI
 was conducted by 2D-DIGE (Figure 15), and a total of 34 proteins of significant 
differential expression were identified (Table 4). The cellular functions and metabolic pathways 
affected by recombinant protein expression of EG2-hFc were identified (Table 5).  
Subsequently, a 1D-
1
H-NMR metabolomics analysis was conducted on CHO
BRI
-1A7 cultures 
and monitored for depleted nutrients and accumulated waste metabolites. Considering these 
metabolic trends and examining the differentially regulated metabolic enzymes of Table 4, four 
cellular metabolic systems were considered for potential impact to cell growth, including: 




(Figure 17), and limitations to lipid synthesis (Figure 18), and redox modulation. A nutrient 
cocktail was assembled based on the metabolic systems under stress (Table 6) and supplemented 
to the production growth medium (Figure 19), yielding a ~75% increase in maximum cell 
density of cultures (Figure 20).  
3.4.1 2D DIGE Proteomics Analysis 
2D-DIGE gels were scanned and the relative quantities of proteins were measured by 
fluorescence. The gels were scanned at 580nm and 670nm corresponding to Cy3 and Cy5 
channels respectively. A representative 2D-DIGE gel is shown in Figure 15. All gels showed 
consistent spot separation. Spot-matching was conducted both within gels, and between gels. The 
number of spots detected was similar across all gels, with a mean of 1840 ± 35 spots. Of these, 
912 protein spots were matched across all gels, and a total of 86 spots exhibited significant 
changes in abundance. These spots were excised and identified by LC-MS/MS. From among 
these 86 selected spots, 34 unique protein IDs were obtained (Table 4). The identified proteins 






Figure 15 – Representative monochrome image of a 2D-DIGE Gel. CHOBRI-1 labeled with Cy5 and CHOBRI-1A7-1 
labeled with Cy3.  
Proteins were separated initially in the first dimension (x-axis) on a non-linear gradient pH 3-10 then separated in the 
second dimension (y-axis) on a 12% polyacrylamide gel. Green and red fluorescence were measured independently (532 
nm for Cy3 and 635 nm for Cy5). From among 86 selected spots excised for LC-MS/MS analysis, 34 unique protein IDs 
were obtained (Table 9). 
The proteins identified reflect observations of metabolic changes within the proteome of 
CHO
BRI
-1A7 as compared with that of parental cells. Enzymes involved in various metabolic 
processes shifted including: up-regulation of anaplerotic TCA cycle replenishment (Cs, Ast); 
NADH and NADPH replenishment including tetrahydrofolate conversions (Mthfd11, Aldh, 
Hsd17b10, Dld, Hibadh); lipid synthesis (Cs, Acot2, Gpd2); and energy metabolism (Abcg3, 




transcription, apoptosis, and cellular respiration were also found to be differentially expressed. 
Certain heat shock proteins (Trap1, Grp75) were up-regulated whereas others (Hspd1, 
Hsp90aa1) were down-regulated. ER chaperones (Serpinh1, Grp94, and Pdia6) were 
differentially down-regulated in EG2-hFc producing cells. The up- regulation of Rplp0, a 
component involved in protein biosynthesis, was also observed while the majority of proteins 
(Actb, Vim, Lmnb1, Chp) related to the structural integrity of the cell showed down-regulation. 
Table 4 – Differentially expressed proteins after transfection of CHOBRI cells to stably express EG2-hFc heavy-chain 











Anaplerotic Replenishment & TCA Cycle 
Aconitate hydratase Aco2 5 EGW13953 -1.12 TCA cycle 
Citrate synthase Cs 17 EGW12503 1.99 TCA cycle 
Aspartate aminotransferase Ast 19 EGW01755 1.21 Anaplerotic TCA metabolism 
NADH/NADPH Replenishment & Tetrahydrofolate Conversions 
Methylenetetrahydrofolate dehydrogenase Mthfd11 1 EGV95936 1.09 Tetrahydrofolate (THF) cycle 
Aldehyde dehydrogenase Aldh 12 EGW07431 1.14 
Oxidation of aldehydes to 
carboxylic acids 
3-hydroxyacyl-CoA dehydrogenase type 2 Hsd17b10 30 EGW02330 1.11 
Degradation of branched chain 
alpha-keto amino acids such as 
leucine isoleucine and valine 
Dihydrolipoyl dehydrogenase Dld 13 EGV93120 1.07 
Catabolism of branch chain amino 
acids 
3-hydroxyisobutyrate dehydrogenase Hibadh 26 EGW08863 1.09 Amino acid catabolism 
Lipid Synthesis      
Acyl-coenzyme A thioesterase 2 Acot2 15 EGW01631 1.21 Lipid metabolism 
Procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 3 
Plod3 4 EGW01863 -1.06 
Hydroxylation of lysyl residues in 
collagen-like peptides 
Glycerol-3-phosphate dehydrogenase Gpd2 16 EGW05701 1.32 Lipid metabolism 
Energy Metabolism      
ATP-binding cassette sub-family G, member 
3 
Abcg3 21 EGV92982 1.05 Peptide transporter 
NADH dehydrogenase Ndufv1 14 EGW12368 1.12 Oxidative phosphorylation 
 Ndufs3 29 EGW03953 1.03 Oxidative phosphorylation 
ATP Synthase subunit beta Atp5b 11 EGW12490 -1.12 ATP synthesis 
SPRY domain-containing protein 4 Spryd4 32 EGW12495 -1.20 Uncharacterized 
Apoptosis and Cell Proliferation      
Proliferating cell nuclear antigen Pcna 22 EGV92404 -1.20 















Histone H2A type 1 Hist1h2ab 34 EGV96120 -1.25 
Regulation of transcription, DNA 
repair, DNA replication, and 
chromosomal stability 
DNA-directed RNA polymerase I, II, and III 
subunit RPABC1 
Polr2e 28 EGV99483 1.17 DNA transcription 
Prohibitin Phb 3 EGW01773 1.12 
Regulation of proliferation, inhibits 
DNA synthesis 
Programmed cell death 6 Pdcd6 33 EGW09040 1.44 
Induction of apoptosis by 
extracellular signal 
Chaperones & Protein Synthesis      
Heat shock 75 kDa protein Trap1 8 EGV93626 1.05 Chaperone – protein folding 
Heat shock 70 kDa protein 9 Grp75 7 EGW06687 1.11 Chaperone – protein folding 
Heat shock 60 kDa protein Hspd1 10 EGW00783 -1.06 Chaperone – protein folding 
Heat shock protein HSP 90-alpha Hsp90aa1 20 EGV94858 -1.38 Chaperone – protein folding 
Serpin H1 Serpinh1 18 EGW02226 -1.14 Chaperone – collagen folding 
Endoplasmin GRP94 2 EGW09701 -1.57 
Chaperone – protein processing 
and transport 
60S Acidic Ribosomal protein P0 Rplp0 24 EGV93157 1.20 Protein synthesis 
Protein disulfide-isomerase A6 Pdia6 25 EGW08481 -1.22 Chaperone – protein folding 
Structural Proteins      
Β-Actin Actb 23 EGW06240 -1.25 Cytoskeleton component 
Vimentin Vim 27 EGW02055 -1.46 Intermediate filament, cell integrity 
Lamin B1 Lmnb1 6 EGV92912 -1.7 Nuclear envelope framework 
Lamin A Lmna 9 EGW07066 1.10 Nuclear envelope framework 
Calcium-binding protein p22 Chp 31 EGV97270 -1.18 
Na+/H+ ion pump regulation; 
intracellular pH, cytoskeletal 
organization 
3.4.2 Cell Function Grouping 
The compiled gene list of differentially expressed proteins identified by 2D-DIGE and LC-
MS/MS was subjected to functional annotation analysis in DAVID to uncover enriched 
functionally related gene groups. An enrichment score was determined by a geometric mean of 
all the enrichment p-values of each annotation term in the group followed by a minus log 
transformation applied on the averaged p-values. The enrichment score is a relative score used to 
rank overall importance of annotation term groups. Three clusters of enriched gene ontology 




cell functions of energy generation (i.e. TCA cycle) and biosynthetic resources such as 
NADH/NADPH and redox activity. An expected increase in stresses related to additional protein 
folding and processing from EG2-hFc expression was also observed. 
Table 5 – Functional annotation analysis in DAVID enriched functionally related gene groups, associated with 
differentially expressed proteins. An enrichment score was determined by a geometric mean of all the enrichment p-
values of each annotation term in the group followed by a minus log transformation applied on the averaged p-values. 









NAD 6 1.40E-05 
Generation of precursor metabolites and 
energy 
6 2.40E-04 
Oxidoreductase activity, acting on NADH 
or NADPH 
3 5.90E-03 
Electron transport chain 3 2.50E-02 
2 2.98 
Chaperone 6 7.70E-06 
Unfolded protein binding 5 1.70E-05 
Stress response 4 7.70E-05 
Protein folding 5 1.70E-04 
3 2.39 
Generation of precursor metabolites and 
energy 
6 2.40E-04 
Cellular respiration 3 7.50E-03 
Citrate cycle (TCA cycle) 3 7.80E-03 




3.4.3 1D-1H-NMR Metabolomics Analysis 
A metabolomic analysis by 1D-1H-NMR tracked fifty compounds in time-course for CHO 
cells cultivated in a 3L bioreactor (see supplementary data in Appendix A). Of these, more than 
forty compounds were found to have a significant correlation to time using a Spearman rank 
correlation coefficient at a 95% confidence level. Eight nutrients, shown in Figure 19, were 




Metabolic enzymes identified in Table 4 involving upregulation of anaplerotic TCA cycle 
replenishment (+1.21 fold Cs, +1.99 fold Ast), corresponded with depletions in asparagine, 
proline, glutamine, aspartate and pyruvate, as well as accumulation of ammonia, lactate, citrate, 
and malate in the supernatant (Figure 16). Cellular processes identified in Table 5 for 
replenishing NADH and NADPH paralleled depletions in serine and accumulation of excreted 
glycine and formate via tetrahydrofolate conversions (+1.09 fold Mthfd11) (Figure 17). 
Upregulation of enzymes for lipid metabolism (+1.32 fold Gpd2, +1.21 fold Acot2), 
corresponded with depletions in choline, as well as the accumulation of excreted lipid precursors 






Figure 16 – Anaplerotic TCA and mitochondrial shuttle metabolism, which contribute to replenishing cytosolic acetyl-
CoA, NAD+, and NADPH. 
Enzymes identified: 1) malate dehydrogenase, 2) ATP citrate lyase, 3) lactate dehydrogenase, 4) aspartate 
aminotransferase (+1.21 fold increase), 5) glutamate dehydrogenase, 6) alanine aminotransferase 7) asparaginase 8*i) 
proline oxidase 8*ii) glutamate-5-semialdehyde dehydrogenase, 9) glutaminase, 10) citrate synathase (+1.99 fold increase), 
11) pyruvate carboxylase. Metabolites concentrations are in mM (y-axis) where indicated or relative concentration, and 
reflect quantitation from extracellular supernatant by targeted profiling with NMR over culture time in hours (x-axis). 
Normal culture conditions (solid lines) and nutrient supplemented (dashed lines) at 0 hrs (circle) and at 50 hrs (triangle) 





Figure 17 – Tetrohydrofolate (THF) C1 cofactors replenishing NADPH from serine, while producing glycine and formate, 
by cycling the THF intermediates between different oxidation states.  
Enzymes identified: 1) thymidine kinase, 2) thymidylate synthase, 3) serine hydroxymethyltransferase, 4) N5,N10-
methenyl-THF reductase, 5) N5,N10-methenyl-THF cyclohydrolase, 6) N10-formyl-THF synthase. Reactions 4, 5, and 6 are 
mediated by a single trifunctional enzyme, methylenetetrahydrofolate dehydrogenase. Metabolite concentrations are 
presented as relative concentration or in mM (y-axis) where indicated, and reflect quantitation from extracellular 
supernatant by targeted profiling with NMR over culture time in hours (x-axis). Normal culture conditions (solid lines) 





Figure 18 – Lipid synthesis requires nutrients such as choline and several precursors observed in this work to be excreted, 
including phosphocholine, cytidine, glycerol and ethanol.  
Enzymes listed include: 1*) glycolysis, 2) G3P dehydrogenase (+1.32 fold increase), 3) G3P acyltransferase, 4) DHAP 
acyltransferase, 5) choline kinase, ethanolamine kinase, 6) acyl-DHAP reductase, 7) acyl-G3P acyltransferase, 8) 
phosophocholine cytidyltransferase, phosphoethanolamine cytidyltransferase, 9) PA phosphatase, 10) CDP-DAG 
synthase, 11) DAG acyltransferase, 12) DAG phosophocholine transferase, DAG phosphoethanolamine transferase, 13) 
PG phosphate synthase, and PG phosphate phosphatase, 14) PI Synthase, 15) phosphatidyl serine synthase 1&2 16) 
cardiolipin synthase. Metabolite concentrations are in mM (y-axis) where indicated or shown as relative concentration, 
and reflect quantitation from extracellular supernatant by targeted profiling with NMR over culture time in hours (x-
axis). Normal culture conditions (solid lines) and nutrient supplemented (dashed lines) at 0 hrs (circle) and at 50 hrs 




Table 6 – Nutrients supplemented to production growth 
medium with respect to their approximate initial 
concentrations (% increase). 











A nutrient cocktail was assembled based on the metabolic systems under stress (Table 6) and 
supplemented to the production growth medium (Figure 19), yielding a ~75% increase in 
maximum cell density of cultures (Figure 20). The increase in maximum cell density generally 
matched up well with increases in the productivity of EG2-hFc; however a tendency for 
precipitation of the protein (common to scFv style antibodies, as reviewed by Lee et al., 2013) 
prevented including these results. Even with supplementation, these compounds still became the 
most depleted amongst the growth medium nutrients. However, doubling the supplementation 
concentrations, or dosing multiple times during cultivation yielded no further improvements to 





Figure 19 – Fully depleted nutrients under normal culture conditions (solid lines) and following additional 
supplementation (dashed lines) at 0 hrs (circle) and at 50 hrs (triangle) as per Table 6. 
 
Figure 20 – Culture growth profile of CHOBRI-1A7 cells in bioreactor and flask-scale cultivations.  
Control conditions (solid lines, closed points) nutrient supplementation (dashed lines, open points). Data-point shapes 





3.5.1 Omics Methods as Tools for Rational Feed Design 
A proteomics analysis by two dimensional in-gel electrophoresis (2D-DIGE) was conducted 
between a parental CHO cell line and a progeny cell line stably expressing a single domain 
chimeric camelid heavy-chain antibody, to measure differential expression of endogenous 
cellular proteins. Subsequently, a metabolomic analysis of the supernatant of the progeny cells 
by targeted profiling of 1D-
1
H-NMR spectra, was conducted to measure depleted nutrients and 
the accumulation of excreted metabolites. Together, these omics methods were utilized to 
evaluate the system stresses of the CHO cells to rationalize a tailored production growth medium 
that increased cell growth, and production of EG2-hFc. The production growth medium was 
supplemented with nutrients corresponding to four identified metabolic systems for the CHO
BRI
-
1A7 cells with up-regulated pathways. These pathways included anaplerotic TCA-replenishment, 
NADH/NADPH replenishment, tetrahydrofolate cycle C1 cofactor conversions, limitations to 
lipid synthesis, and redox modulation. Nutrient depletion corresponding to these pathways has 
also been reported by other metabolomics researchers observing CHO cell cultures and 
discussion of these results is included for global context of reproducibility across CHO 
platforms, as well as potential future targets for metabolic engineering. 
3.5.2 Anaplerotic TCA Metabolism Limitations 
The metabolism of continuous mammalian cell lines such as CHO, as well as various 
cancerous cells, is shifted away from normal cellular respiration towards fermentative pathways 
producing lactate, termed the Warburg effect (Warburg, 1956). Glycolysis is favoured over 
oxidative phosphorylation, even under aerobic conditions, achieving more rapid growth rates (as 




of TCA intermediates, such as malate and citrate, was due to a “truncated TCA cycle”, which has 
been observed in several CHO cultures (Chong et al., 2010a; Dietmair et al., 2012; Ma et al., 
2009; Schaub et al., 2012; Sellick et al., 2011a; Selvarasu et al., 2012), and also reported here in 
Figure 16. The major characteristic of this truncation (Figure 16) is that citrate is transported out 
of mitochondria and catabolized to replenish cytosolic acetyl-CoA, a crucial pool affecting cell 
growth (Blondeel et al., 2015), by the action of ATP citrate lyase (Ma et al., 2009). Citrate 
reverts to oxaloacetate, and subsequently to malate by cytosolic malate dehydrogenase I (as 
reviewed by Chong et al., 2010a). 
The efflux of citrate from mitochondria is hypothesized to drive anaplerotic pathways 
depleting amino-acids, such as asparagine and aspartate to replenish TCA intermediates 
(Dietmair et al., 2012; D. Y. Kim et al., 2012; Ma et al., 2009; Schaub et al., 2012; Sellick et al., 
2011a) and similarly leveraged in feeding strategies (Sellick et al., 2011a) for achieving higher 
levels of growth and productivity. The consumption of asparagine is typically accompanied by 
depletion of aspartate as both are linked by a transaminase pathway (Figure 16, Pathway 7) and 
diverted toward cytosolic oxaloacetate (as reviewed by Ma et al., 2009). Depletion of both 
aspartate and asparagine was observed in this work (Figure 16) and this pathway was further 
observed to be upregulated in CHO
BRI
-1A7 (e.g. +1.21 fold Ast) (Table 5). Goudar et al., 
reported a considerable anaplerotic flux of aspartate accounting for 47% of total anaplerotic flux 
into the TCA cycle for CHO cultures grown in perfusion mode (Goudar et al., 2010). This 
metabolism can be recognized by the accumulation of excreted malate produced from cytosolic 
malate dehydrogenase (as reviewed by Chong et al., 2010a), and shown in (Figure 16). In this 





The enzymes and transport-proteins of anaplerotic pathways also allow for redox balancing 
of NAD
+
 between the mitochondrion and the cytosol (mitochondrial shuttles) and have been 
identified as important targets for enhancing productivity, particularly with regards to shifting 
lactate metabolism from production to consumption (Chong et al., 2010a; Martínez et al., 2013; 
Zagari et al., 2013a, 2013b).  
Mitochondrial shuttles and anaplerotic pathways also share an interesting benefit beyond 
regenerating cytosolic acetyl-CoA, helping boost cytosolic NADPH pools (Figure 16). NADPH 
is an essential reducing agent in most biosynthesis pathways, particularly lipid synthesis (Figure 
18). The major regeneration of NADPH comes from the pentose-phosphate pathway (PPP), 
generating two NADPH for every glucose unit. Goudar et al. reported that as much as 41% of 
CHO glycolytic metabolism passes through the PPP (Goudar et al., 2010).. While the recent 
focus of much research regarding anaplerotic TCA-replenishing metabolism has been towards 
citrate and malate, it may indeed be the regeneration of NADPH as shown in Figure 16 for 
pathways 4, 5, 6, and as well as the catabolism of proline (Pathway 8) observed in this work, that 
have the larger impact on sustaining cell growth and viability near the exhaustion of glucose at 
the end of exponential phase.  
High levels of alanine observed in this work were initially attributed primarily to the L-
alanine-L-glutamine dipeptide GlutaMAX™ present in the culture medium (employed as a stable 
glutamine source). However, while GlutaMAX™ is exhausted in the cultures near 72hrs, alanine 
continues to accumulate until shifting towards uptake after 96hrs (Figure 16). This shift towards 
alanine consumption has similarly been reported in other GS-CHO cultures (Carinhas et al., 
2013; Ma et al., 2009) and corresponds with the rapid-uptake and exhaustion of pyruvate. 




Pathway 6). However, it is interesting that the cells are electing to use alanine rather than lactate 
to accomplish this result. It may be the case that elevated levels of alanine from GlutaMAX™ 
are a factor in preventing the shift from production to consumption of lactate. Another potential 
source for the accumulation of alanine may be tryptophan, the depletion of which increased 
significantly following supplementation. Tryptophan is nearly fully depleted (refer to 
supplementary data in Appendix A), and is catabolized to alanine in order to generate 
quinolinate, a precursor in the synthesis of NADH and NADPH. 
Regarding pyruvate, while this metabolite was observed to be fully exhausted in cultures, and 
has been reported by Sellick et al. (2011), as a successful component of a rational feed to support 
cultures transitioning from exponential to stationary phase, it was not examined as a potential 
additive for supplementation, as it was assumed that additional glucose provided as part of the 
supplemented compounds would similarly provide additional pyruvate for later uptake by the 
cells, which was clearly observed (Figure 16). 
3.5.3 Tetrahydrofolate Conversions and NADPH Regeneration 
DXB11-derived CHO cells, such as CHO
BRI
 lack the enzyme dihydrofolate reductase 
(DHFR-) to make tetrahydrofolate (THF) and its associated C1 cofactors; these CHO cells are 
“triple auxotrophs” requiring supplementation of glycine, hypoxanthine, and thymidine (GHT) in 
their medium (Urlaub and Chasin, 1980). Hypoxanthine was therefore considered an early 
candidate for further supplementation upon observing its depletion in control cultures during 
mid-exponential phase (Figure 19). While conferring little improvement on its own, its absence 
diminished the improvements of supplementing the other seven nutrients, corresponding with the 





Serine is also a major precursor to tetrahydrofolate cofactors for the synthesis of purines and 
pyrimidines (as reviewed by Snell et al., 1987), and has been reported by Lee et al. (1999), as a 
potential growth-limiting nutrient for DHFR- CHO cultures grown in the absence of 
methotrexate, consistent with the culture conditions and results of this work. The enzyme 
forming tetrahydrofolate, serine hydroxymethyltransferase, consumes serine and produces 
glycine (Snell et al., 1987), and glycine was observed to accumulate consistently in all cultures 
(Figure 17). 
The metabolic circuit for C1 tetrohydrofolate cofactors, shown in Figure 17, is mediated by a 
single trifunctional enzyme observed to be upregulated in CHO
BRI
-1A7 cells (+1.09 fold 
Mthfd11) (Table 4). Alongside the depletion in serine, and the excreted accumulation of glycine 
and formate, it becomes apparent that the CHO cultures are cycling this pathway as a means of 
replenishing cytosolic NADPH (Figure 17). As first reported by Bradley et al. (2010), the 
accumulation of excreted volatile organic acid metabolites such as formate and acetate are not 
observable by some conventional HPLC and MS methods, and have only recently been reported 
for CHO cultures by metabolomics researchers employing NMR (Aranibar et al., 2011; Bradley 
et al., 2010; Carinhas et al., 2013; Sokolenko et al., 2014). Therefore, the THF circuit shown in 
Figure 17 may present a new potential target of metabolic engineering to improve culture growth 
by better sustaining intracellular NADPH pools. 
3.5.4 Limitations to Lipid Synthesis 
Choline, a necessary B-complex vitamin in the synthesis of certain lipids, has been observed 
as a potentially growth limiting for CHO IgG producing cultures (Aranibar et al., 2011; Carinhas 
et al., 2013; Kim et al., 2005). Choline, along with the accumulating metabolites glycerol, 




glycerophospholipids, specifically phosphatidylcholine (PC), as shown in Figure 18. Excretion 
of glycerol observed here and reported for other CHO cultures (Aranibar et al., 2011; Carinhas et 
al., 2013; Luo et al., 2012; Sellick et al., 2011a), as well as phosphocholine (Carinhas et al., 
2013) were typically observed to accumulate more rapidly in cultures after 72hrs, corresponding 
to exhaustion of choline. Glycerol-3-phosphate dehydrogenase, in the pathway to produce PC, 
was observed to be upregulated in CHO
BRI
-1A7 cells (+1.32 fold Gpd2) (Figure 18, Pathway 2).  
A review of glycerophospholipid synthesis by Hermansson et al., 2011, identified the 
formation of intracellular CDP-choline by phosphocholine cytidyltransferase (Figure 18, 
Pathway 8) as a potentially rate-limiting step in the production of phosphatidylcholine. Luo et al. 
(2012), have reported that the accumulation of glycerol and 2-hydroxybutyrate is linked with low 
copper containing cultures that are high-lactate producing, and do not shift to lactate 
consumption in later culture phases, matching the lactate profile reported in this work. 
3.5.5 Redox Modulation 
Cystine and proline depletion impact the modulation of intracellular redox potential, as well 
as glutathione pools. Cysteine and its oxidized cohort cystine are essential substrates for the 
synthesis of glutathione, an intracellular tripeptide for regulating cellular redox potential, 
eliminating reactive oxygen species (ROS), and regulating intracellular thiol-disulfide protein 
confirmations (as reviewed by Wallace, 2012). Cystine has been reported in CHO cultures as 
potentially growth-limiting (D. Y. Kim et al., 2012; Kim et al., 2005; Read et al., 2013), and 
intracellular metabolomics analysis of IgG producing CHO cells has observed that higher 
producing cultures typically possess larger pools of glutathione (Chong et al., 2012). Glutathione 




NADPH following the loss of the pentose-phosphate-pathway metabolism, negatively impact 
glutathione pools and the cell’s capacity to regulate ROS (Chong et al., 2012). 
Uptake of cystine can be inhibited in cultures by elevated levels of glutamate (another 
glutathione substrate) affecting the x
-
c transport system (Broadhurst and Butler, 2000). In this 
work, glutamate was observed to accumulate in both control and supplemented cultures, despite 
being a nutrient in the growth medium (refer to supplementary data in Appendix A). 
Kyriakopoulos et al., 2013, determined that the X
-
AG system works cooperatively with the x
-
c 
system excreting glutamate for the uptake of cystine.  
While cystine is commonly reported as growth limiting, proline (also observed in this work 
to be depleted) is more typically reported as either having its intracellular pool accumulate over 
culture when taken up (Kyriakopoulos et al., 2013; Sellick et al., 2011a), or being an excreted 
metabolite (Ahn and Antoniewicz, 2012; Goudar et al., 2010). Krishnan et al., 2008, reported 
proline to be a modulator of intracellular redox states of cells by preserving the intracellular 
glutathione pool. As reviewed by Kim et al., 2012, and shown in Figure 16, proline can be 
converted to intracellular glutamate to regenerate two NADPH units, and has been examined as 
an alternative to glutamine to reduce ammonia in cultures.  
3.6 Conclusions 
A 2D-DIGE proteomics analysis between a parental CHO cell line and progeny stably 
producing a recombinant antibody to measure differential expression of endogenous cellular 
proteins, together with a metabolomics analysis of the supernatant of the progeny by targeted 
profiling of 1D-1H-NMR spectra, demonstrated cell stresses via upregulated metabolism, 




utilized to rationalize a tailored production growth medium that enhanced cell growth. The 
production growth medium was supplemented with eight target nutrients corresponding with 
four identified metabolic systems for CHO cells with upregulated pathways related to anaplerotic 
TCA-replenishment, NADH/NADPH replenishment, tetrahydrofolate cycle C1 cofactor 
conversions, limitations to lipid synthesis, as well as redox modulation. The supplementation 
resulted in a ~75% improvement to peak cell densities demonstrating the potential of these 





Chapter 4 Tuning a MAb glycan profile in cell culture: 
Supplementing N-acetylglucosamine to favour G0 





Glycosylation is a critical quality attribute of many therapeutic proteins, particularly 
monoclonal antibodies (MAbs). Nucleotide-sugar precursors supplemented to growth medium to 
affect the substrate supply chain of glycosylation has yielded promising but varied results for 
affecting glycosylation. Glucosamine (GlcN), a precursor for N-acetylglucosamine (GlcNAc), is 
a major component of mammalian glycans. The supplementation of GlcN to CHO cells stably-
expressing a chimeric heavy-chain monoclonal antibody, EG2-hFc, reduces the complexity of 
glycans to favour G0 glycoforms, while also negatively impacting cell growth. Although several 
researchers have examined the supplementation of glucosamine, no clear explanation of its 
impact on cell growth has been forthcoming. In this work, the glucosamine metabolism is 
examined. We identified the acetylation of GlcN to produce GlcNAc to be the most likely cause 
for the negative impact on growth due to the depletion of intracellular acetyl-CoA pools in the 
cytosol. By supplementing GlcNAc in lieu of GlcN to CHO cells producing EG2-hFc we achieve 
the same shift in glycan complexity with marginal impacts on the cell growth and protein 
production. 
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Glycoprotein biotherapeutics such as monoclonal antibodies (MAbs) require sophisticated 
cellular processing in order to become biologically active (Dordal et al., 1985; Nose and Wigzell, 
1983). As such, MAbs and other biologics have conventionally been manufactured through 
culturing higher-eukaryote mammalian cells. Chinese hamster ovary (CHO) cells are an industry 
standard and are utilized for the majority of commercial biotherapeutics (Ghaderi et al., 2012). 
Mammalian cells such as CHO are capable of a wide range of human-like post-translational 
modifications to proteins including glycosylation, which is acknowledged in several reviews of 
the FDAs quality by design (QbD) program to be a major critical quality attribute (CQA) of 
MAbs and other biologics (del Val et al., 2010; Eon-Duval et al., 2012; Glassey et al., 2011). 
Glycosylation has long been known to affect a host of drug factors including immunogenicity 
(Bosques et al., 2010; Padler-Karavani et al., 2008), secretion by cells (Hickman and Kornfeld, 
1978), drug clearance-rate (Morell et al., 1968), protein stability (Mimura et al., 2001), and 
solubility (Leavitt et al., 1977), as well as effector function for MAbs (Koide et al., 1977) for 
required recognition by the immune-system. Governed by a variable sequence of enzymes 
known as glycosyltransferases, which append and sculpt complex oligosaccharides, also known 
as ‘glycans’, onto biomolecules, glycosylation introduces heterogeneity to therapeutic products 
(as reviewed by Butler, 2006). 
Glycan heterogeneity occurs naturally, but is influenced by numerous factors such as the 
up/down regulation of cellular enzymes and transporter proteins (Chen and Harcum, 2006; N. S. 
C. Wong et al., 2010), perturbations in culture conditions such as temperature, pH and dissolved 
oxygen as reviewed by several researchers (Butler, 2006; del Val et al., 2010; Eon-Duval et al., 




(Nyberg et al., 1999; Pels Rijcken et al., 1995b). With respect to commercial bioprocesses, this 
implies drugs of potentially inconsistent molecule to molecule quality, as well as batch to batch 
variability, and challenges for biosimilars and subsequent entry biologics (SEBs) to match the 
structural characteristics and efficacy of their reference biologics. 
The addition of glycosylation precursors, such as glucosamine (GlcN) (Baker et al., 2001; 
Gawlitzek et al., 1998; Grammatikos et al., 1998; Hills et al., 2001; Pels Rijcken et al., 1995b; N. 
S. C. Wong et al., 2010; Yang and Butler, 2002; Zanghi et al., 1998), galactose (Gal) (Clark et 
al., 2005; Gramer et al., 2011; Hills et al., 2001; N. S. C. Wong et al., 2010), and acetyl-
mannosamine (ManNAc) (Baker et al., 2001; Gu and Wang, 1998; Hills et al., 2001; Pels 
Rijcken et al., 1995b; N. S. C. Wong et al., 2010) to growth medium has been reported to 
increase the intracellular pools of nucleotide-sugars – the substrates for glycosylation – and 
affect final glycan profiles. However, these effects are inconsistent across a range of factors 
including the host cell line, the recombinant protein expressed, and production scales. While 
galactose and ManNAc have each been reported to contribute to glycans of higher complexity, 
glucosamine is the only precursor reported to reduce the complexity, by affecting either by 
galactosylation or sialylation, of glycoforms (Hills et al., 2001; Pels Rijcken et al., 1995b; Yang 
and Butler, 2002; Zanghi et al., 1998). Glucosamine has also been reported in some instances to 
contribute to glycans of higher antennarity (Baker et al., 2001; Gawlitzek et al., 1998; 
Grammatikos et al., 1998); however, this effect is also often associated with elevated ammonia 
levels (Valley et al., 1999). While more complex glycans are often associated with enhanced 
efficacy (Jefferis, 2012), commercial therapeutic MAbs on the market are biased towards G0 




Glucosamine is the only precursor from among these supplementations reported to negatively 
affect cell growth, an effect reported in both cultured cells expressing recombinant proteins 
(Baker et al., 2001; Grammatikos et al., 1998; Hills et al., 2001; N. S. C. Wong et al., 2010; 
Yang and Butler, 2002; Zanghi et al., 1998) and non-producing transformed cells (Bekesi and 
Winzler, 1970; Krug et al., 1984; Liang et al., 2010; Oh et al., 2007; Pederson et al., 1992). 
Historically, the negative growth effects of glucosamine were attributed to either competition 
with glucose transport (Yang and Butler, 2002), depletion of intracellular ATP and UTP pools, 
or interference with normal glycosylation, (as reviewed by Pederson et al., 1992). However, 
giving consideration to the metabolism of transformed mammalian cell lines that feature a 
truncated TCA cycle (Ma et al., 2009), it is proposed that negative growth from glucosamine is 
actually the result of depletion of cytosolic acetyl-CoA to convert GlcN to GlcNAc, essential for 
lipid biosynthesis (Goudar et al., 2010; Quek et al., 2010). 
In this work, the growth medium of CHO cultures expressing a single-domain chimeric 
heavy chain camelid-derived antibody (EG2-hFc) (Agrawal et al., 2012) was supplemented with 
glucosamine (GlcN) and GlcNAc to shift the glycosylation profile toward lower complexity ‘G0’ 
types. While glucosamine severely restricted the cell growth of cultures, N-acetylglucosamine 
(GlcNAc) yielded comparatively marginal impacts to cell growth and protein productivity. 
Glucosamine is converted to GlcNAc, by cytosolic acetyl-CoA, an important compound in lipid 
biosynthetic pathways necessary for cell growth, as shown in Figure 21. 
4.3 Materials & Methods 
4.3.1 Cell Culture 
DUKX-derived CHO
BRI
 cells, negative for dihydrofolate reductase (DHFR-), stably 




acquired from Dr. Yves Durocher (National Research Council Canada, Montreal, QC, Canada). 
Flask experiments were conducted in 125 mL Polycarbonate Erlenmeyer Flasks (Corning Inc.). 
All cultures were grown in duplicate flasks at 37°C, with an agitation speed of 120 rpm. Samples 
of supernatant harvested at the end of flask cultures were stored at −80°C. Cell density 
measurements were taken by trypan-blue exclusion via haemocytometer and by a Coulter 
Counter Z2 (Beckman-Coulter, Miami, USA). 
4.3.2 Growth Medium & Supplemented Nutrients 
Cells were grown in serum-free BioGro-CHO medium (BioGro Technologies Inc., 
Winnipeg, MB, Canada). Glucosamine (Sigma-Aldrich G1514) and N-acetylglucosamine 
(AMRESCO K250) were prepared as 120 mM stock solutions in BioGro. All stock solutions 
were sterile filtered using a 0.2µm filter (Millipore Millex-GP, Bedford, MA, USA).  
4.3.3 Glycan Analysis 
EG2-hFc antibody glycans were analyzed using normal phase HPLC (NP-HPLC) with 
HILIC (hydrophobic interaction liquid chromatography) separation. Supernatant containing 
EG2-hFc was harvested at the end of culturing and exchanged to 1X phosphate buffered saline 
(PBS) using a 10 kDa cut-off Ultracel® column (Merck Millipore Ltd.). Up to 100 µg of protein 
was bound to a Protein-A HP Spintrap column (GE Healthcare, Burlington, NC) for 15 min that 
was prewashed with 20 mM phosphate buffer, pH 7.4. Glycans were removed from the bound 
MAb protein by digesting overnight at 37°C with 1 µL of Peptide-N-Glycosidase-F (PNGaseF; 
Promega, Madison, WI) in 200 µL of phosphate buffer. Following incubation the glycans were 
eluted by washing 2X with water and dried in a Speedvac (ThermoFisher Scientific, Waltham, 
MA). The glycans were labelled with 2-aminobenzamide (Bigge et al., 1995) (ThermoFisher 




(ThermoFisher Scientific, Waltham, MA). Glycans were analyzed by HILIC HPLC with 
fluorescent detection using an X-Bridge 3.5 um amide column (4.6 x 250 mm) (Waters, 
Mississauga, ON) with the column heated to 30°C and a flow rate of 0.86 mL/min. Glycans were 
eluted using 50 mM ammonium formate, pH 4.4: acetonitrile starting with an initial ratio of 
20:80, followed by a gradient to 50:50 over 48 minutes. Peaks were calibrated with a 2-AB 
labeled glucose ladder and glycan standards (Prozyme, Hayward, CA) and compared to a glycan 
database (Glycobase (Campbell et al., 2008)). Glycan structures were confirmed in previous 
experiments by exoglycosidase enzymatic digestion. 
4.3.4 mAb Quantification 
Supernatant samples harvested at the end of culturing containing EG2-hFc MAb were 
concentrated ~10x by centrifugation through a 10 kDa cut-off Ultracel® column (Merck 
Millipore Ltd.). Quantification was achieved with a POROS® A20 column (Life Technologies) 
on a Varian Pro Star 410 HPLC (Agilent). Antibody elution was detected at a wavelength of 280 
nm. 
4.3.5 Extracellular Metabolite Profiling 
NMR spectra were acquired with a Bruker Avance 600MHz spectrometer with a TXI 600 
probe. Following acquisition, spectra were imported into Chenomx NMR Suite 7.7 (Chenomx 
Inc., Edmonton, Canada) and manually profiled (Sokolenko et al., 2014). 
4.3.6 Intracellular Nucleotide and Nucleotide-Sugar Analysis 
Cells were metabolically quenched at 72hrs of culturing as per the method of Sellick et al., 
2009, in 60% methanol with 0.85% w/v ammonium bicarbonate (AMBIC) at -40°C (pH 7.4). 




liquid nitrogen and stored at -80°C before shipping on dry ice to the Butler Lab of the University 
of Manitoba. Extraction was performed as per Räbinä et al., 2001. Quenched cell pellets were 
reconstituted in 0.5 mL PBS and sonicated briefly on ice. Debris was subsequently removed by 
centrifugation at 6000g for 10 min and each extract was diluted to 1 mL with 10 mM AMBIC 
(pH 7.0). Nucleotide and nucleotide sugars were isolated using an ENVI-Carb™ column 
(Supelclean™) and eluted with 25% (v/v) acetonitrile, 50 mM TEAA buffer (pH 7). Nucleotide 
and nucleotide sugar samples were dried in a Speedvac and subsequently dissolved in 40 µL of 
distilled water prior to analysis via HPAEC as per Tomiya et al., 2001, using a CarboPac® PA1 
column (Dionex); UV absorbance for detection (260 nm).  
4.4 Results 
The goal of this work was to utilize glucosamine to affect Mab glycan profiles, while also 
mitigating the negative growth effects associated with this supplementation. Glucosamine 
(GlcN), a precursor for N-glycans reported in many cell culture applications to reduce 
glycosylation, but also to hinder growth was hypothesized based on its metabolism to restrict 
growth by depletion of the cytosolic acetyl-CoA pool (Figure 21, reactions 5 & 11). 
Supplementation of 7.5mM glucosamine restricted growth, leading to an approximately 60% 
drop in the maximum cell density of cultures compared to controls (Figure 22). However, 
glucosamine also succeeded in increasing the proportion of G0 glycoforms for EG2-hFc protein 
produced from CHO
BRI
 cultures by ~25% (Figure 23). To test the acetyl-CoA growth-restriction 
hypothesis, 7.5 mM N-acetylglucosamine (GlcNAc - the acetylated form of glucosamine) was 
supplemented instead of GlcN, achieving a comparable proportionate increase in G0 glycoforms 
(Figure 23), while achieving a maximum cell density with less than a 20% drop compared to 




an equivalent maximum cell density to controls, with a ~15% increase in G0 glycoforms (Figure 
24 & Figure 25). Productivity of EG2-hFc harvested at the end of cultures supplemented with 
GlcNAc also remained consistent with controls (Figure 26). Intracellular nucleotides and 
nucleotide-sugar metabolites extracted from cultures at 72 hrs following supplementation with a 
range of concentrations of GlcNAc, resulted in corresponding increases to intracellular UDP-
GlcNAc and UDP-GalNAc metabolites (Figure 27), an effect matching those reported by 





Figure 21 – Intracellular nucleotide sugar metabolic pathways utilizing glucose or supplemented GlcN or GlcNAc.  
Enzymes: 1. Hexokinase, 2. Glucose-6-phosphate isomerase, 3. Glutamine-fructose-6-phosphate transaminase, 4. 
Glucosamine-6-phosphate deaminase, 5. Glucosamine-phosphate N-acetyltransferase, 6. N-acetylglucosamine-6-
phosphate deacetylase, 7. Phophoglucomutase, 8. Mannose-6-phosphate isomerase, 9. Phosphoglucosamine mutase, 10. 
Phosphoacetylglucosamine mutase, 11. Glucosamine-1-phosphate N-acetyltransferase, 12. UTP-glucose-1-phosphate 
uridylyltransferase, 13. Phosphomannomutase, 14. UDP-N-acetylglucosamine diphosphorylase, 15. UDP-N-
acetylglucosamine 4-epimerase, 16. UDP-glucose 4-epimerase, 17. Mannose-1-phosphate guanylyltransferase, 18. UDP-N-
acetylglucosamine 2-epimerase, 19*. GDP-mannose 4,6-dehydratase and GDP-L-fucose synthase, 20*. N-




4.4.1 Growth Effects GlcN vs. GlcNAc 
Supplementing GlcN and GlcNAc produced comparable effects to the glycan distribution 
(Figure 23) while the effects on cell growth were significantly different. GlcN supplemented 
cultures immediately presented with inhibited growth and an approximately 50% drop in growth 
rate during the exponential phase. GlcNAc supplemented cultures, on the other hand, maintained 
near equivalent growth rates compared to control cultures till the late exponential phase (Figures 
2&5), with a difference in growth rate compared to control cultures of less than 5%. GlcNAc 
supplemented cultures also achieved comparable maximum cell density to control cultures, 
particularly at lower supplemented concentrations (2.5 mM). However, in all GlcNAc 





Figure 22 – Growth and viability of CHO cells severely impacted during supplementation of 7.5 mM glucosamine (GlcN), 
compared to only marginal impacts to growth and viability during supplementation of 7.5 mM N-acetylglucosamine 
(GlcNAc). Duplicate lines represent duplicate flasks.  
4.4.2 Glycosylation Effects GlcN vs. GlcNAc 
GlcN and GlcNAc were each supplemented at 7.5mM to cultures after a cell density of 
0.5x10
6 
 cells/mL was reached (Figure 22). The glycan distribution of the EG2-hFc MAb 
harvested from the supernatant at the end of these cultures showed a shift towards the 
biantennary fucosylated G0 form (FA2G0) with a reduction in the galactosylated forms (FA2G1 
and FA2G2) (Figure 23 and supplementary data). Supplementation of GlcN and GlcNAc each 






Figure 23 – A similar shift to less complex glycoforms is observed from supplementing either 
glucosamine (GlcN) or N-acetylglucosamine (GlcNAc). 
4.4.3 Glycosylation Effects GlcNAc 
Supplementation of GlcNAc at increasing concentrations from 0 to 10 mM yielded 
corresponding increases in the proportion of G0 glycoforms from approximately 25% (control) 
to 50% (10 mM supplementation) (Figure 24 and supplementary data). A similar trend in the 
shift of the glycan distribution was also observed in previous experiments utilizing GlcN (data 





Figure 24 – Increasing the concentration of N-acetylglucosamine (GlcNAc) increases the glycan shift towards G0 
glycoforms. 
4.4.4 Growth and Productivity Effects from GlcNAc Supplementation 
Although GlcNAc had a less severe impact on cell growth compared to GlcN, it showed a 




cultures maintained near equivalent growth rates to the control cultures until late exponential 
phase, with less than a 5% difference from control cultures. 
 
Figure 25 – Increasing the concentration of N-acetyleglucosamine (GlcNAc) supplemented to cultures reduces late-
exponential cell growth with marginal impact to viability. Duplicate lines represent duplicate flasks. 
While cultures supplemented with GlcNAc collapsed more rapidly during stationary phase, 
the productivity of EG2-hFc harvested from the final time-point of the cultures remained 





Figure 26 – A) Final protein titers of EG2-hFc from cultures supplemented with GlcNAc. B) Final acetate concentrations 
from cultures supplemented with GlcNAc. Error bars represent the standard deviation between duplicate flasks.  
1D-
1
H-NMR was utilized to track approximately thirty exometabolites of the cultures 
supplemented with GlcN and GlcNAc (refer to supplementary data). Supplementing cultures 
with GlcNAc produced very similar metabolite trends compared to the control cultures, with the 
exception of acetate. Starting at ~72hrs, prior to the end of exponential phase, a 3-fold higher 
concentration of acetate accumulated compared to the control cultures. This acetate accumulation 
trend was also observed from glucosamine supplemented cultures. Profiling the metabolites from 
supernatant harvested at the final time-point of GlcNAc supplemented cultures revealed a trend 
of increasing acetate excretion corresponding with increasing GlcNAc concentration (Figure 
26B). Clipping acetate to scavenge glucose from GlcNAc is shown in Figure 21 for the activity 




supplementation, follow-up experiments supplementing acetate to CHO cultures did not restrict 
growth at these concentrations. 
4.4.5 Intracellular Nucleotides and Nucleotide-Sugar Pools 
Extracting intracellular metabolites from cells at ~72hrs from cultures supplemented with 
GlcNAc revealed increases in intracellular GlcNAc, UDP-GlcNAc and UDP-GalNAc (Figure 
27) corresponding to increases in the proportion of G0 glycoforms (Figure 24). Other fractions of 
intracellular nucleotides and nucleotide-sugars appeared stable in GlcNAc supplemented 
cultures, presenting no dependence or effect from GlcNAc feeding, with the exception of ATP 
which showed a slight dip with increasing GlcNAc concentrations. 
 
Figure 27 – Nucleotide and nucleotide-sugar ‘per-cell’ intracellular concentrations from quenched cell samples taken at 





4.5.1 Simple Method for Affecting Glycan Distributions 
While glycoengineering of designer cell culture platforms has emerged in recent years as a 
means to introduce mammalian-like post-translational modifications to non-mammalian systems, 
it remains a fact that a significant majority of established FDA-approved therapeutic proteins are 
produced in Chinese hamster ovary (CHO) cells (as reviewed by Ghaderi et al., 2012). 
Therefore, fundamentally improving the quality of these therapeutics through systems like 
Quality by Design (QbD) will demand a method that can be integrated into existing 
bioprocesses, such as supplementing nucleotide sugar precursors (GlcNAc, ManNAc, Gal) to 
growth medium. Also, biosimilars, and subsequent entry biologics (SEBs) attempting to enter the 
market may require the means to tune glycan distributions to match glycoform distributions to 
approved proportions in reference biologics. Nucleotide-sugar precursor supplementation 
represents a promising option both for established bioprocesses and new biosimilars 
manufacturing because of its simplicity and its clear impact to glycan distributions. 
Commercial therapeutic MAbs, which are reference biologics for upcoming biosimilar 
products, are generally biased towards the G0 glycoform (Wacker et al., 2011). While large 
glycan shifts are exhibited in this work when supplementing GlcNAc at higher concentrations, 
partial tuning of glycoforms can be accomplished with smaller concentrations as observed by the 
case of 2.5mM supplementation increasing the G0 proportion by 15% (as per the results shown 
in Figure 24). With respect to the economics of such a supplementation; taking a conservatively 
estimated price of cell culture grade GlcNAc of US$2/g, and a batch process volume of 10,000L, 
the additional cost per batch supplementing 2mM GlcNAc would be on the order of US$10k per 




4.5.2 Diversity of Reported Glycan Effects from Glucosamine 
Glucosamine has historically been associated with reducing glycosylation (as reviewed by 
Nyberg et al., 1999). While most often reported as reduced sialylation (Baker et al., 2001; Hills 
et al., 2001; Pels Rijcken et al., 1995b; Yang and Butler, 2002; Zanghi et al., 1998), due to 
inhibition of transport of CMP-sialic acids to the Golgi by elevated levels of UDP-GlcNAc (Pels 
Rijcken et al., 1995b), glucosamine supplementation has also been reported by Hills and 
colleagues to reduce galactosylation (Hills et al., 2001). In several instances, glucosamine 
supplementation has led to an increase in glycan branching producing greater proportions of tri 
and tetraantennary glycans (Baker et al., 2001; Gawlitzek et al., 1998; Grammatikos et al., 1998; 
Pels Rijcken et al., 1995b). However, the majority of these reports were made with the same 
BHK cell line producing interleukin-2, and these results may also be confounded by varying 
responses to ammonia between mammalian cell culture platforms. As reported by Valley et al., 
when supplementing 
15
N isotopic ammonia, up to 60% was incorporated into elevated UDP-
GlcNAc pools, making glutamine and TCA metabolism important factors affecting 
glycosylation. D.C.F. Wong and colleagues demonstrated that glutamine levels may directly 
impact the up/down regulation of GnT-IV and V, the GlcNAc glycosyltransferases responsible 
for tri and tetraantennary glycan formation (D. C. F. Wong et al., 2010). The cell culture 
platform itself may be a source of variation, as reported by Baker et al. who supplemented 
glucosamine together with uridine in GS-CHO and GS-NS0 cultures expressing tissue inhibitor 
metalloproteinases 1, observing increased glycan branching in CHO, but not in NS0. While most 
researchers have reported either decreased sialylation or increased antennarity effects, other 
researchers have reported the reverse of these results , such as increasing sialylation of 




expressed in CHO (Yang and Butler, 2002). Therefore, the effects of supplementation of 
glucosamine vary from researcher to researcher depending on cell culture platform utilized, 
protein being expressed, and other factors such as glutamine and ammonia concentrations. 
4.5.3 Growth Limitations from Glucosamine 
Growth limitations from glucosamine supplementation are reported in both cultured cells 
expressing recombinant proteins (Baker et al., 2001; Grammatikos et al., 1998; Hills et al., 2001; 
N. S. C. Wong et al., 2010; Yang and Butler, 2002; Zanghi et al., 1998) and non-producing 
transformed cells (Bekesi and Winzler, 1970; Krug et al., 1984; Liang et al., 2010; Oh et al., 
2007; Pederson et al., 1992). 
As a major component in the typical mammalian glycan structure, glucosamine (GlcN) was 
an early candidate for research into supplementation options to affect glycosylation and was 
examined by many researchers (Baker et al., 2001; Gawlitzek et al., 1998; Grammatikos et al., 
1998; Hills et al., 2001; Pels Rijcken et al., 1995b; N. S. C. Wong et al., 2010; Yang and Butler, 
2002; Zanghi et al., 1998). GlcN was also a candidate in some early fully-defined growth 
medium formulations for mammalian cell culture (Evans et al., 1956). Upon being taken up by 
the cells, as shown in Figure 21, glucosamine is phosphorylated and acetylated, then finally 
activated by uridine-triphosphate to produce UDP-GlcNAc, the most common substrate of 
mammalian N-glycosylation.  
The acetylation step to make GlcNAc (Figure 21, reactions 5 & 11) is proposed to be the 
cause of the growth inhibiting effects associated with GlcN supplementation. Acetyl-CoA in the 
mitochondria is not able to migrate out of the organelle to take part in lipid-biosynthesis in the 




cytosolic acetyl-CoA pool via the action of ATP-citrate lyase, a metabolic feature of transformed 
mammalian cell lines described as a truncated TCA cycle (Ma et al., 2009). Goudar and 
colleagues reported that nearly 24% of all TCA flux diverted through ATP-citrate lyase and that 
this was characteristic of slow-growing cells, while nearly 50% had been reported for faster 
growing hybridomas (Bonarius et al., 1996; Goudar et al., 2010). Quek et al. reported that during 
maximum growth rate, all available Acetyl-CoA will be devoted towards lipid biosynthesis 
(Quek et al., 2010).  
 Glucosamine is readily taken up by the cells, and arrives in a metabolic pathway absent of 
much additional regulation to produce UDP-GlcNAc (Freeze and Elbein, 2009). Several 
researchers have reported that supplementing glucosamine therefore leads to a ~10x 
(Grammatikos et al., 1998) to ~60x (Baker et al., 2001) increase in the intracellular UDP-
GlcNAc pools. This acetylation of glucosamine may potentially lead to the depletion of cytosolic 
acetyl-CoA, necessary for many biosynthetic pathways particularly lipid synthesis, necessary for 
cell growth.  
In this work, GlcNAc was supplemented in lieu of glucosamine to skip the acetylation step. 
This supplementation lead to a nearly two-fold increase in intracellular UDP-GlcNAc pools, with 
a negligible impact on other observed intracellular pools apart from UDP-GalNAc, which exists 
in equilibrium with UDP GlcNAc, and ATP, which observed a small dip in pool size. There 
remains some negative impact to cell growth most evident in late exponential phase with 
GlcNAc supplementation and the more rapid decline in stationary phase.  
Historically, the negative growth effects of glucosamine were attributed to either competition 




or interference with normal glycosylation, (as reviewed by Pederson et al., 1992). Glucose, 
glucosamine and N-acetylglucosamine appear to share the same group of transporters on the 
plasma membrane, the GLUT family of hexose transporters (as reviewed by Freeze and Elbein, 
2009), particularly GLUT2 in the case of glucosamine (Uldry et al., 2002), and nearly all GLUT 
transporters at low levels for GlcNAc (Scarcelli et al., 2012). However, glucose uptake appeared 
more or less unchanged between control cultures and GlcNAc supplemented cultures 
(supplementary data). ATP may have been slightly depleted to provide additional UDP to form 
UDP-GlcNAc, since as observed in Figure 27, its pool does appear somewhat declined with 
increasing GlcNAc concentrations. However, given that the recombinant glycoprotein expressed 
by the CHO
BRI
 cells showed such a clear shift in its glycan profile from GlcNAc 
supplementation, it’s possible that further interference with other glycan dependent cell systems 
might have been affected and diminished maximum cell density, leading to the more rapid 
decline at end of culture. 
4.6 Conclusions 
Supplementation of nucleotide sugar precursors to the growth medium of mammalian cell 
cultures is a promising strategy for tuning the glycan profile of therapeutic recombinant proteins 
for existing bioprocesses as well as new biosimilars and SEBs. The supplementation of 
glucosamine (GlcN) reduces the complexity of glycan profiles of EG2-hFc expressed in CHO 
cells to favour the G0 glycoform, but causes a significant restriction to cell growth. 
Alternatively, supplementing N-acetylglucosamine (GlcNAc) yields the same affect to the 
glycan profile with a marginal impact to cell growth, particularly at GlcNAc concentrations of 




GlcN to become GlcNAc, which may deplete intracellular acetyl-CoA pools necessary for 




Chapter 5 Supplementing Growth and Glycoform 
Supplementation of the cocktail of nutrients demonstrated in Chapter 3 to improve growth of 
CHO
BRI
-1A7 cells was repeated to examine any effects to the glycoform distribution of EG2-
hFc. The cocktail did not notably affect the glycoform distribution, as shown in Figure 28. While 
the distribution favoured more galactosylation compared to controls, this was not considered 
unusual for EG2-hFc based on earlier experiments.  
 
Figure 28 – Glycoform distribution for EG2-hFc harvested from a bioreactor fermentation of CHOBRI-1A7 grown in 
BioGro-CHO medium supplemented with the cocktail of nutrients established in Chapter 3. 
Subsequently, supplementation of the cocktail was repeated together with supplementation of 
N-acetylglucosamine (GlcNAc), which had caused some marginal growth restriction, as 




could be alleviated via the cocktail. As demonstrated in Figure 29, addition of the nutrient 
cocktail successfully improved growth for those flasks supplemented with GlcNAc compared to 
the control flasks. While a marginal growth restriction persisted with a similar decay rate in 
stationary phase, overall it was demonstrated that the cocktail and GlcNAc supplementation 
could be utilized together to improve growth and affect the glycan distribution of EG2-hFc. 
 
Figure 29 – Duplicate flasks of CHOBRI-1A7 cultured with a cocktail of supplements to improve growth, detailed in 






Chapter 6 Supplementing Glycosylation: A Review of Applying 
Nucleotide-Sugar Precursors to Growth Medium to 





Glycosylation is a critical quality attribute (CQA) of many therapeutic proteins, particularly 
monoclonal antibodies (mAbs), and is a major consideration in the approval of biosimilar 
biologics due to its effects to therapeutic efficacy. Glycosylation generates a distribution of 
glycoforms, resulting in glycoproteins with inherent molecule-to-molecule heterogeneity, 
capable of activating (or failing to activate) different effector functions of the immune system. 
Glycoforms can be affected by the supplementation of nucleotide-sugar precursors, and related 
components, to culture growth medium, affecting the metabolism of glycosylation. These 
supplementations has been demonstrated to increase nucleotide-sugar intracellular pools, and 
impact glycoform distributions, but with varied results. These variations can be attributed to five 
key factors: Differences between cell platforms (enzyme/transporter expression levels); 
differences between recombinant proteins produced (glycan-site accessibility); the fermentation 
and sampling timeline (glucose availability and exoglycosidase accumulation); glutamine levels 
(affecting ammonia levels, which impact Golgi pH, as well as UDP-GlcNAc pools); and finally, 
a lack of standardized metrics for observing shifts in glycoform distributions (glycosylation 
indices) across different experiments. The purpose of this review is to provide detail and clarity 
                                                          
 
3
 This manuscript was submitted [date] to the Journal of Biotechnology Advances, published by Elsevier. Blondeel, 
E.J.M., Aucoin, M.G., “Supplementing Glycosylation: A Review of Applying Nucleotide-Sugar Precursors to Growth 




on the state of the art of supplementation strategies for nucleotide-sugar precursors for affecting 
glycosylation in cell culture processes, and to apply glycosylation indices for standardized 
comparisons across the field. 
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Glycosylation is acknowledged to be among the most important critical quality attributes 
(CQAs) of therapeutic biologicals, particularly for monoclonal antibodies (mAbs), which must 
be glycosylated for bioactivity (Dordal et al., 1985; Nose and Wigzell, 1983). Glycosylation is 
performed by a varying succession of enzymes, which regulate the sculpting and pruning of 
complex oligosaccharides, referred to broadly as ‘glycans’, onto biomolecules forming 
glycoconjugates. With respect to glycoprotein therapeutics, glycosylation introduces one of the 
major forms of molecule to molecule heterogeneity, which is broadly understood to affect a wide 
range of biotherapeutic efficacy metrics, including function (Dubé et al., 1988), immunogenicity 
(Bosques et al., 2010; Ghaderi et al., 2010; Padler-Karavani et al., 2008), drug clearance-rate 
(Morell et al., 1968), protein stability (Mimura et al., 2001; Wyss and Wagner, 1996), solubility 
(Leavitt et al., 1977), and in the case of mAbs, immune system recognition for effector function 
(Tao and Morrison, 1989). 
Glycan heterogeneity can be influenced broadly by several process conditions including 
perturbations to temperature, pH and dissolved oxygen; an excellent review of which is 
presented by Hossler (2012). Other major factors of influence include the up/down regulation of 
membrane transporters and glycosyltransferases between cell platforms (Chen and Harcum, 
2006; McDonald et al., 2016; N. S. C. Wong et al., 2010), and interruptions to the substrate 
supply chain of nucleotide-sugar metabolism and transport (Liu et al., 2014; McDonald et al., 
2016; Nyberg et al., 1999; Pels Rijcken et al., 1995b). Glycan heterogeneity indicates 
biotherapeutics with molecule-to-molecule quality differences that will activate (or fail to 




match their glycan distributions with that of their reference (innovator) biologics, or at least 
demonstrate that any differences are not clinically significant (FDA, 2015). 
Three major strategies exist to affect the glycosylation of recombinant proteins: 
1. glycoengineering of cell platforms generally targeting either the addition or knock-out 
(including silencing) of glycosyltransferases and glycosyltransferases (Mori et al., 
2004; Yamane-Ohnuki et al., 2004), or similarly targeting nucleotide-sugar Golgi 
transporters (Wright and Morrison, 1998); 
2. downstream in vitro remodelling of glycans (Hodoniczky et al., 2005); or, 
3. supplementation of nucleotide-sugar precursors and associated components, such as 
sugars and amine-sugars (Table 7-Table 9), including nucleosides like uridine and 
cytidine (Carvalhal et al., 2003; Nyberg et al., 1999), and the metallic ion manganese 
(Crowell et al., 2007; St Amand et al., 2014; Surve and Gadgil, 2015). 
This review will focus on the latter of these methods, providing clarity towards five key 
factors that have contributed to varied results for this promising method of tuning glycosylation 
in cell culture processes. The first of these factors are the differences in enzyme/transporter 
expression levels across cell platforms. Secondly, differences between recombinant proteins 
produced, particularly with respect to the accessibility of their glycan sites by 
glycosyltransferases. Thirdly, the fermentation and sampling timeline, both with respect to the 
glucose availability, as well as the accumulation of exoglycosidases at the latter stages of 
cultures. A fourth factor is the glutamine levels, as increases in ammonia alter the pH of Golgi 
compartments, and also increase UDP-GlcNAc intracellular pools. Finally, differences in metrics 
for reporting different glycan attributes (i.e. galactosylation), which prevent more standard 





The variability and probabilistic nature of glycosylation (Spahn et al., 2016) lends itself to a 
security recognition function in vivo, mediating countless lectin/ligand binding scenarios for 
sensing and signaling events, both at the molecular level as well as more broadly for cell 
signalling. Moremen and colleagues (2012) provide an excellent overview of glycosylation in 
vertebrates, and the resulting complexity of system-level interactions. From a therapeutics 
perspective, the significance and potential of glycosylation with respect to current and future 
biologics continues to grow (Dalziel et al., 2014). 
Generally speaking, glycosylation comes in two main forms, N-linked and O-linked, which 
are designated by the functional group of the amino-acids where the glycans are bound. N-
glycans are bound via amide-linkages to asparagine residues, and are typically larger 
oligosaccharides compared to O-glycans, which are bound to serine or threonine by glycosidic 
bonds. With respect to therapeutic glycoproteins, N-linked glycosylation receives the most 
attention in literature, particularly regarding mAbs, as glycosylation of the Fc region is a major 
factor in immune system effector functions, such as complement activation, and binding to Fcγ 
receptors of leukocytes towards various immune responses (Tao and Morrison, 1989). O-
glycosylation is not yet recognized as notably consequential to effector functions or bioefficacy 
for many approved glycoprotein therapeutics, but will affect some basic efficacy characteristics 
like protein stability (Wang et al., 1996). 
6.3.1 Nucleotide-Sugar Metabolism 
Substrates of glycosylation generally take the form of monosaccharides paired to particular 
nucleoside-phosphates (i.e. UDP-GlcNAc, GDP-Fucose, CMP-NeuAc, etc.), and are derived 




produced in the cytoplasm, with the exception of cytidine monophosphate N-acetylneuraminic 
acid (CMP-NeuAc), which is formed in the nucleus (Kean, 1970). Mammalian cells are able to 
take up a wide diversity of saccharide nutrients through the GLUT and SGLT families of cell 
membrane transporters. Supplementing nucleotide-sugar precursors circumvents points of 
regulation and feedback inhibition (Pels Rijcken et al., 1995b), leading to large fold-change 
increases in intracellular metabolic pools (Table 7-Table 9). Augustin and Mayoux (2014) 
present an excellent review of these transporter families, while Freeze and Elbein (2009) provide 
an exceptional review of the points of regulation controlling this metabolic network. The 
formation of amine-sugars like glucosamine (GlcN) require an amine donor, such as glutamine, 
through the action of glutamine-fructose-6-phosphate transaminase (Figure 30, Reaction 3), and 
these intracellular pools will be starved in glutamine’s absence (Nyberg et al., 1999). However, it 
has also been demonstrated that ammonia can be utilized as a donor towards formation of UDP-
GlcNAc and subsequent amine sugar pools (Valley et al., 1999). 
With the exception of the endoplasmic reticulum (ER), where dolichol-linked 
monosaccharide substrates like glucose and mannose are ‘flipped’ from the cytosol into the 
organelle lumen (Figure 30, Reaction 24), nucleotide-sugars are typically transported by means 
of the SLC35 family of transporters, which require the respective nucleotide-monophosphate on 
the opposing side of the membrane to complete the exchange, as shown in Figure 30. Ishida and 
Kawakita (2004) have assembled a comprehensive review of the SLC35 family of transporters. 
Availability of particular nucleoside-monophosphates within the Golgi lumen is dependent on 
the activity of nucleoside diphosphatase (NDPase) to convert nucleoside-diphosphates to their 
monophosphate form (Figure 30); which has been identified as a potential bottleneck in glycan 








Figure 30 – Metabolic pathways for the synthesis and transport of intracellular nucleotide sugars utilizing glucose (Glc), 
galactose (Gal), glucosamine (GlcN), acetylglucosamine (GlcNAc), and acetylmannosamine (ManNAc), towards N-
glycosylation in mammalian cells. This includes the assembly of dolichol-14-sugar oligosaccharide and co-translational 
binding for N-glycosylation of proteins beginning in the cytosol and occurring in ER, followed by the sculpting of further 
monosaccharide modifications in the Golgi by pH-dependent heteromeric glycosyltransferases. 
Enzymes (asterisks* indicate a multi-step process): (1a-e) hexokinase; (2) glucose-6-phosphate isomerase; (3) glutamine-
fructose-6-phosphate transaminase; (4) glucosamine-phosphate N-acetyltransferase; (5) glucosamine-6-phosphate 
deaminase; (6) N-acetylglucosamine-6-phosphate deacetylase; (7) phophoglucomutase; (8) mannose-6-phosphate 
isomerase; (9) phosphoglucosamine mutase; (10) phosphoacetylglucosamine mutase; (11) UTP-galactose-1-phosphate 
uridylyltransferase; (12*) N-acylneuraminate-9-phosphate synthase and phosphatase; (13) glucosamine-1-phosphate N-
acetyltransferase; (14) UTP-glucose-1-phosphate uridylyltransferase; (15) phosphomannomutase; (16) UDP-N-
acetylglucosamine diphosphorylase; (17) UDP-N-acetylglucosamine 4-epimerase; (18) UDP-glucose 4-epimerase; (19) 
mannose-1-phosphate guanylyltransferase; (20) UDP-N-acetylglucosamine 2-epimerase; (21) N- acylneuraminate 
cytidylyltransferase; (22*) GDP-mannose 4,6-dehydratase and GDP-l-fucose synthase; (23*) assembly at the cytoplasmic 
face of the endoplasmic reticulum (ER) of the dolichol diphosphate linked 7-sugar oligosaccharide of mannose and 
GlcNAc prior, which is flipped into the ER; (24*) dolichol phosphate linked glucose and mannose monosaccharide, which 
are flipped into the ER; (25*) dolichol diphosphate linked 14-sugar oligosaccharide precursor of N-glycosylation; (26*) 
transfer of the 14-sugar oligosaccharide to an asparagine residue, part of a sequon in the amino-acid chain Asn-X-Ser/Thr 
where X is not proline, via the action of oligosaccharide transferase (OST); (27*) protein folding and pruning of three 
terminal glucose moieties by α-glucosidases I & II, as well as removal of the central terminal mannose by ER α-
mannosidase I, yielding Man8GlcNAc2 before transition to the Golgi; (28*) cis-Golgi lumen, three terminal mannose 
residues are pruned by Golgi α-mannosidase I, then acetylglucosamine transferase (GnT-I) adds a terminal GlcNAc to the 
α1-3 core mannose residue, finally Golgi α-mannosidase II removes the final terminal α1-3 and α1-6 mannose residues 
yielding GlcNAcMan3GlcNAc2, the lower pH signals homomeric complexes of glycosyltransferases to reform as 
heteromeric dimer complexes acting sequentially on the glycan; (29*) medial-Golgi lumen, acetylglucosamine transferase 
(GnT-II) adds a terminal GlcNAc to the α1-6 core mannose residue, subsequently fucosyltransferase (FucT) adds a core 
α1-6 fucose residue to the GlcNAc closest to the asparagine residue yielding GlcNAc2Man3GlcNAc2-Fuc, the lower pH 
signals homomeric complexes of glycosyltransferases to reform as heteromeric dimer complexes acting sequentially on the 
glycan; (30*) trans-Golgi lumen, heteromeric dimer complexes of galactosyltransferases and sialyltransferases add 
terminal galactose and sialic acid moieties to the glycans.  
6.3.2 N-Linked Glycosylation 
N-linked glycosylation begins in the cytoplasm with the assembly of a seven sugar 
oligosaccharide onto a dolichol diphosphate anchor (Figure 30, Reaction 23). Once assembled, 
this oligosaccharide is flipped into the endoplasmic reticulum (ER) where dolichol phosphate 
linked mannose and glucose species donate the remaining four mannose residues and three 
glucose residues to complete the fourteen sugar N-glycosylation oligosaccharide precursor. This 
lipid-linked oligosaccharide is then detached from its dolichol phosphate anchor and bound to an 
asparagine amino acid of a protein undergoing translation by the oligosaccharyltransferase 
(OST) enzyme complex (Figure 30, Reaction 26). The resulting precursor to N-linked 
glycosylation is bound to the protein at a site referred to as a ‘sequon’. Once bound to its sequon, 




precursor glycan, removing the three terminal glucose moieties as well as the centremost 
terminal mannose (Figure 30, Reaction 27). 
6.3.3 Microheterogeneity 
Glycosylation continues into the Golgi, where further glycosyltransferase activity will 
produce a myriad of glycans that diverge between different cell lines. With particular regards to 
mammalian style complex glycans, forms of microheterogeneity include whether the terminal 
moieties are mannose (Man) or acetyl-glucosamine (GlcNAc). The degree of GlcNAc branching 
is referred to as “antennarity”, which can be as many as four, plus an extra bisecting GlcNAc on 
the central mannose. Other forms of microheterogeneity include the binding of core α1-6 fucose 
(Fuc) to the first GlcNAc bound to Asparagine (Asn); as well as the binding of galactose (Gal) to 
terminal GlcNAc moieties possibly followed by binding of sialic acids (NeuAc/Neu5Gc) to Gal, 
which are the only glycan moieties to confer a negative charge.  
Differences between glycoforms can be written by abbreviated nomenclatures, such as the 
Oxford Glycobiology Institute convention, described by Gornik and colleagues (2007), and 
utilized here. In this convention, the ‘F’ refers to fucose bound by an α1-6 bond, the ‘A’ to the 
degree of antennarity (i.e. GlcNAc branching), ‘B’ for the presence of a bisecting GlcNAc, ‘G’ 
to the degree of galactosylation, and the ‘S’ for the degree of sialylation. 
6.4 Controlling Glycosylation by Supplementation 
Typical glycoforms observed for several commercial mAbs are under-galactosylated, 
hindering their therapeutic potential (Wacker et al., 2011). Research in the field of 
supplementing nucleotide sugar precursors for affecting glycoforms follows a hypothesis that 




with terminal galactose and sialic acid moieties, like those observed in endogenous human sera 
(Flynn et al., 2010). These supplementation strategies, detailed in Table 7-Table 9, and Figure 
32-Figure 34, offer a simple means to adjust product glycoforms without having to completely 
redesign (i.e. glycoengineer) cell platforms.  
Nucleotide-sugar precursors and associated components supplemented to growth media have 
conventionally targeted what were regarded as the most crucial glycan-moieties for mammalian 
N-glycosylation: N-acetylglucosamine (GlcNAc), galactose (Gal), and, N-acetylneuraminic acid 
(NeuAc). Precursors selected for supplementation favour intermediate species at various points 
in the intracellular metabolic synthesis of these nucleotide-sugars that would otherwise be 
synthesized from glucose, as shown in Figure 30.  
The three compounds most commonly supplemented in literature include:  
 Glucosamine (GlcN), and more recently N-acetylglucosamine (GlcNAc), often 
accompanied with uridine (Urd) – as detailed in Table 7 and Figure 32 
 Galactose (Gal), often accompanied with uridine (Urd), and occasionally manganese4 
(Mg
2+
) – as detailed in Table 8 and Figure 33 
 N-acetylmannosamine (ManNAc), often accompanied with cytidine (Cyt) – as 
detailed in Table 9 and Figure 34  
These supplements have repeatedly been reported to increase the intracellular pools of 
nucleotide-sugars, and affect glycoform distributions. Inconsistencies in reported effects can be 
attributed to differences across five key factors: the host cell platform, the recombinant protein 
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 Manganese ions as a supplementation strategy has primarily been utilized in conjunction with uridine and 




expressed, timeline of fermentation from supplementation to sampling/harvest, the amount of 
glutamine present in culture media, and a previous lack of standardized comparison via 
glycosylation index equations (Figure 31) for observing shifts in glycoform distribution, applied 
here. 
6.4.1 Key Factors Impacting Supplementation Results 
6.4.1.1 Cell Platform 
Differences across cell platforms are expected to produce varying glycan distributions, as it is 
common even to have clones of the same cell-line that under or over-express an important 
enzyme or transporter, such as the YB2/0 rat hybridoma cells utilized by Shinkawa and 
colleagues (2003) that had low levels of fucosyltransferase-8 (FUT8), leading to low-fucose 
mAbs. Similarly, differences between different mammalian cell lines will commonly produce 
varying effects under identical nucleotide-sugar precursor supplementation strategies. This can 
be observed in the work of Baker and colleagues (2001), when the same TIMP-1 protein was 
expressed in both GS-CHO and GS-NS0 cells; 10mM glucosamine supplementation resulted in a 
significant antennarity index increase of 9% in the former (P < 0.05), but no change in the latter. 
6.4.1.2 Protein Glycan Site 
The type of protein examined is perhaps the greatest factor leading to differences in glycan 
profiles, as different glycan sequons will have very different solvent accessibility. A literature 
analysis conducted by Thaysen-Andersen and Packer (2012) determined that core α1-6 
fucosylation, glycan antennarity, and complex glycoforms vs high mannose, are all notably 
affected by the solvent-accessibility of glycan sites, and hypothesized the same to be true for 
terminal galactosylation and sialylation. Therefore, drawing a comparison between the glycans 




two proteins will have very different accessibility to the Golgi infrastructure to modify those 
glycans. This issue can be observed in Figure 32-Figure 34, with respect to the antennarity of 
different proteins. In Figure 33, the proteins are predominantly IgGs, and glycans are uniformly 
biantennary or lower, keeping their AI below 40%, while proteins like EPO, TIMP-1, and IL-2 
shown in Figure 32 and Figure 34 can have higher levels of branching due to the accessibility of 
these sequons to latter N-acetylglucosyltransferases (GnT IV&V) (Thaysen-Andersen and 
Packer, 2012). 
6.4.1.3 Fermentation Sampling Timeline 
Another very important factor is the fermentation timeline, particularly the time of sampling 
or harvest of recombinant proteins for glycan analysis. It has been demonstrated by Gramer and 
colleagues (1993, 1995), that CHO cells accumulate sialidase enzymes in their supernatant, and 
growing cultures past exponential phase until loss of viability can diminish the total sialylation of 
secreted recombinant proteins. Furthermore, a clear relationship has recently been demonstrated 
by Liu and colleagues (2014) between availability of glucose and the level of galactosylation and 
sialylation of mAbs grown in CHO cells. Therefore, in experiments where recombinant proteins 
are harvested for glycan analysis near the peak of exponential growth compared to those 
harvested when viability is decreasing, proportions with terminal sialylation will be in greater 
proportion. This can be observed in Figure 33, comparing the experiments of both Liu and 
colleagues (2014) and Surve and Gadgil (2015), who sampled their cultures during exponential 
phase, compared against those of St Amand and colleagues (2014) and Gramer and colleagues 
(2011), who sampled at the end of the culture. In the case of the former, both controls and final 
GI levels are generally higher than the latter, despite similar supplementation regimes, cell lines, 
and IgG proteins. Exceptions can be observed of course in the results of Grainger and James 




and final galactosylation percentage; however these values might have been even higher with 
earlier sampling. 
6.4.1.4 Glutamine Level 
Glutamine is of particular interest due to its relationship with ammonia, which directly 
impacts glycosylation activities in two ways. First, ammonia is a weak base capable of diffusing 
across cellular membranes, impacting the intracellular pH of cellular organelles like the Golgi. 
The cis-, medial-, and trans-Golgi cisternae operate at distinct acidic pH levels, as shown in 
Figure 30. Glycosyltransferases form reversible homomeric and heteromeric dimers, which 
migrate as mobile complexes between the Golgi and the ER (Hassinen and Kellokumpu, 2014). 
Homodimers are favoured closer to the neutral pH of the ER, where these enzymes are 
synthesized, while formation of heteromeric dimers, with enhanced activity, are favoured at the 
reduced pH points of the respective Golgi cisternae where they operate (Hassinen and 
Kellokumpu, 2014). This is illustrated in the Golgi glycosyltransferase enzyme pairings in Figure 
30. Higher ammonia levels will neutralize the intracellular pH of Golgi cisternae, causing 
heterodimer pairs to split and reform to their homodimer formats, reducing their functionality 
(Hassinen and Kellokumpu, 2014). Therefore, elevated supplementation of the labile nutrient 
glutamine, which increases intracellular ammonia levels, will in turn increase Golgi pH, and 
perturb the functionality of glycosyltransferases, particularly galactosyltransferase and 
sialyltransferase, decreasing the GI and SI of glycans. This result was demonstrated directly by 
Aghamohseni and colleagues (2014), who showed that supplementing increasing concentrations 
of glutamine to CHO cultures expressing a heavy-chain antibody (HCAb) reduced 




The second manner in which glutamine supplementation affects glycoform distributions is by 
directly increasing UDP-GlcNAc pools producing similar effects and glycoform shifts to those 
detailed in Table 7. Valley and colleagues (1999) supplementing ammonium ions with 
15
N 
tracers to BHK-21 cells produced a significant increase in UDP-GlcNAc intracellular nucleotide 
sugar pools. Approximately 60% of this pool incorporated the 
15
N tracers – a proportion 
approximately equivalent to the increase in the pool itself (Valley et al., 1999). As is 
demonstrated in Figure 32, elevated glucosamine levels will shrink levels of galactosylation and 
sialyation of glycoproteins. Therefore, elevated glutamine supplementations to cultures can have 
a similar effect as either ammonium or glucosamine supplementation, which has been 
demonstrated by several researchers (Gawlitzek et al., 1998; Grammatikos et al., 1998; Yang and 
Butler, 2002).  
CHO cells expressing glutamine synthase (GS) require little or no glutamine in their growth 
medium. St Amand and colleagues (2014), Kildegaard and colleagues (2015), and Surve and 
Gadgil (2015) all utilized glutamine nutrient in their cultures; 4mM for the former, and 8mM for 
the latter two respectively (Table 8). Galactose supplementation improves GI for all three of 
these research groups, but it’s typically an increase on the order of only 10%, while researchers 
supplementing galactose to GS-CHO cultures achieve GI increases for mAbs of 20% or higher 
(Figure 33). Therefore, addition of glutamine nutrient may limit the potential improvement to GI 
of galactose supplementation. 
6.4.1.5 Standardized Metrics for Reporting Glycan Shifts 
Lastly, given the various experimental differences across reports in literature, it is difficult to 
make comparisons and draw conclusions regarding the effectiveness of a particular 




As such, glycoform distribution index calculations have been employed, as detailed in the 
following section, to standardize comparisons between experimental controls and resulting shifts. 
These comparisons are detailed in Table 7-Table 9 and Figure 32-Figure 34. 
6.4.2 Glycoform Distribution Indexes 
Glycosylation indices are employed in order to provide a consistent comparison between 
experiments. These indices summarize the degree of glycosylation with respect to glycoform 
characteristics such as galactosylation (GI), sialylation (SI), core α1-6 fucosylation (FI), 
antennarity (AI), and high-mannose types (MI). These equations can be described generally as a 
measurement of how much of an available glycan substrate has received a particular glycan 
moiety. This is typically calculated as the total number of a particular glycan moiety, such as a 
terminal galactose unit, divided by all the available sites that could have received that moiety. As 
an example, if half of glycans with available terminal galactose sites are sialylated, the SI will be 
50%, despite whether only 5% of total glycans receive some degree of sialylation. These 
equations are designed to benefit tuning glycoform distributions in bioprocesses, rather than 
describing the distributions towards clinical applications. Figure 31 details each of the five 
equations, their derivation from a glycan distribution, and provides sample calculations with 
respect to human serum IgG1 (Flynn et al., 2010) and a recombinant HCAb (Blondeel et al., 
2015). Figure 32-Figure 34 provide detailed comparisons regarding both the shifts in the 
glycosylation of cultures under the reported supplementation regimes, but also comparisons of 








Figure 31 – A monoclonal antibody glycan distribution segmented to demonstrate the glycosylation index formulae. In 
each case the proportion of the glycan distribution with a particular moiety (i.e. sialic acid, terminal galactose, etc.) is 
divided by the proportion that could have received that particular moiety, with respect to the sequence of 
glycosyltransferase enzymes acting on the protein undergoing glycosylation. 
Formulae are presented for Equation 1) galactosylation index (GI); Equation 2) sialylation index (SI); Equation 3) 
fucosylation index (FI); Equation 4) antennarity index (AI); and Equation 5) mannose index (MI). A demonstration of the 
calculations is provided with respect to glycan distributions from serum-derived IgG1 pooled from five healthy donors 
(Flynn et al., 2010) and a recombinant heavy-chain antibody (Blondeel et al., 2015). 
6.4.3 Supplementation of Nucleotide-Sugar Precursors 
6.4.3.1 Glucosamine (GlcN) & Acetyl-glucosamine (GlcNAc) 
Glucosamine (GlcN) supplementation is consistently reported to increase intracellular pools 
of UDP-HexNAc (i.e. UDP-GlcNAc & UDP-GalNAc), as detailed in Table 7. UDP-
GlcNAc/GalNAc intracellular pools form in the cytoplasm and are linked by an epimerase 
(Figure 30, Reaction 17), which holds them in relatively fixed concentration proportions of 




Table 7 – Comparison of glycoform shifts and differences between reported experiments for the supplementation of 
glucosamine (GlcN), its acetylated form acetyl-glucosamine (GlcNAc), and the nucleoside uridine (Urd), towards 
expanding intracellular nucleotide-sugar pools of UDP-GlcNAC in cultured mammalian cells to affect N-linked 
glycoforms of recombinant glycoproteins. Experimental differences reported include: Supplementation cocktails and 
concentrations with multiple bullet-points representing separate flask or bioreactor conditions; The cell line utilized and 
the lineage of that cell line where reported; The protein being expressed and whether it is a mutant variant or fusion; The 
bioprocess scale, time of supplementation, and time of harvest; The amount of glutamine (Gln) utilized in the growth 
medium.  

















8  Reduced glycan complexity 
to favour G0 and FG0 
glycoforms 

















5  Reduced glycan complexity 
to favour G0 and FG0 
glycoforms – both GlcN & 
GlcNAc supplementation 
 ~50% drop in growth rate 
with GlcN supplementation 
 <5% drop in growth rate with 
GlcNAc supplementation 
 proportional increase in 
UDP-GlcNAc pool up to 2x 
with GlcNAc 
supplementation 










 Harvest 96h 
0.4 
(GS) 
 17x UDP HexNAc 
 -56% Galactosylation 
 -63% UDP-Hex 
 Reduced growth 






EPO  Flasks 
 250mL 
 Addition 0h 
 Harvest day 
4-5 
-  18.5x UDP-GlcNAc 
 Increased glycan 
heterogeneity 







BHK IL-2  Perfusion 
 2.5 L 
 Addition: 
day 21 
 Harvest:  
days 26-28 
and 29-30 
0  Greater antennarity, but 
lower complexity of glycans 
 3x UDP-HexNAc 
 Greater proportion of 
monosialylation with GlcN 
 +58% sialylation in std 














 Harvest 48h 
0.4 
(GS) 
 58x UDP-HexNAc 
 8x UDP-Hex 
 +9% antennarity 
 -8% sialylation 
















  Perfusion 
 2.5 L 
 Addition 
10d 
 Harvest 14d 
0  12x UDP-GlcNAc 
 5x UTP 





 +5mM Urd 
CHO 
(Dukx) 







 Harvest 96h 
4  Reduced growth 
 +28% sialylation 
 6-15x increase UDP-
HexNAc 
(N. S. C. Wong 
et al., 2010) 












6  25x UDP GlcNAc 










IFN-γ  Flasks 
 100mL 
3  Increased UTP correlated to 
increased UDP-HexNAc 
except in absence of 
glutamine 
(Nyberg et al., 
1999) 
 0.5mM Urd RH N/A  Culture dish 
 3 mL 
 Addition 
16h 
 Harvest 24h 
2.4
8
  Reduced sialylation 
 6.7x UTP 
 3.8x UDP-hexose 
 4.6x UDP-HexNAc 
(Pels Rijcken et 
al., 1995b) 
 
Glucosamine supplementation is commonly reported to reduce the complexity of N-glycan 
terminal moieties, favouring “G0” glycoforms featuring terminal GlcNAc (i.e with reduced 
galactosylation and sialylation) (Hills et al., 2001; Pels Rijcken et al., 1995b; Yang and Butler, 
2002; Zanghi et al., 1998). GlcN is also reported to increase glycan antennarity (Baker et al., 
2001; Gawlitzek et al., 1998; Grammatikos et al., 1998); however, this is only reported for non-
IgG proteins with higher-antennarity glycans (Thaysen-Andersen and Packer, 2012), such as 
TIMP-1 & IL-2 to-date (Table 7, Figure 32). Conversely, Yang and Butler (2002) actually 
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 Modified Il-2 variant featuring an artificial N-glycan site 
6
 Only a single flask for each experiment, and only one control flask appears to have been used 
7
 NCAM protein glycan results reported only relative to controls 
8




reported the opposite effect, with a reduction in antennarity of EPO from glucosamine feeding. 
Interestingly, Yang and Butler also reported elevated ammonia levels and increased glutamine 
uptake during GlcN supplementation, while Baker and colleagues (2001) reported minimal 
increase in ammonia in their GS cells; as such, this effect may depend on how efficiently the cell 
platform converts ammonia to UDP-GlcNAc (Valley et al., 1999), as opposed to harvesting the 
glucose from glucosamine via glucosamine-6-phosphate deaminase (Figure 30, Reaction 5). As 
noted in the previous section, Valley and colleagues (1999) supplementing 
15
N traced 
ammonium ions, determined that BHK-21 cells produced a significant increase in UDP-GlcNAc 
intracellular nucleotide sugar pools, and that approximately 60% of this pool incorporated 
15
N – 
a proportion approximately equivalent to the increase in the pool itself. Metabolomic analysis of 
CHO cultures producing HCAbs supplemented with both GlcN and GlcNAc reported neither 
elevated ammonia, nor increased uptake of glutamine; however, a three-fold increase in acetate 
was observed after glucose exhaustion, which has been attributed to scavenging of glucose from 
UDP-GlcNAc pools in stationary phase (Blondeel et al., 2015). Elevated ammonia levels will 
raise the pH of Golgi compartments, and prevent heteromeric glycosyltransferase dimer 
complexes, such as GnT-IV/V from functioning properly (Hassinen and Kellokumpu, 2014). 
Further, increasing glutamine can produce a similar effect as supplementing GlcN and GlcNAc 
to mammalian cultures (Aghamohseni et al., 2014). Therefore, the effect of increasing 
antennarity may depend on whether the metabolism favours formation of UDP-GlcNAc pools or 





Figure 32 – Comparison of glycoform shifts reported for experiments employing the supplementation of glucosamine 
(GlcN), its acetylated form acetyl-glucosamine (GlcNAc), and the nucleoside uridine (Urd), to affect N-linked glycoforms 
of recombinant glycoproteins produced in mammalian cell cultures. 
The %-shift in glycoforms, reported in Table 16, relative to reported control cultures is demonstrated as a shift from a 
starting control glycoform, indicated with a ‘C’ within the respective symbol, to a final glycoform following 
supplementation, as per the directional arrow between the two construction points. The glycosylation % values for 
mannose-type, antennarity, galactosylation, sialylation, and fucosylation are represented by their respective 
monosaccharide symbols. 
Wong and colleagues (2010) reported the only instance where GlcN supplementation 
increases the complexity of N-glycans’ terminal moieties, with increased sialylation of IFN-γ. It 
is worth noting that increased sialylation was observed for all of Wong et al.’s experimental 




nucleosides. Furthermore, the experiment appears to be n=1, with only a single control flask. 
Therefore, it is possible that the control flask for this experiment is merely an outlier of reduced 
sialylation. Nyberg and colleagues (1999) similarly cultured CHO cells expressing IFN-γ, and 
supplemented uridine rather than GlcN, reporting smaller but significant increases to intracellular 
UDP-GlcNAc pools (Table 7); however, no such increase in sialylation of IFN-γ glycoforms was 
observed.  
While more complex glycans (i.e. those possessing terminal galactose and sialic acid 
moieties) are therapeutically more desirable, commercial therapeutic mAbs favour terminal 
GlcNAc “G0” glycoforms (Wacker et al., 2011), therefore innovator biologics for biosimilars 
also favour G0 glycan types. Therefore, GlcN/GlcNAc supplementation has been demonstrated 
as a useful tool for tuning N-glycan distributions towards G0 forms in cultures (Blondeel et al., 
2015). For supplementation strategies, GlcNAc should be considered more favourable compared 
to GlcN, which has been shown to restrict growth in mammalian cultures producing recombinant 
proteins (Baker et al., 2001; Blondeel et al., 2015; Grammatikos et al., 1998; Hills et al., 2001; 
N. S. C. Wong et al., 2010; Yang and Butler, 2002; Zanghi et al., 1998), as well as transformed 
cancerous cells not expressing recombinant proteins (Bekesi and Winzler, 1970; Krug et al., 
1984; Oh et al., 2007; Pederson et al., 1992). A similar species to GlcN, galactosamine (GalN) 
also produces cytotoxic effects when supplemented to cultures (Pels Rijcken et al., 1995a). 
Restricted growth from supplementation of hexosamines (GlcN/GalN) have been attributed to 
either competition with glucose transport (Yang and Butler, 2002), or depletion of intracellular 
ATP and UTP pools (Pels Rijcken et al., 1995a). Pels Rijcken and colleagues (1995a) 
supplementing GalN to cultures hypothesized that what they considered cytotoxic effects of 




synthesis. However, it has more recently been demonstrated that negative growth from GlcN 
(and likely GalN) is actually from depleting pools of cytosolic acetyl-CoA, which convert GlcN 
to GlcNAc (Blondeel et al., 2015), an essential pool for lipid biosynthesis and cell division 
(Goudar et al., 2010; Quek et al., 2010). Supplementing GlcNAc has been demonstrated to 
remove this growth inhibition, while still producing an increase in intracellular UDP-GlcNAc 
pools (Blondeel et al., 2015; Kildegaard et al., 2015). GlcNAc supplementation may still draw 
phosphorylated pyrimidines away from pools for RNA synthesis leading to more rapid loss of 
viability in stationary phase; however, the demonstrated improved growth from avoiding 
acetylation by supplementing GlcNAc makes the activity of glucosamine-phosphate N-
acetyltransferase the more likely source of growth inhibition for this group of glycosylation 
supplements. 
6.4.3.2 Galactose 
Galactose (Gal) supplementation represents the most successful example of nucleotide-sugar 
precursor feeding to affect glycoforms to-date. This strategy has been reliably reported across 
several different research groups, utilizing different cell platforms, expressing different proteins, 
to increase galactosylation (Table 8). Even beyond galactosylated glycoforms, supplementation 
of Gal has also been demonstrated to relieve bottlenecks towards improving the sialylation of Fc-
fusion glycoproteins in GS-CHO cultures (Liu et al., 2015). Increased galactosylation is 
generally accepted to be of therapeutic benefit, with lack of galactosylation associated 




Table 8 – Comparison of glycoform shifts and differences between reported experiments for the supplementation of 
galactose (Gal), the nucleoside uridine (Urd), and the enzyme cofactor manganese (Mn2+), towards expanding 
intracellular nucleotide-sugar pools of UDP-galactose in cultured mammalian cells and affecting N-linked glycoforms of 
recombinant glycoproteins. Experimental differences reported include: Supplementation cocktails and concentrations 
with multiple bullet-points representing separate flask or bioreactor conditions; The cell line utilized and the lineage of 
that cell line where reported; The protein being expressed and whether it is a mutant variant or fusion; The bioprocess 
scale, time of supplementation, and time of harvest; The amount of glutamine (Gln) utilized in the growth medium. 






 20mM Gal CHO 
(DG44) 
IgG  Fed-batch 
bioreactor 
 1L 
 Addition 48h 
 Harvest 336h 
8  +12% galactosylation 




 10mM galactose NS0 
(GS) 
IgG  Flasks 
 500mL 
 Addition 48h 
 Harvest 96h 
0.4 
(GS) 
 5x UDP-Gal (Hills et al., 
2001)  
 10mM Gal  
 20mM Gal  








 Addition 120h 
 Harvest 288h 
GS  +22% galactosylation 
 +14% sialylation 
 No negative growth effects 
 Glycan distribution scaled 
well to 200L bioreactor 
(Liu et al., 
2015) 
 20mM galactose CHO IL-4/13  Batch 
bioreactor 
 1L 
 Addition 0h 
 Harvest 112h 
2  No notable effects to 
sialylation or gene expression 
(Clark et al., 
2005)  
 10mM Gal 
 +5mM Urd 
CHO 
(Dukx) 




 Addition 48h 
 Harvest 96h 
4  20x UDP-Gal 
 +12% sialylation 
(N. S. C. 
Wong et al., 
2010) 














 Harvest 19d 




 UDP-Gal pools unchanged 
 Improved galactosylation and 
sialylation 
(Crowell et al., 
2007) 






FII  Flasks 
 Addition 48h 
 Harvest 144h 
-  +26% sialylation from 
galactose addition 
 +30% sialylation from 
addition of MnSO4 
 Temperature-shift resulted in 
similar sialyation 
improvement for final process 
(Lee et al., 
2017) 
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 100mM Gal 





IgG  Flasks 
 250mL 
 Addition 0h 
 Harvest 168h 
4  +9% galactosylation 
 -31% fucosylation and +21% 
high-mannose glycans for 
Mn+Gal 
 -30% fucosylation and +14% 
high-mannose glycans for Mn 
alone 
 9x UDP-Gal pool 
 Increased expression of β-Gal 
II, III, IV and UDP-GalT 
transcripts 




















IgG  Flasks 
 100mL 
 Addition 0h 
 Harvest 72h 
8  -30-50% IgG when Replacing 
/lowering Glc or matching Gal 
 +11% galactosylation 



















IgG  Fed-batch 
bioreactor 
 2L 
 Addition 0h 
 Harvest 360h 
GS  +20% galactosylation for 1st 
cell line at 100mM Gal  
 +24% galactosylation for 2
nd
 
cell line at 40mM Gal 
 Glycan distribution scaled 
well to 100L and 1000L 
bioreactors 











IgG  Flasks 
 125mL 
 Addition 72h 
 Harvest 192h 
GS  +21-24% galactosylation 
 +1.5-5% sialylation 
 Best overall IVCC, MAb titre 
and galactosylation results 
with low Mn
2+
/Urd and high 
Gal condition 
 Mab galactosylation 
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 Additional experiments changed the main carbon source to fructose, glucose-free (only gal), and low-glucose 
delivered from a hydrogel for slow release. 
11
 Galactose, urdine and manganese (Mn
2+
) fed in ratios of 5:1:0.002 mM (UMG cocktail) for two CHO-K1SV cell 
lines expressing two separate IgGs under GS expression system 
12
 Face-centred DOE design for main-effects modeling of UMG cocktail developed by Gramer et al. cocktail, tested 





Figure 33 – Comparison of glycoform shifts reported for experiments employing the supplementation of glucosamine (GlcN), its acetylated form acetyl-glucosamine 
(GlcNAc), and the nucleoside uridine (Urd), to affect N-linked glycoforms of recombinant glycoproteins produced in mammalian cell cultures. 
The %-shift in glycoforms, reported in Table 17, relative to reported control cultures is demonstrated as a shift from a starting control glycoform, indicated with a ‘C’ 
within the respective symbol, to a final glycoform following supplementation, as per the directional arrow between the two construction points. The glycosylation % 




Precursor supplementation strategies often include the complementary nucleoside for a 
supplemented sugar, such as uridine (Urd) for GlcN and Gal, or cytidine (Cyt) for ManNac. 
Galactose supplementation strategies are the first to also incorporate manganese ions (Mn
2+
) to 
enhance the activity of galactosyltransferase, demonstrated by Gramer and colleagues (2011) in 
GS-CHO cultures producing IgG. These researchers proposed a synergistic cocktail (in static 
proportions), featuring uridine, manganese ions, and galactose (UMG), and experimented with 
increasing concentrations up to 20mM galactose, to achieve more than a 20% increase in 
galactosylation (Figure 33), with improvements plateauing at 8x UMG (16µM Mn2+, 8mM Urd, 
and 40mM galactose).  
The results of the UMG cocktail were replicated by Grainger and James (2013) utilizing a 
face-centred designed experiment (i.e. varying the proportions of the UMG supplements), for 
main effects analysis in two CHO cell lines expressing IgG. These researchers also demonstrated 
more than a 20% increase in IgG galactosylation (Figure 33); however, they determined the best 
results overall – including growth, mAb titre, mAb galactosylation – from supplementing the 
low-low-high (LLH) condition (1µM Mn
2+
, 0.5mM Urd, and 100mM Gal). Variations on the 
UMG cocktail have continued to be utilized by researchers reporting varying degrees of success 
for increasing glycoprotein galactosylation (Liu et al., 2014; St Amand et al., 2014; Surve and 
Gadgil, 2015). 
Towards better understanding the main effects of supplementing Gal, Urd, and Mn
2+
, 
researchers have pursued various experimental arrangements and concentrations (Table 8, Figure 
33). While galactose together with uridine is reported to generate superior results (Grainger and 
James, 2013; Gramer et al., 2011; N. S. C. Wong et al., 2010), galactose together with 




(Figure 33). Manganese supplementation has been reported to actually reduce fucosylation of 
IgG in CHO cultures (St Amand et al., 2014; Surve and Gadgil, 2015); however, St Amand and 
colleagues (2014) report this effect coincides with increased high-mannose type glycans and loss 
of antennarity (Figure 33). 
6.4.3.3 ManNac 
N-acetylmannosamine (ManNAc), often accompanied by the nucleoside cytidine (Cyt) is 
supplemented to cultures to increase the intracellular nucleotide-sugar pool of CMP-
acetylneuraminic acid (CMP-NeuAc) (detailed in Table 9), with the goal of improving the 
sialylation of glycoproteins (Figure 34). Several researchers have reported improvements in the 
sialylation of glycoproteins in mammalian cell culture following supplementation of ManNAc 
(Gu and Wang, 1998; N. S. C. Wong et al., 2010; Zanghi et al., 1998). Gu and Wang reported a 
15% increase in sialylation, and when supplementing 20mM radiolabelled ManNAc, all of the 
resulting sialylation included the tracer (Gu and Wang, 1998). Interestingly, researchers that do 
not observe increases in sialylation typically reported a deficit of galactosylation that could be 
improved with galactose feeding (Hills et al., 2001; Kildegaard et al., 2015; Liu et al., 2015). Liu 
and colleagues (2015) supplementing galactose improved galactosylation in cultures, which 
subsequently also lead to increased sialylation by 14%. Synergistic supplementation of galactose 




Table 9 – Comparison of glycoform shifts and differences between reported experiments for the supplementation of the 
acetylated amine sugar N-acetylmannosamine (ManNAc), and the nucleoside cytidine (Cyt), towards expanding 
intracellular nucleotide-sugar pools of CMP-NeuAc in cultured mammalian cells and affecting N-linked glycoforms of 
recombinant glycoproteins. Experimental differences reported include: Supplementation cocktails and concentrations 
with multiple bullet-points representing separate flask or bioreactor conditions; The cell line utilized and the lineage of 
that cell line where reported; The protein being expressed and whether it is a mutant variant or fusion; The bioprocess 
scale, time of supplementation, and time of harvest; The amount of glutamine (Gln) utilized in the growth medium. 



















8  Hypothesis that increases in 
CMP-NeuAc lead to feedback 
inhibition, UDP-GlcNAc 












 Harvest 96h 
0.4 
(GS) 
 44x CMP-NeuAc 
 No improvement to sialylation 








TIMP-1  1L - Flasks 
 Addition 
24h 
 Harvest 48h 
0.4 
(GS) 
 -22% Neu5Gc content in NS0 
cultures 
 +1% shifts in %-sialylation 
 12x increase in CMP-SA 
(CHO) 
 30x increase in CMP-SA (NS0) 
(Baker et al., 
2001) 





FII  Flasks 
 Addition 48h 
 Harvest 144h 
-  +20% sialylation from ManNAc 
addition 
 Temperature-shift resulted in 
similar sialyation improvement 
for final process 
(Lee et al., 
2017) 





IFN-γ  100mL 
Flasks 
 Addition 0h 
 Harvest 96h 
-   27x increase CMP-SA 
 +15% complete sialylation 
 60% & 100% of sialylation 
from radiolabelled 
supplemented ManNAc fed at 
2mM & 20mM respectively 








 Harvest 24h 
2.4
14
  3.0x CTP 
 3.2x UDP-HexNAc 
 2.6x UDP-hexose 
(Pels Rijcken 
et al., 1995b) 
                                                          
 
13
 Supplementations of mannose, NeuAc, and cytidine were also attempted, but did not vary significantly from 
control cultures 
14

























GS  Statistically insignificant sialic-
acid content increase (terminal 
galactose determined to be 
limiting) 


















 -20-30% NCAM production 












 Harvest 96h 
4  30-120x increase in CMP-SA 
 +32-36% sialylation -/+ Cyt 
 +26-52% higher specific 
productivity 
(N. S. C. 
Wong et al., 
2010) 
 
Sialylation of glycoproteins by rodent-derived mammalian cell cultures comes with some 
risk of the immunogenic glycoform CMP-Neu5Gc, a glycan which does not occur endogenously 
in humans (Ghaderi et al., 2010; Padler-Karavani et al., 2008). A benefit of ManNAc 
supplementation reported by Baker and colleagues (2001) is that Neu5Gc moieties were reduced 
by 22%, making this an intelligent culture addition regardless of whether overall sialylation 
increases. 
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Figure 34 – Comparison of glycoform shifts reported for experiments employing the supplementation of acetyl-
mannosamine (ManNAc), and the nucleoside cytidine (Cyt), to affect N-linked glycoforms of recombinant glycoproteins 
produced in mammalian cell cultures.  
The %-shift in glycoforms, reported in Table 18, relative to reported control cultures is demonstrated as a shift from a 
starting control glycoform, indicated with a ‘C’ within the respective symbol, to a final glycoform following 
supplementation, as per the directional arrow between the two points. The glycosylation % values for mannose-type, 





Nucleoside supplementation on its own has been considered a viable strategy for affecting 
glycoforms, as they have similarly been shown, if more moderately, to increase nucleotide-sugar 
pools (Table 7 and Table 9). Nyberg and colleagues (1999) reported that supplementing up to 
10mM uridine to CHO cultures expressing IFN-γ observed a linear correlation between increased 
UTP levels and UDP-GlcNAc pools. Pels Rijcken and colleagues (1995b) similarly observed 
corresponding increases of UTP, UDP-glucose/galactose, and UDP-GlcNAc/GalNAc upon 
supplementing either 0.5mM uridine or cytidine to primary cultures of rat hepatocytes. Few 
strategies for supplementation of nucleotides, nucleosides, or nitrogenous bases beyond the 
pyrimidines exist, as these have been demonstrated to produce negative growth effects 
(Carvalhal et al., 2003). 
6.4.3.5 Other Exotic Sugars and Supplements 
Beyond the classic nucleotide sugar precursor supplements detailed in Table 7-Table 9, 
several additional supplementation strategies have been attempted to exert control over glycan 
distributions. Inhibitors to particular glycosyltransferases may be utilized to produce hybrid and 
high-mannose type glycans; however, these present little therapeutic advantage (Section 4). 
Several unconventional monosaccharides have been attempted, including mannose, fucose, 
and N-acetylneuraminic acid (NeuAc); however, none of these produced any notable shifts to 
glycoforms (Kildegaard et al., 2015). Hossler and colleagues (2017) have recently reported 
supplementation of nine unconventional sugars to CHO cultures expressing a mAb glycoprotein. 
While several of these sugars produced high-mannose and hybrid type glycoforms, melezitose, 
turanose and to a lesser extent lactose supplemented at 1, 10, 25 and 50mM, created significant 




previously demonstrated that supplementing D-arabinose and L-galactose at 50 mM to CHO 
cultures expressing a mAb glycoprotein can achieve a complete exchange of fucose moieties for 
these alternate sugars producing benefits for bioactivity by antibody dependent cell cytotoxicity 
(ADCC) (Hossler et al., 2017). 
6.5 Glycoforms: Bioefficacy and Functionality 
Glycoprotein biotherapeutics include mAbs, cytokines, hormones, clotting factors, and 
growth factors, a thorough listing of these approved by the FDA are available (Ghaderi et al., 
2012). Much research has been devoted to understanding how shifts in glycoforms change 
effector function for mAbs, due the myriad ways IgGs activate the immune system (Table 10-
Table 14). For other glycoproteins, the primary concern is generally terminal sialylation, as this 
has the greatest impact on extending serum half-life for most glycoprotein therapeutics like 
tissue plasminogen activator (tPA) and erythropoietin (EPO), and reducing how often drugs must 
be re-administered to patients (Cole et al., 1993; Elliott et al., 2004). Albrecht and colleagues 
(2014) provide an excellent examination of the impact of glycoform on commercial therapeutics, 
particularly Darbepoetin-α, a commercial therapeutic recombinant erythropoietin (EPO), which 
is modified to possess two additional N-glycan sites compared to the usual three in human EPO. 
Darbepoetin-α carries a much greater proportion of sialic acid moieties compared to the two 
other commercial forms of EPO, epoetin-α/β (Egrie et al., 2003). These additional sialylated 
glycan sites effectively double the half-life and bioactivity; however, Darbepoetin’s higher 
aggregate sialylation causes a 5-fold reduced receptor binding, requiring higher dosages (Egrie et 
al., 2003; Elliott et al., 2004). This result corresponds to reports by Scallon and colleagues 




receptors to activate antibody dependent cell cytotoxicity (ADCC), a major bioactivity metric of 
mAbs (Table 13).  
Serum clearance of glycoproteins is often the result of receptors for specific terminal glycans, 
like mannose binding receptors on liver endothelial cells, or asialoglycoprotein receptors for 
galactose moieties, also of the liver (Smedsrød and Einarsson, 1990). Conversely to most 
glycoproteins, it has been reported that sialylation does not extend serum half-life in vivo for 
mAbs (Kaneko et al., 2006; Wright and Morrison, 1998), a result possibly due to the positioning 
of the glycan site on the Fc region, where IgG glycans are predominantly located. 
6.5.1 Immune Effector Functions for Antibodies 
The Fab regions of antibodies allow them to bind to their target antigens with high 
specificity, but it is their glycosylated Fc regions that interact with and activate immune 
responses. IgGs possess paired glycosylation sequons at ‘asparagine 297’ (Asn297) on the heavy 
chain CH2 domain of their Fc region, and produce varying immune response activation 
capability in vivo depending on their glycoform (Table 10-Table 14). Jefferis (2012) provides an 
excellent overview of antibody isotypes, their key features, and interactions with the immune 
system. 
The Fc region of antibodies interacts with the immune system by binding to numerous 
different Fc receptors on the surfaces of immune cells, as well as complexing with C1q, which 
activates the Complement system cascade. Complement can also be activated by G0 and high-
mannose glycans via mannose-binding lectin (MBL) activation; however, such glycoforms also 
observe rapid clearance from serum (Table 12) (Malhotra et al., 1995; Nimmerjahn et al., 2007). 




mediates a host of immune effector functions, such as antibody-dependent cell phagocytosis 
(ADCP), cytolysis or cytotoxicity (ADCC), and the release of cytokines and chemokines 
spurring further cascades of immune responses within the highly regulated immune system. 
Vidarsson and colleagues (2014) provide a comprehensive review of these effector functions. 
Therapeutic monoclonal antibody (mAb) glycoforms are often characterized by how well they 
can recruit immune effector functions, particularly ADCC and Complement dependent cell 
cytotoxicity (CDC).  
Regarding activation of ADCC and CDC endogenously, a typical glycan distribution for human 
serum IgG1&2 from five healthy volunteers showed a prevalence for five main glycoforms: 
fucosylated biantennary G0, G1, G2, G2S1, and bisecting G1 (Flynn et al., 2010). While this and 
similar studies provide a general conception of a “normal” glycan distribution for mAbs, an 
important characteristic of antibody glycoforms in vivo, is their tendency to shift with pathology, 
as evidenced by Kaneko and colleagues (2006), who reported the downregulation of sialylated 
antibodies in vivo during antigenic challenge removing their anti-inflammatory properties (Table 
13). Therefore, the optimal distribution of glycans on therapeutic antibodies likely varies from 
the distribution reported by Flynn and colleagues for treating a particular disorder/pathology. 
Kapur and colleagues (2014) provide a summary of patterns of IgG-antibody glycosylation with 
respect to their effects in reported pathologies. 
6.5.2 Glycoforms and Antibody Immune Effector Functions 
Recognition and binding of IgGs by C1q and Fc receptors are affected by glycoforms 
yielding different binding affinities, or steric effects (Ferrara et al., 2006), and therefore 
significant variation in triggering the immune system. Table 10-Table 14 demonstrate how 





Core α1-6 fucosylation on the first GlcNAc moiety of the N-glycoform is typical for the 
majority of human glycans both for antibodies (Flynn et al., 2010) and other secreted 
glycoproteins (Takeuchi et al., 1988). However, absence of fucosylation has been reported to 
dramatically increase affinity of IgGs for FcγRIIIa receptors of NK cells, increasing ADCC 
responses by purified peripheral blood monocytes during in vitro assays (Table 10). Steric 
interaction between the Asn297 glycan of the antibody Fc and the Asn162 glycan of the FcγRIIIa 
receptor has been proposed as the mechanism behind this improvement (Ferrara et al., 2006). 
This also corresponds with research linking individuals with polymorphic FcγRIIIa receptors to 
improved clinical outcomes when treated with rituximab where core-fucosylation is still present 
(Cartron et al., 2002). While a clear relationship between fucosylation and ADCC has been 
reported, several researchers have found no relationship between the core α1-6 fucose moiety and 
CDC (Chung et al., 2012; Shields et al., 2002; Yamane-Ohnuki et al., 2004). 
Table 10 – Therapeutic efficacy of monoclonal antibodies (mAbs) and immune effector function (IEF) with respect to 
fucosylation of N-glycans. A biantennary glycan with a circled region is provided to indicate the moiety. IEFs include 
antibody dependent cell cytotoxicity (ADCC), complement dependent cell cytotoxicity (CDC), as well as binding to the 
immune antibody receptor FcγRIIIa. 











 50 fold improvement in binding in vitro of IgGs to FcγRIIIa 
receptors enhancing ADCC 
 ~90% afucosylated IgGs expressed in CHO and HEK cells 
deficient in FucT produce IgGs with 40-60% increase ADCC 
(Shields et al., 2002) 
ADCC 
 30% increase in ADCC for anti-CD20 IgGs produced in FUT8 
mRNA deficient YB2/0 rat hybridoma produced IgGs (-91% 
fucosylation) compared to Rituxan™ 
 40% increase in ADCC for afucosylated IgGs produced YB2/0 
compared to CHO (-21% fucosylation) 
 Overexpression of FUT8 removes ADCC enhancement in anti-
CD20 IgGs from YB2/0 cells 
(Shinkawa et al., 2003) 
ADCC 
 ~40-100% increase in ADCC from a 90% reduction in 
fucosylation of IgG demonstrated both via in vitro ADCC 
assays from four donors and via an in vivo mouse model, which 
prevented tumor formation in mice injected with leukemia cells 
for ~25 days 




N-Glycoform IEF Effects Researchers 
ADCC 
 ~50% increase ADCC from IgG with a 52-63% decrease in 
fucosylation; plasmids coding siRNA for FUT8 mRNA 
introduced to CHO 
(Mori et al., 2004) 
ADCC 
 20% increase in ADCC from complete removal of fucose 
moiety; FUT8 mRNA knockout CHO culture producing anti-
CD20 IgGs 
(Yamane-Ohnuki et al., 
2004) 
ADCC 
 ~20-30% increase in ADCC reactivity with afucosylated IgG 
pools 
 Galactosidase treated pools of IgG were 100% fucosylated or 
afucosylated mixed in defined proportions 
(Chung et al., 2012) 
CDC  Fucose moiety on Fc glycans yields no effect to complement 
(Chung et al., 2012; 
Shields et al., 2002; 
Yamane-Ohnuki et al., 
2004) 
FcγRIIIa 
 Afucosylation of just one Fc glycan (G0/G0F) sufficient to 
enhance ADCC because of steric hindrance between receptor 
glycan at Asn162 and fucose moiety on Fc-glycan at Asn297  
(Ferrara et al., 2006) 
 
6.5.2.2 Bisecting N-Acetylglucosamine (biGlcNAc) 
Core α1-6 fucosylation of the N-glycoform is partially inhibited by the GnT-III enzyme, 
absent in the CHO genome (Xu et al., 2011). GnT-III acts to append a bisecting GlcNAc moiety 
to the first mannose residue of the glycan (Schachter, 1986). The higher ADCC response from 
NK cells via FcγRIIIa binding was initially associated with antibodies bearing the bisecting N-
GlcNAc (these results are detailed in Table 11); however, it was reported that in vitro 
remodelling of rituximab and trastuzumab glycans to produce antibodies with both core-fucose 
and bisecting GlcNAc glycoforms demonstrated little improvement (~10%) to ADCC 
(Hodoniczky et al., 2005). In contrast, Shinkawa and colleagues (2003) column-purified 
fractions of IgG produced from rat hybridoma YB2/0 cells to obtain fractions high in both 
bisecting GlcNAc and core α1-6 fucosylation, and determined no improvement towards ADCC. 
Therefore, the benefit of the bisecting glycoform, at least with respect to ADCC mediated by NK 




vivo possess bisecting GlcNAc with approximately 12% and 9.3% proportions, respectively  
(Flynn et al., 2010). As such, this glycoform may bear some yet unknown regulatory property for 
antibodies. 
Table 11 – Therapeutic efficacy of monoclonal antibodies (mAbs) and immune effector function (IEF) with respect to N-
glycans possessing the bisecting N-acetylglucosamine (GlcNAc) moiety. A biantennary glycan with a circled region is 
provided to indicate the moiety. IEFs include antibody dependent cell cytotoxicity (ADCC). 











 10% increase in ADCC of Rituxan & Herceptin mAbs remodelled in vitro 




 15-25% increase in ADCC from a 48-71% increase in bisecting GlcNAc 
on IgG from CHO modified to express GnT-III 
(Davies et al., 
2001) 
 ~30% increase in ADCC after GnT-III enzyme introduced to CHO, 
reducing fucosylation and increasing bisecting GlcNAc structures 
(Umaña et al., 
1999) 
 No improvement in ADCC resulted from column-purified fractions of 
IgG1 from rat hybridoma YB2/0 possessing bisecting GlcNAc increased 
from 4-30%, and 0-45% (separate experiments), but constant fucosylation 
proportions 




Terminal galactosylation is not perceived to be an essential factor for stimulating ADCC 
responses; however, non-galactosylated IgGs have consistently been shown to have weaker C1q 
binding and complement-dependent cytotoxicity (CDC) responses (Table 12). Reviews of mAb 
effector function with respect to N-glycoforms have noted that lower galactosylation in vivo has 
been linked to aging, auto-immune disorders and disease states such as rheumatoid arthritis 
(Harris et al., 2010; Jefferis, 2012; Spearman et al., 2011). Therefore, increased galactosylation is 
viewed as therapeutically favourable; however, compared to human IgG, commercial 




Table 12 – Therapeutic efficacy of monoclonal antibodies (mAbs) and immune effector function (IEF) with respect to 
galactosylation of N-glycans. A biantennary glycan with circled regions is provided to indicate the moieties. IEFs include 
antibody dependent cell cytotoxicity (ADCC), and complement dependent cell cytotoxicity (CDC). 









 Reduced C1q binding in vitro for agalactosylated IgG from 
patient serum with rheumatoid arthritis 
(Tsuchiya et al., 1989) 
 35-50% reduction complement lysis activity in vitro for rIgG1 
expressed in CHO treated with sialidase and galactosidase 
(Boyd et al., 1995) 
 3-fold reduction in CDC for rituximab treated with galactosidase 
(Hodoniczky et al., 
2005) 
 ~2-fold enhanced binding of mannose-binding-lectin (MBL) for 
IgGs treated with galactosidase to convert from 20% to 100% 
G0 Fc glycans 
(Malhotra et al., 1995) 
 60-70% increase in binding to mannose-binding-lectin (MBL) 
protein activating complement by agalactosylated IgGs 
 25-45% decrease in C1Q binding for complement activation 
(Nimmerjahn et al., 
2007) 
 G0 IgGs produced in CHO knockout cultures, without UDP-gal 
transport and CMP-NeuAC transport, do not to activate 
complement 
(Wright and Morrison, 
1998) 
ADCC  Limited improvement to ADCC with galactosylation 
(Kumpel et al., 1995, 
1994) 
ADCC 
 No observed relationship between galactosylation and in vitro 
ADCC 
(Boyd et al., 1995; 
Shinkawa et al., 2003) 
 
6.5.2.4 Sialylation 
Terminal sialylation, unlike other glycoforms, introduces a negative charge to glycans. This 
glycoform has been reported to reduce binding affinity of mAbs to antigens, FcγR receptors, and 
reduce ADCC immune responses (Table 13). However, it does possess anti-inflammatory 
properties, and is credited with the success of intravenous immunoglobulin (IVIG) therapies  
(Kaneko et al., 2006; Scallon et al., 2007). This seems to mainly be a feature of α2-6 linked sialic 
glycoforms rather than α2-3 (Anthony et al., 2008).  Unlike other therapeutic glycoproteins, mAbs 
with elevated sialylation have not been reported to receive improvements to serum half-life 
(Kaneko et al., 2006; Wright and Morrison, 1998). Raju and Lang (2014) provide a thorough 




Table 13 – Therapeutic efficacy of monoclonal antibodies (mAbs) and immune effector function (IEF) with respect to 
sialylation of N-glycans. A biantennary glycan with circled regions is provided to indicate the moiety. IEFs include 
antibody dependent cell cytotoxicity (ADCC), complement dependent cell cytotoxicity (CDC), anti-inflammatory 
properties, as well as protein serum half-life (serum t1/2). 









 ~20% reduced ADCC in populations fractionated to include 
increased sialylated glycans (~10-60% increased sialylated 
content) or treated with SialT to increase sialylated content. 
 ~40% reduced ADCC for glycoengineered glycans (~90% 
sialylated) 
 Increased sialylation reduces affinity for FcγRIIIa as well as 
antibody-antigen affinity 
 Sialylated glycans on Fc region impact hinge flexibility 
impeding FcγR binding 




 Terminal sialylation provides anti-inflammatory action 
 Sialylated glycoform is actively downregulated in vivo upon 
antigenic challenge 
 60-80-fold increase of sialylated IgGs from hybridomas 
purified via affinity chromatography 
 40-80% reduction in IgG cytotoxicity (reversible with 
sialidase), and 5-10-fold reduction in FcR binding affinity  
 10-fold increase in anti-inflammatory reaction when high 
sialic-acid fraction IgG injected into in vivo mouse 
rheumatoid arthritis model 





 No effect towards complement lysis activity in vitro for 
rIgG1 expressed in CHO treated with sialidase 
(Boyd et al., 1995) 
Serum t1/2 
 No effect for IgGs produced in galT and sialT deficient CHO 
cells 
 No effect for high sialylated fraction (Kaneko) 
(Kaneko et al., 
2006; Wright and 
Morrison, 1998) 
 
6.5.2.5 High Mannose 
High mannose glycans typically represent an early departure from glycosylation, either after 
the endoplasmic reticulum, or the cis-Golgi (Figure 30). This glycoform possesses minimal 





Table 14 – Therapeutic efficacy of monoclonal antibodies (mAbs) and immune effector function (IEF) with respect to 
high-mannose N-glycans. Two N-glycans are provided to describe this glycoform. IEFs include binding to the immune 
antibody receptor FcγRI, complement dependent cell cytotoxicity (CDC), and protein serum half-life (serum t1/2). 










 4-6-fold impairment in binding of FcγRI receptor 
compared to complex glycoforms 
(Wright and Morrison, 
1998, 1994) 
CDC 
 Nearly complete loss of CDC activity and C1q binding 
with Man5 glycoforms on GnT-I knockout CHO cells 
(Wright and Morrison, 
1998, 1994) 
CDC 
 Loss of CDC activity in IgGs with high mannose glycans 
from yeast cells with up to 30 mannose structures 
(Tao and Morrison, 
1989) 
Serum t1/2 
 Rapid in vivo clearance in mice of 80% of antibodies, 
significantly shorter overall serum half-life 
(Wright and Morrison, 
1998, 1994) 
Serum t1/2 
 High-mannose MAbs administered to patients cleared 
rapidly out of circulation before other glycoforms 
(Goetze et al., 2011) 
 
6.5.3 Immunogenic Glycoforms 
Several established rodent-derived cell lines such as NS0 and CHO form glycosylation 
structures immunogenic in humans such as terminal alpha-gal and a sialic acid variant, N-
glycolylneuraminic acid (Neu5Gc) (Bosques et al., 2010; Ghaderi et al., 2010; Padler-Karavani 
et al., 2008). As such, fully human cell lines have grown more popular and attempts have been 
made with some success to “glycoengineer” human-like glycosylation in alternative production 
platforms of bacteria, yeast, insect cells, as well as making improvements to mammalian 
platforms currently in use. Ghaderi and colleagues provide an excellent examination of this 





Glycosylation remains among the most important critical quality attributes (CQAs) of 
recombinant therapeutic glycoproteins, particularly regarding mAbs, where they directly impact 
the immune effector function of therapeutics. Galactosylation and afucosylation are the most 
desirable glycoforms for mAbs, while sialylation is the most desirable for other therapeutic 
glycoproteins.  
Supplementation of nucleotide sugar precursors to tune glycan distributions for more 
desirable therapeutically active glycoforms continues to demonstrate strong potential as a 
process improvement strategy. These supplementations, while often effective, but reported with 
inconsistent results. This is primarily due to five key factors beyond the supplementations 
themselves. The first is differences across cell platforms, such as the up/down regulation of 
enzymes and transporters; two different cell platforms expressing the same recombinant protein 
can produce different effects from the same supplementation regime. Secondly, differences 
between expressed proteins, and by extension differences in the accessibility of the protein 
glycan sites, can translate to hard limits on the potential glycan complexity and effectiveness of 
supplementation; mAbs for instance are naturally limited to only having biantennary glycans 
compared to other therapeutic glycoproteins. The third factor is the fermentation and sampling 
timeline, specifically glucose availability, which is inversely correlated to galactosylation and 
sialylation of glycans. This, together with accumulation of exoglycosidases in cultures, 
particularly sialidase means that harvesting at the end of exponential phase will result in a 
different glycan distribution than during stationary phase, following a decrease in cell viability. 
The fourth factor is the concentration of glutamine supplemented to cultures, as the subsequent 




the pH of Golgi compartments preventing the proper formation of heteromeric dimer 
glycosyltransferases necessary for complex terminal glycan additions such as galactosylation and 
sialylation. Finally, a lack of standardized glycosylation index metrics for observing shifts in 
glycoform distribution, which can provide better accounting for differences between control 
cultures and associated reported effects. 
The supplementation of glucosamine (GlcN) and acetylglucosamine (GlcNAc) reduces the 
terminal complexity of glycans to favour the G0 glycoforms, and can increase antennarity of 
non-IgG proteins. GlcN causes significant restriction to cell growth, but its acetylated form 
GlcNAc does not. Galactose supplementation achieves increased galactosylation with the 
greatest reported consistency, and can be enhanced by the addition of uridine and manganese 
ions, with best results in a glutamine-synthase cell platform. Acetylmannosamine (ManNAc) 
supplementation, optionally with cytidine, has been reported to significantly increase sialylation; 
reports of it not succeeding tend to coincide with cell platforms that already have a deficit in 
galactosylation. Several other exotic sugars also have the potential to affect factors such as 
fucosylation in the case of D-arabinose, and galactosylation in the case of melezitose, turanose 
and to a lesser extent lactose. 
While this field continues to present exciting new paths like to achieve more therapeutic 
glycoforms, there remains much opportunity for examining the synergistic supplementation of 
galactose and ManNac to improve sialylation of glycoproteins. Using these supplementation 
methods to tune glycan distributions towards targeted glycoforms should enter the toolkit of 





Conclusions & Recommendations 
The work presented in this thesis was intended to demonstrate supplementation strategies to 
both enhance cell growth of CHO mammalian cell cultures, and tune glycosylation to improve 
product quality with respect to protein glycosylation. Towards these objectives, omics methods 
were applied to elucidate factors at the scale of the metabolome and proteome, to create a 
nutrient cocktail to enhance culture growth. Further, supplementation of a class nutrients capable 
of shifting glycan distributions was subsequently examined to tune glycosylation of product 
monoclonal antibodies to improve quality. Fingerprinting metabolomics was also employed here 
to observe changes to intracellular nucleotide-sugar pools. Supplementing this class of nutrients 
was further examined across literature to better resolve conflicting reports of effects to glycan 
distributions from mammalian cell culture researchers. 
In order to enhance culture growth, a multi-omics analysis was undertaken utilizing a two-
dimensional differential in-gel electrophoresis (2D-DIGE) proteomics analysis between a 
parental CHO cell line and a daughter cell line engineered to stably express a recombinant 
heavy-chain antibody. Measurements of differential endogenous cellular protein expression were 
subsequently coupled with a metabolomics analysis of the culture supernatant of the daughter 
CHO cells by targeted profiling of 1D-1H-NMR spectra. Together, these omics methods 
demonstrated cell stresses via upregulated metabolism, depleted nutrients and accumulated waste 
metabolites. These results were utilized to modify the culture growth medium with a cocktail of 
nutrients, which enhanced cell growth. Eight target nutrients corresponding with four identified 
metabolic systems for CHO cells with upregulated pathways related to anaplerotic TCA-




limitations to lipid synthesis, as well as redox modulation. The supplementation resulted in a 
~75% improvement to peak cell densities. 
Towards tuning glycosylation, N-acetylglucosamine (GlcNAc) and glucosamine (GlcN), 
nucleotide sugar precursors, were supplemented to the growth medium of CHO cell cultures. The 
supplementation of GlcN reduced the complexity of glycan profiles of EG2-hFc expressed in 
CHO cells to favour the G0 glycoform, but caused a significant restriction to cell growth. By 
supplementing N-acetylglucosamine (GlcNAc) instead – the acetylated form of GlcN – the same 
affect to the glycan profile was achieved, but with a marginal impact to cell growth, particularly 
at GlcNAc concentrations of 2.5 mM. The difference in growth effects were attributed to the 
necessary acetylation of GlcN, which depletes intracellular acetyl-CoA pools necessary for 
supporting lipid biosynthetic pathways, a result confirmed by the increased excretion of acetate 
in GlcNAc supplemented cultures by metabolomic analysis. 
Supplementation of nucleotide sugar precursors to the growth medium of cell cultures is a 
promising strategy for tuning the glycan profile of therapeutic recombinant proteins to achieve 
desired glycan distributions and achieve more therapeutically active glycoforms. However, 
supplementation of these precursors has been reported with conflicting results. This is due to five 
key factors: differences across cell platforms; different solvent-accessibility of glycan sites on 
expressed proteins; the fermentation timeline (glucose availability runs inverse to glycan 
complexity) and sampling timeline (accumulation of exoglycosidases); the concentration of 
glutamine (ammonia alters Golgi pH and increases UDP-GlcNAc pools); and finally, a lack of 




The supplementation of glucosamine (GlcN) and acetylglucosamine (GlcNAc) reduces the 
terminal complexity of glycans to favour the G0 glycoforms, and can increase antennarity of 
non-IgG proteins. Galactose supplementation achieves increased galactosylation with the 
greatest reported consistency, and can be enhanced by the addition of uridine and manganese 
ions. Acetylmannosamine (ManNAc) supplementation, optionally with cytidine, has been 
reported to significantly increase sialylation; reports of it not succeeding tend to coincide with 
cell platforms that already have a deficit in galactosylation. 
While the metabolomics analysis of Chapter 3 was conducted at bioreactor scale, the 
proteomics analysis was not. Similarly, the experiments of Chapter 4 were conducted at the flask 
scale. As such, the proteomics analysis, glycan analysis, and fingerprinting metabolomics 
analysis of intracellular metabolite pools, were all conducted at a single time-point for these 
cultures. It is recommended that a multi omics analysis, proteomics, glycans and intracellular 
fingerprinting, be conducted at bioreactor scale for time-course analysis experiments, 
supplementing nucleotide-sugar precursors to determine how the proteome, metabolome, and 
glycoform distribution shift during culturing. Of particular interest would be determining what 
cell stresses could be identified from glucosamine supplementation compared to N-
acetylglucosamine (GlcNAc) supplementation. Given that the latter cultures did not have growth 
restriction, but still lost viability faster than control cultures, it would be interesting to determine 
whether addition of uridine could alleviate these stresses similar to the UMG cocktail utilized 
during galactose supplementation.  
Transformed cells, such as CHO, exhibit a truncated TCA metabolism, and the growth 
effects of glucosamine on cytosolic acetyl-CoA pools seems an important factor in the 




continue to fail to make a distinction between the intracellular acetyl-CoA pools in the 
mitochondrion and the cytosol, even though these two pools are not connected. It is 
recommended that this particular metabolic node be examined by models and experiments to 
elucidate its impact on cell growth. Much of the analysis and results presented in this thesis 
would lend well to the development of metabolic and glycan modeling.  
Beyond supplementing glucosamine and GlcNAc, there is also much opportunity for 
examining the synergistic supplementation of galactose and ManNac to improve sialylation of 
glycoproteins. While galactose cocktails of manganese and uridine are very common, inclusion 
of cytidine and ManNAc are not, but I suspect would yield fruitful results. Similarly, among 
nucleosides, only cytidine and uridine are used with regularity, generally from one report 
claiming cytotoxic effects from adenine, guanine and uracil. Supplementing these latter 
nucleosides may produce interesting results. 
Additional supplementation experiments that would have been valuable include the potential 
for supplementation of exotic sugars to achieve more therapeutic glycoforms, particularly those 
that can create substitutions in glycans such as D-arabinose taking the place of the core fucose 
moiety, there are a large variety of natural and synthetic carbohydrates that might prove useful in 
similar strategies. Testing their immunogenicity would also be important. Ultimately, 
supplementation should continue to be explored as a key method of affecting cell culture 






Aghamohseni, H., Ohadi, K., Spearman, M., Krahn, N., Moo-Young, M., Scharer, J.M., Butler, M., 
Budman, H.M., 2014. Effects of nutrient levels and average culture pH on the glycosylation pattern 
of camelid-humanized monoclonal antibody. J. Biotechnol. 186, 98–109. 
doi:10.1016/j.jbiotec.2014.05.024 
Agrawal, V., Slivac, I., Perret, S., Bisson, L., St-Laurent, G., Murad, Y., Zhang, J., Durocher, Y., 2012. 
Stable expression of chimeric heavy chain antibodies in CHO cells. Methods Mol. Biol. 911, 287–
303. doi:10.1007/978-1-61779-968-6_18 
Ahmad, Z.A., Yeap, S.K., Ali, A.M., Ho, W.Y., Banu, N., Alitheen, M., Hamid, M., 2012. scFv 
Antibody : Principles and Clinical Application. Clin. Dev. Immunol. 2012, 15. 
doi:10.1155/2012/980250 
Ahn, W.S., Antoniewicz, M.R., 2012. Towards dynamic metabolic flux analysis in CHO cell cultures. 
Biotechnol. J. 7, 61–74. doi:10.1002/biot.201100052 
Albrecht, S., Hilliard, M., Rudd, P., 2014. Therapeutic proteins : facing the challenges of glycobiology. J. 
Heal. Policy Outcomes Res. 12–17. doi:10.7365/JHPOR.2014.5.2 
Allen, J., Davey, H.M., Broadhurst, D., Heald, J.K., Rowland, J.J., Oliver, S.G., Kell, D.B., 2003. High-
throughput classification of yeast mutants for functional genomics using metabolic footprinting. Nat. 
Biotechnol. 21, 692–6. doi:10.1038/nbt823 
Anthony, R.M., Nimmerjahn, F., Ashline, D.J., Reinhold, V.N., Paulson, J.C., Ravetch, J. V, 2008. 
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320, 373–6. 
doi:10.1126/science.1154315 
Aranibar, N., Borys, M., Mackin, N. a, Ly, V., Abu-Absi, N., Abu-Absi, S., Niemitz, M., Schilling, B., 
Li, Z.J., Brock, B., Russell, R.J., Tymiak, A., Reily, M.D., 2011. NMR-based metabolomics of 
mammalian cell and tissue cultures. J. Biomol. NMR 49, 195–206. doi:10.1007/s10858-011-9490-8 
Augustin, R., Mayoux, E., 2014. Mammalian Sugar Transporters, in: Glucose Homeostasis. InTech. 
doi:10.5772/58325 
Aumiller, J.J., Mabashi-Asazuma, H., Hillar, A., Shi, X., Jarvis, D.L., 2012. A new glycoengineered 
insect cell line with an inducibly mammalianized protein N-glycosylation pathway. Glycobiology 
22, 417–28. doi:10.1093/glycob/cwr160 
Baker, K.N., Rendall, M.H., Hills, A.E., Hoare, M., Freedman, R.B., James, D.C., 2001. Metabolic 
Control of Recombinant Protein N-Glycan Processing in NS0 and CHO Cells. Biotechnol. Bioeng. 
73, 188–202. doi:10.1002/bit.1051 
Bekesi, J.G., Winzler, R.J., 1970. Inhibitory effects of D-glucosamine on the growth of Walker 256 
carcinosarcoma and on protein, RNA, and DNA synthesis. Cancer Res. 30, 2905–2912. 
Bell, A., Wang, Z.J., Arbabi-Ghahroudi, M., Chang, T. a, Durocher, Y., Trojahn, U., Baardsnes, J., 
Jaramillo, M.L., Li, S., Baral, T.N., O’Connor-McCourt, M., Mackenzie, R., Zhang, J., 2010. 
Differential tumor-targeting abilities of three single-domain antibody formats. Cancer Lett. 289, 81–
90. doi:10.1016/j.canlet.2009.08.003 
Benjamini, Y., Hochberg, Y., 1995. Controlling the false discovery rate: a practical and powerful 
approach to multiple testing. J. R. Stat. Soc. doi:10.2307/2346101 
Bigge, J.C., Patel, T.P., Bruce, J.A., Goulding, P.N., Charles, S.M., Parekh, R.B., 1995. Nonselective and 





Blondeel, E.J.M., Braasch, K., McGill, T., Chang, D., Engel, C., Spearman, M., Butler, M., Aucoin, 
M.G., 2015. Tuning a MAb glycan profile in cell culture: Supplementing N-acetylglucosamine to 
favour G0 glycans without compromising productivity and cell growth. J. Biotechnol. 214, 105–12. 
doi:10.1016/j.jbiotec.2015.09.014 
Bonarius, H.P., Hatzimanikatis, V., Meesters, K.P., de Gooijer, C.D., Schmid, G., Tramper, J., 1996. 
Metabolic flux analysis of hybridoma cells in different culture media using mass balances. 
Biotechnol. Bioeng. 50, 299–318. doi:10.1002/(SICI)1097-0290(19960505)50:3<299::AID-
BIT9>3.0.CO;2-B 
Bosques, C.J., Collins, B.E., Meador, J.W., Sarvaiya, H., Murphy, J.L., Dellorusso, G., Bulik, D.A., Hsu, 
I.-H., Washburn, N., Sipsey, S.F., Myette, J.R., Raman, R., Shriver, Z., Sasisekharan, R., 
Venkataraman, G., 2010. Chinese hamster ovary cells can produce galactose-α-1,3-galactose 
antigens on proteins. Nat. Biotechnol. 28, 1153–6. doi:10.1038/nbt1110-1153 
Boyd, P.N., Lines, A.C., Patel, A.K., 1995. The effect of the removal of sialic acid, galactose and total 
carbohydrate on the functional activity of Campath-1H. Mol. Immunol. 32, 1311–8. 
Braasch, K., Villacrés, C., Butler, M., 2015. Evaluation of Quenching and Extraction Methods for 
Nucleotide/Nucleotide Sugar Analysis. Methods Mol. Biol. 1321, 361–72. doi:10.1007/978-1-4939-
2760-9_24 
Bradley, S. a, Ouyang, A., Purdie, J., Smitka, T. a, Wang, T., Kaerner, A., 2010. Fermentanomics: 
monitoring mammalian cell cultures with NMR spectroscopy. J. Am. Chem. Soc. 132, 9531–3. 
doi:10.1021/ja101962c 
Broadhurst, E.R., Butler, M., 2000. The inhibitory effect of glutamate on the growth of a murine 
hybridoma is caused by competitive inhibition of the x(-) (C) transport system required for cystine 
utilization. Cytotechnology 32, 31–43. doi:10.1023/A:1008143716374 
Brokhausen, I., Schachter, H., Stanley, P., 2009. O-GalNAc Glycans, in: Varki, A., Cummings, R.D., 
Esko, J.D., Stanley, P., Bertozzi, C.R., Hart, G.W., Etzler, M.E. (Eds.), Essentials of Glycobiology. 
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 
Burda, P., Aebi, M., 1999. The dolichol pathway of N-linked glycosylation. Biochim. Biophys. Acta 
1426, 239–57. 
Butler, M., 2013. Serum-free media: standardizing cell culture system. Pharm. Bioprocess. 1, 315–318. 
doi:10.4155/pbp.13.45 
Butler, M., 2006. Optimisation of the cellular metabolism of glycosylation for recombinant proteins 
produced by Mammalian cell systems. Cytotechnology 50, 57–76. doi:10.1007/s10616-005-4537-x 
Butler, M., 2004a. The Glycosylation of Proteins in Cell Culture, in: Animal Cell Culture & Technology. 
BIOS Scientific Publishers, London, New York, pp. 113–134. 
Butler, M., 2004b. Growth and Maintenance of Cells in Culture, in: Animal Cell Culture & Technology. 
BIOS Scientific Publishers, London, New York, pp. 47–66. 
Butler, M., Meneses-Acosta, A., 2012. Recent advances in technology supporting biopharmaceutical 
production from mammalian cells. Appl. Microbiol. Biotechnol. 96, 885–894. doi:10.1007/s00253-
012-4451-z 
Campbell, M.P., Royle, L., Radcliffe, C.M., Dwek, R.A., Rudd, P.M., 2008. GlycoBase and autoGU: 
tools for HPLC-based glycan analysis. Bioinformatics 24, 1214–6. 
doi:10.1093/bioinformatics/btn090 
Carinhas, N., Duarte, T.M., Barreiro, L.C., Carrondo, M.J.T., Alves, P.M., Teixeira, A.P., 2013. 
Metabolic signatures of GS-CHO cell clones associated with butyrate treatment and culture phase 




Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., Watier, H., 2002. 
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc 
receptor FcgammaRIIIa gene. Blood 99, 754–8. doi:10.1182/blood.V99.3.754 
Carvalhal, A. V, Santos, S.S., Calado, J., Haury, M., Carrondo, M.J.T., 2003. Cell growth arrest by 
nucleotides, nucleosides and bases as a tool for improved production of recombinant proteins. 
Biotechnol. Prog. 19, 69–83. doi:10.1021/bp0255917 
Chatenoud, L., Ferran, C., Legendre, C., Franchimont, P., Reuter, A., Kreis, H., Bach, J.-F., 1988. 
Clinical use of OKT3: The role of cytokine release and xenosensitization. J. Autoimmun. 1, 631–
640. doi:10.1016/0896-8411(88)90054-6 
Chen, P., Harcum, S.W., 2006. Effects of elevated ammonium on glycosylation gene expression in CHO 
cells. Metab. Eng. 8, 123–32. doi:10.1016/j.ymben.2005.10.002 
Chenu, S., Grégoire, A., Malykh, Y., Visvikis, A., Monaco, L., Shaw, L., Schauer, R., Marc, A., Goergen, 
J.-L., 2003. Reduction of CMP-N-acetylneuraminic acid hydroxylase activity in engineered Chinese 
hamster ovary cells using an antisense-RNA strategy. Biochim. Biophys. Acta - Gen. Subj. 1622, 
133–144. doi:10.1016/S0304-4165(03)00137-5 
Chong, W., Goh, L., Reddy, S., 2009. Metabolomics profiling of extracellular metabolites in recombinant 
Chinese Hamster Ovary fed‐batch culture. Rapid Commun. Mass Spectrom. 23, 3763–3771. 
doi:10.1002/rcm 
Chong, W.P.K., Reddy, S.G., Yusufi, F.N.K., Lee, D.-Y., Wong, N.S.C., Heng, C.K., Yap, M.G.S., Ho, 
Y.S., 2010a. Metabolomics-driven approach for the improvement of Chinese hamster ovary cell 
growth: overexpression of malate dehydrogenase II. J. Biotechnol. 147, 116–21. 
doi:10.1016/j.jbiotec.2010.03.018 
Chong, W.P.K., Thng, S.H., Hiu, A.P., Lee, D.-Y., Chan, E.C.Y., Ho, Y.S., 2012. LC-MS-based 
metabolic characterization of high monoclonal antibody-producing Chinese hamster ovary cells. 
Biotechnol. Bioeng. 109, 3103–11. doi:10.1002/bit.24580 
Chong, W.P.K., Yusufi, F.N.K., Lee, D.-Y., Reddy, S.G., Wong, N.S.C., Heng, C.K., Yap, M.G.S., Ho, 
Y.S., 2010b. Metabolomics-based identification of apoptosis-inducing metabolites in recombinant 
fed-batch CHO culture media. J. Biotechnol. 151, 218–224. doi:10.1016/j.jbiotec.2010.12.010 
Chrysanthopoulos, P.K., Goudar, C.T., Klapa, M.I., 2010. Metabolomics for high-resolution monitoring 
of the cellular physiological state in cell culture engineering. Metab. Eng. 12, 212–22. 
doi:10.1016/j.ymben.2009.11.001 
Chung, S., Quarmby, V., Gao, X., Ying, Y., Lin, L., Reed, C., Fong, C., Lau, W., Qiu, Z.J., Shen, A., 
Vanderlaan, M., Song, A., 2012. Quantitative evaluation of fucose reducing effects in a humanized 
antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities. 
MAbs 4, 326–40. doi:10.4161/mabs.19941 
Clark, K.J.-R., Griffiths, J., Bailey, K.M., Harcum, S.W., 2005. Gene-expression profiles for five key 
glycosylation genes for galactose-fed CHO cells expressing recombinant IL-4/13 cytokine trap. 
Biotechnol. Bioeng. 90, 568–77. doi:10.1002/bit.20439 
Cole, E.S., Nichols, E.H., Poisson, L., Harnois, M.L., Livingston, D.J., 1993. In vivo clearance of tissue 
plasminogen activator: The complex role of sites of glycosylation and level of sialylation. 
Fibrinolysis and Proteolysis 7, 15–22. doi:10.1016/0268-9499(93)90050-6 
Crowell, C.K., Grampp, G.E., Rogers, G.N., Miller, J., Scheinman, R.I., 2007. Amino acid and 
manganese supplementation modulates the glycosylation state of erythropoietin in a CHO culture 
system. Biotechnol. Bioeng. 96, 538–49. doi:10.1002/bit.21141 




and future directions. Drug Discov. Today 15, 610–21. doi:10.1016/j.drudis.2010.06.012 
Dalziel, M., Crispin, M., Scanlan, C.N., Zitzmann, N., Dwek, R.A., 2014. Emerging principles for the 
therapeutic exploitation of glycosylation. Science 343, 1235681. doi:10.1126/science.1235681 
Davies, J., Jiang, L., Pan, L.Z., LaBarre, M.J., Anderson, D., Reff, M., 2001. Expression of GnTIII in a 
recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms 
leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol. Bioeng. 74, 
288–94. doi:10.1002/bit.1119 
del Val, I.J., Kontoravdi, C., Nagy, J.M., 2010. Towards the implementation of quality by design to the 
production of therapeutic monoclonal antibodies with desired glycosylation patterns. Biotechnol. 
Prog. 26, 1505–27. doi:10.1002/btpr.470 
Dietmair, S., Hodson, M.P., Quek, L.-E., Timmins, N.E., Chrysanthopoulos, P., John, S.S., Gray, P., 
Nielsen, L.K., 2012. Metabolite profiling of CHO cells with different growth characteristics. 
Biotechnol. Bioeng. 109, 1404–1414. doi:10.1002/bit.24496 
Dietmair, S., Timmins, N.E., Gray, P.P., Nielsen, L.K., Krömer, J.O., 2010. Towards quantitative 
metabolomics of mammalian cells: development of a metabolite extraction protocol. Anal. Biochem. 
404, 155–64. doi:10.1016/j.ab.2010.04.031 
Dordal, M.S., Wang, F.F., Goldwasser, E., 1985. The role of carbohydrate in erythropoietin action. 
Endocrinology 116, 2293–9. 
Dubé, S., Fisher, J.W., Powell, J.S., 1988. Glycosylation at specific sites of erythropoietin is essential for 
biosynthesis, secretion, and biological function. J. Biol. Chem. 263, 17516–21. 
Durocher, Y., Perret, S., Kamen, A., 2002. High-level and high-throughput recombinant protein 
production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids 
Res. 30, E9. doi:10.1093/nar/30.2.e9 
Eagle, H., 1955. Nutrition needs of mammalian cells in tissue culture. Science 122, 501–14. 
Ecker, D.M., Jones, S.D., Levine, H.L., 2015. The therapeutic monoclonal antibody market. MAbs 7, 9–
14. doi:10.4161/19420862.2015.989042 
Egrie, J.C., Dwyer, E., Browne, J.K., Hitz, A., Lykos, M.A., 2003. Darbepoetin alfa has a longer 
circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp. 
Hematol. 31, 290–299. doi:10.1016/S0301-472X(03)00006-7 
Elliott, S., Egrie, J., Browne, J., Lorenzini, T., Busse, L., Rogers, N., Ponting, I., 2004. Control of 
rHuEPO biological activity: The role of carbohydrate. Exp. Hematol. 32, 1146–1155. 
doi:10.1016/j.exphem.2004.08.004 
Elvin, J.G., Couston, R.G., van der Walle, C.F., 2011. Therapeutic antibodies: Market considerations, 
disease targets and bioprocessing. Int. J. Pharm. 440, 83–98. doi:10.1016/j.ijpharm.2011.12.039 
Emwas, A.-H.M., 2015. The strengths and weaknesses of NMR spectroscopy and mass spectrometry with 
particular focus on metabolomics research., in: Methods in Molecular Biology (Clifton, N.J.). pp. 
161–93. doi:10.1007/978-1-4939-2377-9_13 
Eon-Duval, A., Broly, H., Gleixner, R., 2012. Quality attributes of recombinant therapeutic proteins: an 
assessment of impact on safety and efficacy as part of a quality by design development approach. 
Biotechnol. Prog. 28, 608–22. doi:10.1002/btpr.1548 
Evans, V.J., Bryant, J.C., Mcquilkin, W.T., Fioramonti, M.C., Sanford, K.K., Westfall, B.B., Earle, W.R., 
1956. Studies of nutrient media for tissue cells in vitro. II. An improved protein-free chemically 
defined medium for long-term cultivation of strain L-929 cells. Cancer Res. 16, 87–94. 




for Industry, Biosimilarity. Silver Spring, MD. 
Fernandes, S., Robitaille, J., Bastin, G., Jolicoeur, M., Wouwer, A. Vande, 2016. Application of Dynamic 
Metabolic Flux Convex Analysis to CHO-DXB11 Cell Fed-batch Cultures. IFAC-PapersOnLine 49, 
466–471. doi:10.1016/j.ifacol.2016.07.386 
Ferrara, C., Stuart, F., Sondermann, P., Brünker, P., Umaña, P., 2006. The carbohydrate at FcgammaRIIIa 
Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. 
Chem. 281, 5032–6. doi:10.1074/jbc.M510171200 
Ferrari, J., Gunson, J., Lofgren, J., Krummen, L., Warner, T.G., 1998. Chinese hamster ovary cells with 
constitutively expressed sialidase antisense RNA produce recombinant DNase in batch culture with 
increased sialic acid. Biotechnol. Bioeng. 60, 589–95. 
Fiehn, O., 2002. Metabolomics--the link between genotypes and phenotypes. Plant Mol. Biol. 48, 155–71. 
Flynn, G.C., Chen, X., Liu, Y.D., Shah, B., Zhang, Z., 2010. Naturally occurring glycan forms of human 
immunoglobulins G1 and G2. Mol. Immunol. 47, 2074–82. doi:10.1016/j.molimm.2010.04.006 
Freeze, H.H., Elbein, A.D., 2009. Glycosylation Precursors, 2nd ed, Essentials of Glycobiology. Cold 
Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 
Gawlitzek, M., Valley, U., Wagner, R., 1998. Ammonium ion and glucosamine dependent increases of 
oligosaccharide complexity in recombinant glycoproteins secreted from cultivated BHK-21 cells. 
Biotechnol. Bioeng. 57, 518–528. 
Gemmill, T.R., Trimble, R.B., 1999. Overview of N- and O-linked oligosaccharide structures found in 
various yeast species. Biochim. Biophys. Acta 1426, 227–37. 
Ghaderi, D., Taylor, R.E., Padler-Karavani, V., Diaz, S., Varki, A., 2010. Implications of the presence of 
N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat. Biotechnol. 28, 863–7. 
doi:10.1038/nbt.1651 
Ghaderi, D., Zhang, M., Hurtado-Ziola, N., Varki, A., 2012. Production platforms for biotherapeutic 
glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol. Genet. 
Eng. Rev. 28, 147–175. doi:10.5661/bger-28-147 
Glaser, L., 1959. The biosynthesis of N-acetylgalactosamine. J. Biol. Chem. 234, 2801–5. 
doi:10.1177/036985646700400518 
Glassey, J., Gernaey, K. V, Clemens, C., Schulz, T.W., Oliveira, R., Striedner, G., Mandenius, C.-F., 
2011. Process analytical technology (PAT) for biopharmaceuticals. Biotechnol. J. 6, 369–77. 
doi:10.1002/biot.201000356 
Goeddel, D. V, Kleid, D.G., Bolivar, F., Heyneker, H.L., Yansura, D.G., Crea, R., Hirose, T., 
Kraszewski,  a, Itakura, K., Riggs,  a D., 1979. Expression in Escherichia coli of chemically 
synthesized genes for human insulin. Proc. Natl. Acad. Sci. U. S. A. 76, 106–10. 
Goetze, A.M., Liu, Y.D., Zhang, Z., Shah, B., Lee, E., Bondarenko, P. V., Flynn, G.C., 2011. High-
mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in 
humans. Glycobiology 21, 949–59. doi:10.1093/glycob/cwr027 
Gornik, O., Royle, L., Harvey, D.J., Radcliffe, C.M., Saldova, R., Dwek, R. a, Rudd, P., Lauc, G., 2007. 
Changes of serum glycans during sepsis and acute pancreatitis. Glycobiology 17, 1321–32. 
doi:10.1093/glycob/cwm106 
Goudar, C., Biener, R., Boisart, C., Heidemann, R., Piret, J., de Graaf, A., Konstantinov, K., 2010. 
Metabolic flux analysis of CHO cells in perfusion culture by metabolite balancing and 2D [13C, 1H] 
COSY NMR spectroscopy. Metab. Eng. 12, 138–149. doi:10.1016/j.ymben.2009.10.007 




monoclonal antibody N-glycosylation. Biotechnol. Bioeng. 110, 2970–83. doi:10.1002/bit.24959 
Gramer, M.J., Eckblad, J.J., Donahue, R., Brown, J., Shultz, C., Vickerman, K., Priem, P., van den 
Bremer, E.T.J., Gerritsen, J., van Berkel, P.H.C., 2011. Modulation of antibody galactosylation 
through feeding of uridine, manganese chloride, and galactose. Biotechnol. Bioeng. 108, 1591–602. 
doi:10.1002/bit.23075 
Gramer, M.J., Goochee, C.F., 1993. Glycosidase activities in Chinese hamster ovary cell lysate and cell 
culture supernatant. Biotechnol. Prog. 9, 366–73. doi:10.1021/bp00022a003 
Gramer, M.J., Goochee, C.F., Chock, V.Y., Brousseau, D.T., Sliwkowski, M.B., 1995. Removal of sialic 
acid from a glycoprotein in CHO cell culture supernatant by action of an extracellular CHO cell 
sialidase. Biotechnology. (N. Y). 13, 692–8. 
Grammatikos, S.I., Valley, U., Nimtz, M., Conradt, H.S., Wagner, R., 1998. Intracellular UDP-N-
acetylhexosamine pool affects N-glycan complexity: a mechanism of ammonium action on protein 
glycosylation. Biotechnol. Prog. 14, 410–419. doi:10.1021/bp980005o 
Green, L.L., Hardy, M.C., Maynard-Currie, C.E., Tsuda, H., Louie, D.M., Mendez, M.J., Abderrahim, H., 
Noguchi, M., Smith, D.H., Zeng, Y., David, N.E., Sasai, H., Garza, D., Brenner, D.G., Hales, J.F., 
McGuinness, R.P., Capon, D.J., Klapholz, S., Jakobovits, A., 1994. Antigen-specific human 
monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat. 
Genet. 7, 13–21. doi:10.1038/ng0594-13 
Gu, X., Wang, D.I., 1998. Improvement of interferon-gamma sialylation in Chinese hamster ovary cell 
culture by feeding of N-acetylmannosamine. Biotechnol. Bioeng. 58, 642–8. 
Guile, G.R., Rudd, P.M., Wing, D.R., Prime, S.B., Dwek, R. a, 1996. A rapid high-resolution high-
performance liquid chromatographic method for separating glycan mixtures and analyzing 
oligosaccharide profiles. Anal. Biochem. 240, 210–26. doi:10.1006/abio.1996.0351 
Ham, R.G., 1965. Clonal Growth of Mammalian Cells in a Chemically Defined, Synthetic Medium. Proc. 
Natl. Acad. Sci. U. S. A. 53, 288–93. 
Hamilton, S.R., Davidson, R.C., Sethuraman, N., Nett, J.H., Jiang, Y., Rios, S., Bobrowicz, P., Stadheim, 
T.A., Li, H., Choi, B.-K., Hopkins, D., Wischnewski, H., Roser, J., Mitchell, T., Strawbridge, R.R., 
Hoopes, J., Wildt, S., Gerngross, T.U., 2006. Humanization of yeast to produce complex terminally 
sialylated glycoproteins. Science 313, 1441–3. doi:10.1126/science.1130256 
Harris, R.J., Chin, E.T., Macchi, F., Keck, R.G., Shyong, B.-J., Ling, V.T., Cordoba, A.J., Marian, M., 
Sinclair, D., Battersby, J.E., Jones, A.J.S., 2010. Analytical Characterization of Monoclonal 
Antibodies: Linking Structure to Function, in: Shire, S.J., Gombotz, W., Bechtold-Peters, K., 
Andya, J. (Eds.), Biotechnology: Pharmaceutical Aspects, Volume XI: Current Trends in 
Monoclonal Antibody Development and Manufacturing. Springer, pp. 193–205. doi:10.1007/978-0-
387-76643-0_12 
Hassinen, A., Kellokumpu, S., 2014. Organizational interplay of Golgi N-glycosyltransferases involves 
organelle microenvironment-dependent transitions between enzyme homo- and heteromers. J. Biol. 
Chem. 289, 26937–48. doi:10.1074/jbc.M114.595058 
Hermansson, M., Hokynar, K., Somerharju, P., 2011. Mechanisms of glycerophospholipid homeostasis in 
mammalian cells. Prog. Lipid Res. 50, 240–57. doi:10.1016/j.plipres.2011.02.004 
Hickman, S., Kornfeld, S., 1978. Effect of tunicamycin on IgM, IgA, and IgG secretion by mouse 
plasmacytoma cells. J. Immunol. 121, 990–6. 
Hills, A.E., Patel, A., Boyd, P., James, D.C., 2001. Metabolic control of recombinant monoclonal 
antibody N-glycosylation in GS-NS0 cells. Biotechnol. Bioeng. 75, 239–251. doi:10.1002/bit.10022 




functions by Fc N-glycan remodeling in vitro. Biotechnol. Prog. 21, 1644–52. 
doi:10.1021/bp050228w 
Hossler, P., 2012. Protein glycosylation control in mammalian cell culture: past precedents and 
contemporary prospects. Adv. Biochem. Eng. Biotechnol. 127, 187–219. doi:10.1007/10_2011_113 
Hossler, P., Chumsae, C., Racicot, C., Ouellette, D., Ibraghimov, A., Serna, D., Mora, A., McDermott, S., 
Labkovsky, B., Scesney, S., Grinnell, C., Preston, G., Bose, S., Carrillo, R., 2017. Arabinosylation 
of recombinant human immunoglobulin-based protein therapeutics. MAbs 9, 1–20. 
doi:10.1080/19420862.2017.1294295 
Hossler, P., Khattak, S.F., Li, Z.J., 2009. Optimal and consistent protein glycosylation in mammalian cell 
culture. Glycobiology 19, 936–949. doi:10.1093/glycob/cwp079 
Hossler, P., Racicot, C., Chumsae, C., McDermott, S., Cochran, K., 2016. Cell culture media 
supplementation of infrequently used sugars for the targeted shifting of protein glycosylation 
profiles. Biotechnol. Prog. 30, 429–42. doi:10.1002/btpr.2429 
Huang, D.W., Sherman, B.T., Lempicki, R. a, 2009a. Systematic and integrative analysis of large gene 
lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57. doi:10.1038/nprot.2008.211 
Huang, D.W., Sherman, B.T., Lempicki, R. a., 2009b. Bioinformatics enrichment tools: Paths toward the 
comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1–13. 
doi:10.1093/nar/gkn923 
Ishida, N., Kawakita, M., 2004. Molecular physiology and pathology of the nucleotide sugar transporter 
family (SLC35). Pflugers Arch. 447, 768–75. doi:10.1007/s00424-003-1093-0 
Jefferis, R., 2012. Isotype and glycoform selection for antibody therapeutics. Arch. Biochem. Biophys. 
526, 159–66. doi:10.1016/j.abb.2012.03.021 
Jefferis, R., 2009. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of 
action. Trends Pharmacol. Sci. 30, 356–62. doi:10.1016/j.tips.2009.04.007 
Jefferis, R., 2009. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug 
Discov. 8, 226–34. doi:10.1038/nrd2804 
Jones, P.T., Dear, P.H., Foote, J., Neuberger, M.S., Winter, G., 1986. Replacing the complementarity-
determining regions in a human antibody with those from a mouse. Nature 321, 522–5. 
doi:10.1038/321522a0 
Kaneko, Y., Nimmerjahn, F., Ravetch, J. V, 2006. Anti-inflammatory activity of immunoglobulin G 
resulting from Fc sialylation. Science 313, 670–3. doi:10.1126/science.1129594 
Kapur, R., Einarsdottir, H.K., Vidarsson, G., 2014. IgG-effector functions: “The Good, The Bad and The 
Ugly.” Immunol. Lett. 160, 139–144. doi:10.1016/j.imlet.2014.01.015 
Kean, E.L., 1970. Nuclear cytidine 5’-monophosphosialic acid synthetase. J. Biol. Chem. 245, 2301–8. 
doi:10.1207/s15516709cog1902 
Kell, D.B., Brown, M., Davey, H.M., Dunn, W.B., Spasic, I., Oliver, S.G., 2005. Metabolic footprinting 
and systems biology: the medium is the message. Nat. Rev. Microbiol. 3, 557–65. 
doi:10.1038/nrmicro1177 
Khoo, S.H.G., Al-Rubeai, M., 2007. Metabolomics as a complementary tool in cell culture. Biotechnol. 
Appl. Biochem. 47, 71–84. doi:10.1042/BA20060221 
Kildegaard, H.F., Fan, Y., Sen, J.W., Larsen, B., Andersen, M.R., 2015. Glycoprofiling effects of media 
additives on IgG produced by CHO cells in fed-batch bioreactors. Biotechnol. Bioeng. 113, 359–
366. doi:10.1002/bit.25715 




J.M., 2012. Fed-batch CHO cell t-PA production and feed glutamine replacement to reduce 
ammonia production. Biotechnol. Prog. 29, 165–75. doi:10.1002/btpr.1658 
Kim, D.Y., Lee, J.C., Chang, H.N., Oh, D.J., 2005. Effects of supplementation of various medium 
components on chinese hamster ovary cell cultures producing recombinant antibody. 
Cytotechnology 47, 37–49. doi:10.1007/s10616-005-3775-2 
Kim, J.Y., Kim, Y.-G., Lee, G.M., 2012. CHO cells in biotechnology for production of recombinant 
proteins: current state and further potential. Appl. Microbiol. Biotechnol. 93, 917–30. 
doi:10.1007/s00253-011-3758-5 
Kim, J.Y., Kim, Y.G., Han, Y.K., Choi, H.S., Kim, Y.H., Lee, G.M., 2011. Proteomic understanding of 
intracellular responses of recombinant Chinese hamster ovary cells cultivated in serum-free medium 
supplemented with hydrolysates. Appl. Microbiol. Biotechnol. 89, 1917–1928. doi:10.1007/s00253-
011-3106-9 
Kim, S.H., Lee, G.M., 2009. Development of serum-free medium supplemented with hydrolysates for the 
production of therapeutic antibodies in CHO cell cultures using design of experiments. Appl. 
Microbiol. Biotechnol. 83, 639–48. doi:10.1007/s00253-009-1903-1 
Köhler, G., Milstein, C., 1975. Continuous cultures of fused cells secreting antibody of predefined 
specificity. Nature 256, 495–497. doi:10.1038/256495a0 
Koide, N., Nose, M., Muramatsu, T., 1977. Recognition of IgG by Fc receptor and complement: effects of 
glycosidase digestion. Biochem. Biophys. Res. Commun. 75, 838–44. 
Krishnan, N., Dickman, M.B., Becker, D.F., 2008. Proline modulates the intracellular redox environment 
and protects mammalian cells against oxidative stress. Free Radic. Biol. Med. 44, 671–81. 
doi:10.1016/j.freeradbiomed.2007.10.054 
Krug, E., Zweibaum,  a, Schulz-Holstege, C., Keppler, D., 1984. D-glucosamine-induced changes in 
nucleotide metabolism and growth of colon-carcinoma cells in culture. Biochem. J. 217, 701–708. 
Kumpel, B.M., Rademacher, T.W., Rook, G.A., Williams, P.J., Wilson, I.B., 1994. Galactosylation of 
human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is 
dependent on culture method and affects Fc receptor-mediated functional activity. Hum. Antibodies 
Hybridomas 5, 143–51. 
Kumpel, B.M., Wang, Y., Griffiths, H.L., Hadley, A.G., Rook, G.A., 1995. The biological activity of 
human monoclonal IgG anti-D is reduced by beta-galactosidase treatment. Hum. Antibodies 
Hybridomas 6, 82–8. 
Kyriakopoulos, S., Polizzi, K.M., Kontoravdi, C., 2013. Comparative analysis of amino acid metabolism 
and transport in CHO variants with different levels of productivity. J. Biotechnol. 168, 543–51. 
doi:10.1016/j.jbiotec.2013.09.007 
Lalonde, M.-E., Durocher, Y., 2017. Therapeutic glycoprotein production in mammalian cells. J. 
Biotechnol. 251, 128–140. doi:10.1016/j.jbiotec.2017.04.028 
Lazar, G.A., Desjarlais, J.R., 2009. Engineering the Antibody Fc Region for Optimal Effector Function, 
in: An, Z. (Ed.), Therapeutic Monoclonal Antibodies From Bench to Clinic. John Wiley & Sons, pp. 
349–370. 
Leavitt, R., Schlesinger, S., Kornfeld, S., 1977. Impaired intracellular migration and altered solubility of 
nonglycosylated glycoproteins of vesicular stomatitis virus and Sindbis virus. J. Biol. Chem. 252, 
9018–23. 
Lee, C.C., Perchiacca, J.M., Tessier, P.M., 2013. Toward aggregation-resistant antibodies by design. 




Lee, G.M., Kim, E.J., Kim, N.S., Yoon, S.K., Ahn, Y.H., Song, J.Y., 1999. Development of a serum-free 
medium for the production of erythropoietin by suspension culture of recombinant Chinese hamster 
ovary cells using a statistical design. J. Biotechnol. 69, 85–93. 
Lee, J.H., Reier, J., Heffner, K.M., Barton, C., Spencer, D., Schmelzer, A.E., Venkat, R., 2017. 
Production and characterization of active recombinant human factor II with consistent sialylation. 
Biotechnol. Bioeng. 114, 1991–2000. doi:10.1002/bit.26317 
Liang, C.-M., Tai, M.-C., Chang, Y.-H., Chen, Y.-H., Chen, C.-L., Chien, M.-W., Chen, J.-T., 2010. 
Glucosamine inhibits epidermal growth factor-induced proliferation and cell-cycle progression in 
retinal pigment epithelial cells. Mol. Vis. 16, 2559–2571. 
Lindsley, C.W., 2017. New 2016 Data and Statistics for Global Pharmaceutical Products and Projections 
through 2017. ACS Chem. Neurosci. 8, 1635–1636. doi:10.1021/acschemneuro.7b00253 
Liu, B., Spearman, M., Doering, J., Lattová, E., Perreault, H., Butler, M., 2014. The availability of 
glucose to CHO cells affects the intracellular lipid-linked oligosaccharide distribution, site 
occupancy and the N-glycosylation profile of a monoclonal antibody. J. Biotechnol. 170, 17–27. 
doi:10.1016/j.jbiotec.2013.11.007 
Liu, J., Wang, J., Fan, L., Chen, X., Hu, D., 2015. Galactose supplementation enhance sialylation of 
recombinant Fc-fusion protein in CHO cell : an insight into the role of galactosylation in sialylation. 
World J. Microbiol. Biotechnol. 31, 1147–1156. doi:10.1007/s11274-015-1864-8 
Lizak, C., Fan, Y., Weber, T.C., Aebi, M., 2011. N-Linked Glycosylation of Antibody Fragments in 
Escherichia coli. Bioconjug. Chem. 22, 488–496. doi:10.1021/bc100511k 
Lonberg, N., Taylor, L.D., Harding, F.A., Trounstine, M., Higgins, K.M., Schramm, S.R., Kuo, C.C., 
Mashayekh, R., Wymore, K., McCabe, J.G., 1994. Antigen-specific human antibodies from mice 
comprising four distinct genetic modifications. Nature 368, 856–9. doi:10.1038/368856a0 
Lu, W., Su, X., Klein, M.S., Lewis, I.A., Fiehn, O., Rabinowitz, J.D., 2017. Metabolite Measurement: 
Pitfalls to Avoid and Practices to Follow. Annu. Rev. Biochem. 86, 277–304. doi:10.1146/annurev-
biochem-061516-044952 
Luo, J., Vijayasankaran, N., Autsen, J., Santuray, R., Hudson, T., Amanullah, A., Li, F., 2012. 
Comparative metabolite analysis to understand lactate metabolism shift in Chinese hamster ovary 
cell culture process. Biotechnol. Bioeng. 109, 146–56. doi:10.1002/bit.23291 
Ma, N., Ellet, J., Okediadi, C., Hermes, P., McCormick, E., Casnocha, S., 2009. A single nutrient feed 
supports both chemically defined NS0 and CHO fed-batch processes: Improved productivity and 
lactate metabolism. Biotechnol. Prog. 25, 1353–63. doi:10.1002/btpr.238 
Malhotra, R., Wormald, M.R., Rudd, P.M., Fischer, P.B., Dwek, R.A., Sim, R.B., 1995. Glycosylation 
changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-
binding protein. Nat. Med. 1, 237–43. doi:10.1038/nm0495-365 
Martínez, V.S., Dietmair, S., Quek, L.-E., Hodson, M.P., Gray, P., Nielsen, L.K., 2013. Flux balance 
analysis of CHO cells before and after a metabolic switch from lactate production to consumption. 
Biotechnol. Bioeng. 110, 660–6. doi:10.1002/bit.24728 
McDonald, A.G., Hayes, J.M., Davey, G.P., 2016. Metabolic flux control in glycosylation. Curr. Opin. 
Struct. Biol. 40, 97–103. doi:10.1016/j.sbi.2016.08.007 
Meleady, P., 2018. Two-Dimensional Gel Electrophoresis and 2D-DIGE. Methods Mol. Biol. 1664, 3–14. 
doi:10.1007/978-1-4939-7268-5_1 
Mimura, Y., Church, S., Ghirlando, R., Ashton, P.R., Dong, S., Goodall, M., Lund, J., Jefferis, R., 2001. 
The influence of glycosylation on the thermal stability and effector function expression of human 




Moore, G.E., Gerner, R.E., Franklin, H. a, 1967. Culture of normal human leukocytes. JAMA 199, 519–
24. 
Moran, N., 2011. Boehringer splashes out on bispecific antibody platforms. Nat. Biotechnol. 29, 5–6. 
doi:10.1038/nbt0111-5 
Morell, A.G., Irvine, R.A., Sternlieb, I., Scheinberg, I.H., Ashwell, G., 1968. Physical and chemical 
studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasmin in vivo. J. Biol. 
Chem. 243, 155–9. 
Moremen, K.W., Tiemeyer, M., Nairn, A. V, 2012. Vertebrate protein glycosylation: diversity, synthesis 
and function. Nat. Rev. Mol. Cell Biol. 13, 448–62. doi:10.1038/nrm3383 
Morgan, J.F., Morton, H.J., Parker, R.C., 1950. Nutrition of animal cells in tissue culture; initial studies 
on a synthetic medium. Proc. Soc. Exp. Biol. Med. 73, 1–8. 
Mori, K., Kuni-Kamochi, R., Yamane-Ohnuki, N., Wakitani, M., Yamano, K., Imai, H., Kanda, Y., Niwa, 
R., Iida, S., Uchida, K., Shitara, K., Satoh, M., 2004. Engineering Chinese hamster ovary cells to 
maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol. Bioeng. 88, 
901–8. doi:10.1002/bit.20326 
Morrison, S.L., Johnson, M.J., Herzenberg, L. a, Oi, V.T., 1984. Chimeric human antibody molecules: 
mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. U. S. 
A. 81, 6851–5. 
Morton, H.J., 1970. A survey of commercially available tissue culture media. In Vitro 6, 89–108. 
Nicholson, J.K., Lindon, J.C., Holmes, E., 1999. “Metabonomics”: understanding the metabolic responses 
of living systems to pathophysiological stimuli via multivariate statistical analysis of biological 
NMR spectroscopic data. Xenobiotica. 29, 1181–9. doi:10.1080/004982599238047 
Nimmerjahn, F., Anthony, R.M., Ravetch, J. V, 2007. Agalactosylated IgG antibodies depend on cellular 
Fc receptors for in vivo activity. Proc. Natl. Acad. Sci. U. S. A. 104, 8433–7. 
doi:10.1073/pnas.0702936104 
Niwa, R., Shoji-Hosaka, E., Sakurada, M., Shinkawa, T., Uchida, K., Nakamura, K., Matsushima, K., 
Ueda, R., Hanai, N., Shitara, K., 2004. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 
with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell 
leukemia and lymphoma. Cancer Res. 64, 2127–33. doi:10.1158/0008-5472.CAN-03-2068 
Nose, M., Wigzell, H., 1983. Biological significance of carbohydrate chains on monoclonal antibodies. 
Proc. Natl. Acad. Sci. 80, 6632–6636. 
Nyberg, G.B., Balcarcel, R.R., Follstad, B.D., Stephanopoulos, G., Wang, D.I., 1999. Metabolic effects 
on recombinant interferon-gamma glycosylation in continuous culture of Chinese hamster ovary 
cells. Biotechnol. Bioeng. 62, 336–47. 
Oh, H.-J., Lee, J.S., Song, D.-K., Shin, D.-H., Jang, B.-C., Suh, S.-I., Park, J.-W., Suh, M.-H., Baek, W.-
K., 2007. D-glucosamine inhibits proliferation of human cancer cells through inhibition of p70S6K. 
Biochem. Biophys. Res. Commun. 360, 840–845. doi:10.1016/j.bbrc.2007.06.137 
Padler-Karavani, V., Yu, H., Cao, H., Chokhawala, H., Karp, F., Varki, N., Chen, X., Varki, A., 2008. 
Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: 
potential implications for disease. Glycobiology 18, 818–30. doi:10.1093/glycob/cwn072 
Palmberger, D., Wilson, I.B.H., Berger, I., Grabherr, R., Rendic, D., 2012. SweetBac : A New Approach 
for the Production of Mammalianised Glycoproteins in Insect Cells. PLoS One 7, 1–8. 
doi:10.1371/journal.pone.0034226 




and uridine in NCI N-417 variant small cell lung cancer cells: 31P nuclear magnetic resonance 
results. Cancer Res. 52, 3782–3786. doi:10.1016/0169-5002(93)90356-3 
Pels Rijcken, W.R., Ferwerda, W., Van den Eijnden, D.H., Overdijk, B., 1995a. Influence of D-
galactosamine on the synthesis of sugar nucleotides and glycoconjugates in rat hepatocytes. 
Glycobiology 5, 495–502. 
Pels Rijcken, W.R., Overdijk, B., Van den Eijnden, D.H., Ferwerda, W., 1995b. The effect of increasing 
nucleotide-sugar concentrations on the incorporation of sugars into glycoconjugates in rat 
hepatocytes. Biochem. J. 305 ( Pt 3, 865–70. 
Quek, L.-E., Dietmair, S., Krömer, J.O., Nielsen, L.K., 2010. Metabolic flux analysis in mammalian cell 
culture. Metab. Eng. 12, 161–71. doi:10.1016/j.ymben.2009.09.002 
Räbinä, J., Mäki, M., Savilahti, E.M., Järvinen, N., Penttilä, L., Renkonen, R., 2001. Analysis of 
nucleotide sugars from cell lysates by ion-pair solid-phase extraction and reversed-phase high-
performance liquid chromatography. Glycoconj. J. 18, 799–805. doi:5108619 [pii] 
Raju, T.S., Lang, S.E., 2014. Diversity in structure and functions of antibody sialylation in the Fc. Curr. 
Opin. Biotechnol. 30, 147–152. doi:10.1016/j.copbio.2014.06.014 
Rathore, A.S., Kumar Singh, S., Pathak, M., Read, E.K., Brorson, K.A., Agarabi, C.D., Khan, M., 2015. 
Fermentanomics: Relating quality attributes of a monoclonal antibody to cell culture process 
variables and raw materials using multivariate data analysis. Biotechnol. Prog. 31, 1586–1599. 
doi:10.1002/btpr.2155 
Raymond, C., Robotham, A., Spearman, M., Butler, M., Kelly, J., Durocher, Y., 2015. Production of 
α2,6-sialylated IgG1 in CHO cells. MAbs 7, 571–83. doi:10.1080/19420862.2015.1029215 
Read, E.K., Bradley, S. a, Smitka, T. a, Agarabi, C.D., Lute, S.C., Brorson, K. a, 2013. Fermentanomics 
informed amino acid supplementation of an antibody producing mammalian cell culture. Biotechnol. 
Prog. 29, 745–53. doi:10.1002/btpr.1728 
Reichert, J.M., 2017. Antibodies to watch in 2017. MAbs 9, 167–181. 
doi:10.1080/19420862.2016.1269580 
Scallon, B.J., Tam, S.H., McCarthy, S.G., Cai, A.N., Raju, T.S., 2007. Higher levels of sialylated Fc 
glycans in immunoglobulin G molecules can adversely impact functionality. Mol. Immunol. 44, 
1524–34. doi:10.1016/j.molimm.2006.09.005 
Scarcelli, J.J., Colussi, P. a., Fabre, A.L., Boles, E., Orlean, P., Taron, C.H., 2012. Uptake of radiolabeled 
GlcNAc into Saccharomyces cerevisiae via native hexose transporters and its in vivo incorporation 
into GPI precursors in cells expressing heterologous GlcNAc kinase. FEMS Yeast Res. 12, 305–
316. doi:10.1111/j.1567-1364.2011.00778.x 
Schachter, H., 1986. Biosynthetic controls that determine the branching and microheterogeneity of 
protein-bound oligosaccharides. Biochem. Cell Biol. 64, 163–81. 
Schaub, J., Clemens, C., Kaufmann, H., Schulz, T.W., 2012. Advancing biopharmaceutical process 
development by system-level data analysis and integration of omics data. Adv. Biochem. Eng. 
Biotechnol. 127, 133–63. doi:10.1007/10_2010_98 
Schlenke, P., Grabenhorst, E., Nimtz, M., Conradt, H.S., 1999. Construction and characterization of 
stably transfected BHK-21 cells with human-type sialylation characteristic. Cytotechnology 30, 17–
25. doi:10.1023/A:1008049603947 
Schroeder, H.W., Cavacini, L., 2010. Structure and function of immunoglobulins. J. Allergy Clin. 
Immunol. 125, S41-52. doi:10.1016/j.jaci.2009.09.046 




immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 45, 879–
85. 
Sellick, C.A., Knight, D., Croxford, A.S., Maqsood, A.R., Stephens, G.M., Goodacre, R., Dickson, A.J., 
2010. Evaluation of extraction processes for intracellular metabolite profiling of mammalian cells: 
matching extraction approaches to cell type and metabolite targets. Metabolomics 6, 427–438. 
doi:10.1007/s11306-010-0216-9 
Sellick, C. a, Croxford, A.S., Maqsood, A.R., Stephens, G., Westerhoff, H. V, Goodacre, R., Dickson, 
A.J., 2011a. Metabolite profiling of recombinant CHO cells: designing tailored feeding regimes that 
enhance recombinant antibody production. Biotechnol. Bioeng. 108, 3025–31. 
doi:10.1002/bit.23269 
Sellick, C. a, Hansen, R., Maqsood, A.R., Dunn, W.B., Stephens, G.M., Goodacre, R., Dickson, A.J., 
2009. Effective quenching processes for physiologically valid metabolite profiling of suspension 
cultured Mammalian cells. Anal. Chem. 81, 174–83. doi:10.1021/ac8016899 
Sellick, C. a, Hansen, R., Stephens, G.M., Goodacre, R., Dickson, A.J., 2011b. Metabolite extraction 
from suspension-cultured mammalian cells for global metabolite profiling. Nat. Protoc. 6, 1241–9. 
doi:10.1038/nprot.2011.366 
Selvarasu, S., Ho, Y.S., Chong, W.P.K., Wong, N.S.C., Yusufi, F.N.K., Lee, Y.Y., Yap, M.G.S., Lee, D.-
Y., 2012. Combined in silico modeling and metabolomics analysis to characterize fed-batch CHO 
cell culture. Biotechnol. Bioeng. 109, 1415–29. doi:10.1002/bit.24445 
Shields, R.L., Lai, J., Keck, R., O’Connell, L.Y., Hong, K., Meng, Y.G., Weikert, S.H.A., Presta, L.G., 
2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human 
Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277, 26733–40. 
doi:10.1074/jbc.M202069200 
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., 
Anazawa, H., Satoh, M., Yamasaki, M., Hanai, N., Shitara, K., 2003. The absence of fucose but not 
the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type 
oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. 
Biol. Chem. 278, 3466–73. doi:10.1074/jbc.M210665200 
Smedsrød, B., Einarsson, M., 1990. Clearance of tissue plasminogen activator by mannose and galactose 
receptors in the liver. Thromb. Haemost. 63, 60–6. 
Snell, K., Natsumeda, Y., Weber, G., 1987. The modulation of serine metabolism in hepatoma 3924A 
during different phases of cellular proliferation in culture. Biochem. J. 245, 609–12. 
Sokolenko, S., Blondeel, E.J.M.M., Azlah, N., George, B., Schulze, S., Chang, D., Aucoin, M.G., 2014. 
Profiling convoluted single-dimension proton NMR spectra: a Plackett-Burman approach for 
assessing quantification error of metabolites in complex mixtures with application to cell culture. 
Anal. Chem. 86, 3330–7. doi:10.1021/ac4033966 
Sokolenko, S., George, S., Wagner, A., Tuladhar, A., Andrich, J.M.S., Aucoin, M.G., 2012. Co-
expression vs. co-infection using baculovirus expression vectors in insect cell culture: Benefits and 
drawbacks. Biotechnol. Adv. 30, 766–81. doi:10.1016/j.biotechadv.2012.01.009 
Sokolenko, S., McKay, R., Blondeel, E.J.M., Lewis, M.J., Chang, D., George, B., Aucoin, M.G., 2013. 
Understanding the variability of compound quantification from targeted profiling metabolomics of 
1D-1H-NMR spectra in synthetic mixtures and urine with additional insights on choice of pulse 
sequences and robotic sampling. Metabolomics 9, 887–903. doi:10.1007/s11306-013-0503-3 
Spahn, P.N., Hansen, A.H., Hansen, H.G., Arnsdorf, J., Kildegaard, H.F., Lewis, N.E., 2016. A Markov 
chain model for N-linked protein glycosylation--towards a low-parameter tool for model-driven 




Spearman, M., Dionne, B., Butler, M., 2011. The Role of Glycosylation in Therapeutic Antibodies, in: 
Al-Rubeai, M. (Ed.), Antibody Expression and Production, Cell Engineering. Springer Netherlands, 
Dordrecht, pp. 251–292. doi:10.1007/978-94-007-1257-7_12 
Spiro, R.G., 2002. Protein glycosylation: nature, distribution, enzymatic formation, and disease 
implications of glycopeptide bonds. Glycobiology 12, 43R–56R. 
St Amand, M.M., Radhakrishnan, D., Robinson, A.S., Ogunnaike, B.A., 2014. Identification of 
manipulated variables for a glycosylation control strategy. Biotechnol. Bioeng. 111, 1957–70. 
doi:10.1002/bit.25251 
Stolfa, G., Smonskey, M.T., Boniface, R., Hachmann, A.-B., Gulde, P., Joshi, A.D., Pierce, A.P., Jacobia, 
S.J., Campbell, A., 2017. CHO-Omics Review: The Impact of Current and Emerging Technologies 
on Chinese Hamster Ovary Based Bioproduction. Biotechnol. J. 1700227, 1700227. 
doi:10.1002/biot.201700227 
Surve, T., Gadgil, M., 2015. Manganese increases high mannose glycoform on monoclonal antibody 
expressed in CHO when glucose is absent or limiting: Implications for use of alternate sugars. 
Biotechnol. Prog. 31, 460–7. doi:10.1002/btpr.2029 
Swinnen, J. V, Brusselmans, K., Verhoeven, G., 2006. Increased lipogenesis in cancer cells: new players, 
novel targets. Curr. Opin. Clin. Nutr. Metab. Care 9, 358–65. 
doi:10.1097/01.mco.0000232894.28674.30 
Szymanski, C.M., Yao, R., Ewing, C.P., Trust, T.J., Guerry, P., 1999. Evidence for a system of general 
protein glycosylation in Campylobacter jejuni. Mol. Microbiol. 32, 1022–30. 
Takeuchi, M., Takasaki, S., Miyazaki, H., Kato, T., Hoshi, S., Kochibe, N., Kobata, A., 1988. 
Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from 
urine and the culture medium of recombinant Chinese hamster ovary cells. J. Biol. Chem. 263, 
3657–63. 
Tao, M.H., Morrison, S.L., 1989. Studies of aglycosylated chimeric mouse-human IgG. Role of 
carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. 
Immunol. 143, 2595–601. 
Thaysen-Andersen, M., Packer, N.H., 2012. Site-specific glycoproteomics confirms that protein structure 
dictates formation of N-glycan type, core fucosylation and branching. Glycobiology 22, 1440–52. 
doi:10.1093/glycob/cws110 
Tomiya, N., Ailor, E., Lawrence, S.M., Betenbaugh, M.J., Lee, Y.C., 2001. Determination of nucleotides 
and sugar nucleotides involved in protein glycosylation by high-performance anion-exchange 
chromatography: sugar nucleotide contents in cultured insect cells and mammalian cells. Anal. 
Biochem. 293, 129–37. doi:10.1006/abio.2001.5091 
Tsuchiya, N., Endo, T., Matsuta, K., Yoshinoya, S., Aikawa, T., Kosuge, E., Takeuchi, F., Miyamoto, T., 
Kobata, A., 1989. Effects of galactose depletion from oligosaccharide chains on immunological 
activities of human IgG. J. Rheumatol. 16, 285–90. 
Uldry, M., Ibberson, M., Hosokawa, M., Thorens, B., 2002. GLUT2 is a high affinity glucosamine 
transporter. FEBS Lett. 524, 199–203. doi:10.1016/S0014-5793(02)03058-2 
Umaña, P., Jean-Mairet, J., Moudry, R., Amstutz, H., Bailey, J.E., 1999. Engineered glycoforms of an 
antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. 
Biotechnol. 17, 176–80. doi:10.1038/6179 
Urlaub, G., Chasin, L. a, 1980. Isolation of Chinese hamster cell mutants deficient in dihydrofolate 
reductase activity. Proc. Natl. Acad. Sci. U. S. A. 77, 4216–20. 




UDP-activated N-acetylhexosamines and into carbohydrate structures in glycoproteins. Biotechnol. 
Bioeng. 64, 401–17. doi:10.1002/(SICI)1097-0290(19990820)64:4<401::AID-BIT3>3.0.CO;2-M 
Van den Steen, P., Rudd, P.M., Dwek, R. a, Opdenakker, G., 1998. Concepts and principles of O-linked 
glycosylation. Crit. Rev. Biochem. Mol. Biol. 33, 151–208. doi:10.1080/10409239891204198 
van der Valk, J., Brunner, D., De Smet, K., Fex Svenningsen,  a, Honegger, P., Knudsen, L.E., Lindl, T., 
Noraberg, J., Price,  a, Scarino, M.L., Gstraunthaler, G., 2010. Optimization of chemically defined 
cell culture media--replacing fetal bovine serum in mammalian in vitro methods. Toxicol. In Vitro 
24, 1053–63. doi:10.1016/j.tiv.2010.03.016 
Vidarsson, G., Dekkers, G., Rispens, T., 2014. IgG subclasses and allotypes: From structure to effector 
functions. Front. Immunol. 5, 1–17. doi:10.3389/fimmu.2014.00520 
Wacker, C., Berger, C.N., Girard, P., Meier, R., 2011. Glycosylation profiles of therapeutic antibody 
pharmaceuticals. Eur. J. Pharm. Biopharm. 79, 6–10. doi:10.1016/j.ejpb.2011.06.010 
Wacker, M., Linton, D., Hitchen, P.G., Nita-Lazar, M., Haslam, S.M., North, S.J., Panico, M., Morris, 
H.R., Dell, A., Wren, B.W., Aebi, M., 2002. N-linked glycosylation in Campylobacter jejuni and its 
functional transfer into E. coli. Science 298, 1790–3. doi:10.1126/science.298.5599.1790 
Wallace, D.C., 2012. Mitochondria and cancer. Nat. Rev. Cancer 12, 685–98. doi:10.1038/nrc3365 
Wang, C., Eufemi, M., Turano, C., Giartosio, A., 1996. Influence of the carbohydrate moiety on the 
stability of glycoproteins. Biochemistry 35, 7299–307. doi:10.1021/bi9517704 
Warburg, O.H., 1956. On the Origin of Cancer Cells. Oncol. 9, 75–83. 
Weikert, S., Papac, D., Briggs, J., Cowfer, D., Tom, S., Gawlitzek, M., Lofgren, J., Mehta, S., Chisholm, 
V., Modi, N., Eppler, S., Carroll, K., Chamow, S., Peers, D., Berman, P., Krummen, L., 1999. 
Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant 
glycoproteins. Nat. Biotechnol. 17, 1116–21. doi:10.1038/15104 
Weljie, A.M., Newton, J., Mercier, P., Carlson, E., Slupsky, C.M., 2006. Targeted profiling: quantitative 
analysis of 1H NMR metabolomics data. Anal. Chem. 78, 4430–42. doi:10.1021/ac060209g 
Westermeier, R., 2016. 2D gel-based Proteomics: there’s life in the old dog yet. Arch. Physiol. Biochem. 
122, 236–237. doi:10.1080/13813455.2016.1179766 
Wong, D.C.F., Wong, N.S.C., Goh, J.S.Y., May, L.M., Yap, M.G.S., 2010. Profiling of N-glycosylation 
gene expression in CHO cell fed-batch cultures. Biotechnol. Bioeng. 107, 516–528. 
doi:10.1002/bit.22828 
Wong, N.S.C., Wati, L., Nissom, P.M., Feng, H.T., Lee, M.M., Yap, M.G.S., 2010. An investigation of 
intracellular glycosylation activities in CHO cells: effects of nucleotide sugar precursor feeding. 
Biotechnol. Bioeng. 107, 321–36. doi:10.1002/bit.22812 
Wong, N.S.C., Yap, M.G.S., Wang, D.I.C., 2006. Enhancing recombinant glycoprotein sialylation 
through CMP-sialic acid transporter over expression in Chinese hamster ovary cells. Biotechnol. 
Bioeng. 93, 1005–16. doi:10.1002/bit.20815 
Wright, A., Morrison, S.L., 1998. Effect of C2-associated carbohydrate structure on Ig effector function: 
studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster 
ovary cells. J. Immunol. 160, 3393–402. 
Wright, A., Morrison, S.L., 1994. Effect of altered CH2-associated carbohydrate structure on the 
functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med 
180, 1087–1096. doi:10.1084/jem.180.3.1087 





Xing, Z., Kenty, B., Koyrakh, I., Borys, M., Pan, S.-H., Li, Z.J., 2011. Optimizing amino acid 
composition of CHO cell culture media for a fusion protein production. Process Biochem. 46, 1423–
1429. doi:10.1016/j.procbio.2011.03.014 
Xu, X., Nagarajan, H., Lewis, N.E., Pan, S., Cai, Z., Liu, X., Chen, W., Xie, M., Wang, W., Hammond, 
S., Andersen, M.R., Neff, N., Passarelli, B., Koh, W., Fan, H.C., Wang, J., Gui, Y., Lee, K.H., 
Betenbaugh, M.J., Quake, S.R., Famili, I., Palsson, B.O., Wang, J., 2011. The genomic sequence of 
the Chinese hamster ovary (CHO)-K1 cell line. Nat. Biotechnol. 29, 735–41. doi:10.1038/nbt.1932 
Yamada, K., Shibata, H., Suzuki, K., Citterio, D., 2017. Toward practical application of paper-based 
microfluidics for medical diagnostics: state-of-the-art and challenges. Lab Chip 17, 1206–1249. 
doi:10.1039/c6lc01577h 
Yamane-Ohnuki, N., Kinoshita, S., Inoue-Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, 
M., Niwa, R., Sakurada, M., Uchida, K., Shitara, K., Satoh, M., 2004. Establishment of FUT8 
knockout Chinese hamster ovary cells: an ideal host cell line for producing completely 
defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. 
Bioeng. 87, 614–22. doi:10.1002/bit.20151 
Yang, M., Butler, M., 2002. Effects of ammonia and glucosamine on the heterogeneity of erythropoietin 
glycoforms. Biotechnol. Prog. 18, 129–38. doi:10.1021/bp0101334 
Yi, L., Dong, N., Yun, Y., Deng, B., Ren, D., Liu, S., Liang, Y., 2016. Chemometric methods in data 
processing of mass spectrometry-based metabolomics: A review. Anal. Chim. Acta 914, 17–34. 
doi:10.1016/j.aca.2016.02.001 
Zagari, F., Jordan, M., Stettler, M., Broly, H., Wurm, F.M., 2013a. Lactate metabolism shift in CHO cell 
culture: the role of mitochondrial oxidative activity. N. Biotechnol. 30, 238–45. 
doi:10.1016/j.nbt.2012.05.021 
Zagari, F., Stettler, M., Baldi, L., 2013b. High expression of the aspartate-glutamate carrier Aralar1 favors 
lactate consumption in CHO cell culture. Pharm. … 1, 19–27. 
Zang, L., Frenkel, R., Simeone, J., Lanan, M., Byers, M., Lyubarskaya, Y., 2011. Metabolomics Profiling 
of Cell Culture Media Leading to the Identification of Riboflavin Photosensitized Degradation of 
Tryptophan Causing Slow Growth in Cell Culture. Anal. Chem. 83, 5422–5430. 
doi:10.1021/ac2009492 
Zanghi, J.A., Mendoza, T.P., Schmelzer, A.E., Knop, R.H., Miller, W.M., 1998. Role of nucleotide sugar 
pools in the inhibition of NCAM polysialylation by ammonia. Biotechnol. Prog. 14, 834–44. 
doi:10.1021/bp9800945 
Zhang, J., Liu, X., Bell, A., To, R., Baral, T.N., Azizi, A., Li, J., Cass, B., Durocher, Y., 2009. Transient 
expression and purification of chimeric heavy chain antibodies. Protein Expr. Purif. 65, 77–82. 
doi:10.1016/j.pep.2008.10.011 
Zhang, L., Elias, J.E., 2017. Relative Protein Quantification Using Tandem Mass Tag Mass Spectrometry. 
Methods Mol. Biol. 1550, 185–198. doi:10.1007/978-1-4939-6747-6_14 
Zhang, X., Lok, S.H., Kon, O.L., 1998. Stable expression of human alpha-2,6-sialyltransferase in Chinese 
hamster ovary cells: functional consequences for human erythropoietin expression and bioactivity. 
Biochim. Biophys. Acta 1425, 441–52. 
Zielinska, D.F., Gnad, F., Wiśniewski, J.R., Mann, M., 2010. Precision mapping of an in vivo N-







Appendix A – Chapter 3 Supplementary Data 





















Chaperones & Protein Synthesis            
Heat shock 75 kDa protein Trap1 364 EGV93626 99.2 2.08E-03 80.3 6.64 43 22 1.05 
Chaperone – protein 
folding 
Heat shock 70 kDa protein 9 Grp75 372 EGW06687 99.2 1.32E-03 65.8 5.83 57 29 1.11 
Chaperone – protein 
folding 
  359  98.2 9.76E-04   7 3 1.08  
  369  99.2 9.66E-03   59 31 1.05  
Heat shock 60 kDa protein Hspd1 465 EGW00783 99.2 7.70E-03 56.5 6.90 52 19 -1.06 
Chaperone – protein 
folding 
Heat shock protein HSP 90-alpha Hsp90aa1 929 EGV94858 98.9 3.84E-03 38.1 4.58 22 5 -1.38 
Chaperone – protein 
folding 
Serpin H1 Serpinh1 635 EGW02226 99.2 4.22E-03 46.6 8.74 38 12 -1.14 
Chaperone – collagen 
folding 
Endoplasmin GRP94 841 EGW09701 99.1 3.41E-04 92.6 4.74 15 8 -1.57 
Chaperone – protein 
processing and transport 
60S Acidic Ribosomal protein P0 Rplp0 893 EGV93157 99.2 6.40E-03 29.9 8.68 38 7 1.20 Protein synthesis 
Protein disulfide-isomerase A6 Pdia6 `026 EGW08481 99.0 1.47E-03 28.4 4.80 27 5 -1.22 
Chaperone – protein 
folding 
Structural Proteins            
Β-Actin Actb 726 EGW06240 99.1 2.15E-03 41.7 5.29 29 7 -1.16 
Cytoskeleton 
component 
  1028  99.1 9.82E-03   27 5 -1.14  
  1228  98.9 6.74E-03   26 5 -1.25  
  837  99.1 9.79E-03   25 7 -1.08  
Vimentin Vim 1202 EGW02055 99.2 1.56E-03 53.7 5.05 38 9 -1.31 
Intermediate filament, 
cell integrity 
























  1210  99.2 4.04E-05   41 12 -1.39  
  1215  99.2 1.42E-04   34 7 -1.31  
  1301  98.6 2.35E-03   8 4 -1.32  
  1522  98.2 2.46E-03   17 5 -1.46  
  544  99.2 1.02E-02   62 25 -1.12  
Lamin B1 Lmnb1 379 EGV92912 99.1 5.64E-03 55.0 4.99 33 11 -1.7 
Nuclear envelope 
framework 
Lamin A Lmna 410 EGW07066 99.2 6.97E-03 64.0 7.75 60 33 1.08 
Nuclear envelope 
framework 
  428  99.2 2.13E-03   64 39 1.10  
Calcium-binding protein p22 Chp 1304 EGV97270 98.7 8.49E-03 22.5 4.97 25 4 -1.18 




Metabolic Enzymes            
Aconitate hydratase Aco2 313 EGW13953 98.8 6.07E-03 85.4 8.07 10 4 -1.12 TCA cycle 
Aldehyde dehydrogenase Aldh 543 EGW07431 99.2 2.49E-03 45.9 5.55 44 15 1.11 
Oxidation of aldehydes 
to carboxylic acids 
  545  99.2 5.96E-03   59 20 1.14  
  549  99.2 4.45E-03   44 16 1.10  
Acyl-coenzyme A thioesterase 2 Acot2 651 EGW01631 99.1 4.19E-03 49.8 8.27 25 9 1.21 Lipid metabolism 
Citrate synthase Cs 679 EGW12503 99.1 2.70E-05 51.7 8.70 32 5 1.99 TCA cycle 
  663  99.0 6.85E-05   22 5 1.55  





Hsd17b10 1234 EGW02330 99.2 5.68E-03 27.2 7.70 72 12 1.11 
Oxidation of fatty acids, 
alcohols and steroids 
Methylenetetrahydrofolate 
dehydrogenase 
Mthfd11 234 EGV95936 99.1 7.31E-03 105.4 7.02 23 15 1.09 
Tetrahydrofolate (THF) 
cycle 
  187  99.1 7.71E-04       


























Plod3 316 EGW01863 98.9 9.92E-03 37.7 5.88 20 4 -1.06 
Hydroxylation of lysyl 
residues in collagen-like 
peptides 
Dihydrolipoyl dehydrogenase Dld 524 EGV93120 99.2 6.31E-04 54.1 7.96 30 12 1.07 
Catabolism of branch 
chain amino acids 
  529  99.2 2.00E-03   44 14 1.06  
3-hydroxyisobutyrate 
dehydrogenase 
Hibadh 1027 EGW08863 99.1 4.20E-03 31.7 5.17 33 6 1.09 Amino acid catabolism 
Glycerol-3-phosphate 
dehydrogenase 
Gpd2 660 EGW05701 99.2 2.79E-03 80.7 5.92 34 17 1.32 
Carbohydrate and lipid 
metabolism 
Apoptosis and Cell Proliferation            




Histone H2A type 1 Hist1h2ab 1779 EGV96120 98.9 1.35E-04 28.5 11.04 24 4 -1.25 
Regulation of 
transcription, DNA 
repair, DNA replication, 
and chromosomal 
stability 
DNA-directed RNA polymerase I, 
II, and III subunit RPABC1 
Polr2e 1159 EGV99483 98.3 1.86E-03 25.4 5.52 27 3 1.17 DNA transcription 




Programmed cell death 6 Pdcd6 1505 EGW09040 99.0 1.10E-03 25.5 5.56 27 5 1.44 
Induction of apoptosis 
by extracellular signal 
Energy Metabolism            
SPRY domain-containing protein 4 Spryd4 1299 EGW12495 98.9 3.17E-04 23.1 8.85 30 5 -1.20 Uncharacterized 
ATP-binding cassette sub-family 
G, member 3 
Abcd3 918 EGV92982 99.1 1.77E-04 69.6 5.43 13 6 1.05 Peptide transporter 

























 Ndufs3 1138 EGW03953 99.1 1.03E-02 30.1 7.78 34 7 1.03 
Oxidative 
phosphorylation 






Figure 35 – Complete set of nutrients and metabolites tracked by 1D-1H-NMR under normal culture conditions (solid lines) 















Figure 37 – Growth rate comparison of CHO-K1-CC1-61 cells supplemented with 7.5 mM GlcN & GlcNAc, demonstrating that 
the negative growth effect of glucosamine supplementation, as well as the lack of negative growth effect from GlcNAc 
supplementation, is independent of the CHO
BRI
 cell line utilized in Chapter 4. 
Cells of the cell line CHO-K1 CCl-61 were grown adherently in vent capped flasks in F-12 
Kaighn’s modification medium (GE LifeSciences), and supplemented with 10 % FBS (Gibco 
Life technologies). An experiment was conducted in which the medium was supplemented with 
either 7.5 mM Glucosamine (GlcN) or 7.5 mM N-Acetylglucosamine (GlcNAc), with two flasks 
per condition; the control contained only the regular medium. To observe the cell growth two 
pictures of two different areas where taken per flask twice a day and cells on the pictures were 
counted manually. For time points 19 h, 27 h and 43 h the natural logarithm of the cell number 
was plotted against the time and the growth rate estimated from the slope of a linear fit. The 
graph shows the average growth rates estimated per condition (n=4). Errors with a 95 % 
confidence interval were calculated from the average variance of all slopes. Time points 19 to 43 



































The results of this growth rate comparison in CHO-K1 CCl-61, an adherent non-producing 
culture match the results observed with the CHO
BRI
 cells expressing EG2-hFc camelid chimeric 
monoclonal antibody reported in this work. Therefore, the negative growth effect of glucosamine 
supplementation, as well as the lack of negative growth effect from GlcNAc supplementation is 




Appendix C – Chapter 6 Supplementary Data 
Table 16 – Comparison of glycoform shifts and differences between reported experiments for the supplementation of glucosamine (GlcN), its acetylated form acetyl-
glucosamine (GlcNAc), and the nucleoside uridine (Urd), towards expanding intracellular nucleotide-sugar pools of UDP-GlcNAC in cultured mammalian cells to affect 
N-linked glycoforms of recombinant glycoproteins. N-linked glycoforms of recombinant glycoproteins. Glycoform shifts are reported as %-shifts in indices of 
mannosylation (MI), antennarity (AI), fucosylation (FI), galactosylation (GI), and sialylation (SI) (as per Equations 1-5, Figure 31) relative to reported control culture 
glycoforms. Experimental differences reported include: Supplementation cocktails and concentrations with multiple bullet-points representing separate flask or 
bioreactor conditions; The cell line utilized and the lineage of that cell line where reported; The protein being expressed and whether it is a mutant variant or fusion; 
The bioprocess scale, time of supplementation, and time of harvest; The amount of glutamine (Gln) utilized in the growth medium. 
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CHO 
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 Reduced glycan 
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 Reduced glycan 
complexity to favour 
G0 and FG0 
glycoforms – both 
GlcN & GlcNAc 
supplementation 
 ~50% drop in growth 
rate with GlcN 
supplementation 
 <5% drop in growth 
rate with GlcNAc 
supplementation 
proportional increase in 
UDP-GlcNAc pool up 
to 2x with GlcNAc 
supplementation 










Control Glycoform Affected Glycoform 




















 10mM GlcN NS0 
(GS) 








12.8 34.9 100 16 0 10.6 35.8 100 7 0  17x UDP HexNAc 
 -56% Galactosylation 
 -63% UDP-Hex 
 Reduced growth 
(Hills et al., 
2001)  
 10mM GlcN CHO 
(K1) 
EPO  Flasks 
 250mL 
 Addition 0h 
 Harvest day 
4-5 
- - 87 - - 5416 - 73 - - 32  18.5x UDP-GlcNAc 
 Increased glycan 
heterogeneity 
 -22% tetrasialylation 
(Yang and 
Butler, 2002) 
 10mM GlcN; free of 
Gln 
BHK IL-2  Perfusion 
 2.5 L 
 Addition: 
day 21 
 Harvest:  
days 26-28 
and 29-30 
0 - 44 - - - - 50 - - -  Greater antennarity, 
but lower complexity 
of glycans 
 3x UDP-HexNAc 
 Greater proportion of 
monosialylation with 
GlcN 
 +58% sialylation in 


















































 58x UDP-HexNAc 
 8x UDP-Hex 
 +9% antennarity 
 -8% sialylation 
(Baker et al., 
2001) 
 10mM GlcN + 2mM 
Urd 
BHK IL-217  Perfusion 





0 - 48 - - 
 
86  52 - - 83  12x UDP-GlcNAc 
 5x UTP 
 Rise antennarity 
(Grammatikos 
et al., 1998) 
 10mM GlcN 
 +5mM Urd 
CHO 
(Dukx) 






















 Reduced growth 
 +28% sialylation 
 6-15x increase UDP-
HexNAc 
(N. S. C. Wong 
et al., 2010) 
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 Measured as a proportion of tetra-sialylated glycans 
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Control Glycoform Affected Glycoform 




















 3.5 & 17.5mM GlcN 
+ 1mM Urd 
CHO 
SCLC 






6  -  - -  -  - -  25x UDP GlcNAc 
 Reduced growth 
 -90% polysialylation 
(Zanghi et al., 
1998) 
 1-10mM Urd CHO 
(Dukx) 
IFN-γ  Flasks 
 100mL 
3  -  - -  -  - -  18.5x UDP-GlcNAc 
 Increased glycan 
heterogeneity 
 -22% tetrasialylation 
(Nyberg et al., 
1999) 
 0.5mM Urd RH N/A  Culture 
dish 





2.4  -  - -  -  - -  58x UDP-HexNAc 
 8x UDP-Hex 
 +9% antennarity 
 -8% sialylation 






Table 17 – Comparison of glycoform shifts and differences between reported experiments for the supplementation of galactose (Gal), the nucleoside uridine (Urd), and 
the enzyme cofactor manganese (Mn2+), towards expanding intracellular nucleotide-sugar pools of UDP-galactose in cultured mammalian cells and affecting. 
Glycoform shifts are reported as %-shifts in indices of mannosylation (MI), antennarity (AI), fucosylation (FI), galactosylation (GI), and sialylation (SI) (as per 
Equations 1-5, Figure 31) relative to reported control culture glycoforms. Experimental differences reported include: Supplementation cocktails and concentrations with 
multiple bullet-points representing separate flask or bioreactor conditions; The cell line utilized and the lineage of that cell line where reported; The protein being 
expressed and whether it is a mutant variant or fusion; The bioprocess scale, time of supplementation, and time of harvest; The amount of glutamine (Gln) utilized in the 
growth medium. 





Control Glycoform Affected Glycoform 
























IgG  Fed-batch 
bioreactor 
 1L 
 Addition 48h 
 Harvest 336h 
8 5.6 38 93.4 13.8 0.5 5.9 38 93.1 25.5 0.3  +12% 
galactosylation 




et al., 2015) 
 10mM Gal NS0 
(GS) 
IgG  Flasks 
 500mL 
 Addition 48h 
 Harvest 96h 
0.4 
(GS) 
12.8 34.9 100 16 0 15.3 33.9 100 17 0  5x UDP-Gal 
 +6% 
galactosylation 
(Hills et al., 
2001)  
 10mM Gal  
 
 20mM Gal  
 










 Harvest 288h 



























 +14% sialylation 
 No negative growth 
effects 
 Glycan distribution 
scaled well to 200L 
bioreactor 




CHO IL-4/13  Batch 
bioreactor 
 1L 
 Addition 0h 
 Harvest 112h 
2 - - - - - - - - -   No notable effects 
to sialylation or 
gene expression 
(Clark et al., 
2005)  
 10mM Gal 
 
 +5mM Urd 
CHO 
(Dukx) 
IFN-γ  Flasks (n=1)18 
 1000mL 
 Addition 48h 
 Harvest 96h 















 20x UDP-Gal 
 +12% sialylation 
(N. S. C. 
Wong et al., 
2010) 
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Control Glycoform Affected Glycoform 




























every 7 days 
 Addition 
 Harvest 19d 
15 - - - - - - - - - -  Reduced titres at 
40µM Mn2+ feed 















FII  Flasks 
 Addition 48h 





























































 +26% sialylation 
from galactose 
addition 
 +30% sialylation 
from addition of 
MnSO4 
 Temperature-shift 




(Lee et al., 
2017) 













 Addition 0h 













































increased GI in 
both cases19  
(Liu et al., 
2014) 
 100mM Gal 
 
 40µM Mn2+ 
 
 100mM Gal 




IgG  Flasks 
 250mL 
 Addition 0h 
 Harvest 168h 































 -30% fucosylation 
and +14% high-
mannose glycans 
for Mn alone 
 9x UDP-Gal pool 
 Increased 
expression of β-Gal 
II, III, IV and UDP-
GalT transcripts 
(St Amand et 
al., 2014) 
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Control Glycoform Affected Glycoform 




















 4µM Mn2+ 
 











IgG  Flasks 
 100mL 
 Addition 0h 





























































 -30-50% IgG when 
Replacing 




 -5% fucosylation 


















IgG  Fed-batch 
bioreactor 
 2L 
 Addition 0h 












































































































1st cell line at 
100mM Gal  
 +24% 
galactosylation for 
2nd cell line at 
40mM Gal 
 Glycan distribution 














IgG  Flasks 
 125mL 
 Addition 72h 

































 +1.5-5% sialylation 
 Best overall IVCC, 
MAb titre and 
galactosylation 
results with low 
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 Additional experiments changed the main carbon source to fructose, glucose-free (only gal), and low-glucose delivered from a hydrogel for slow release. 
21
 Galactose, urdine and manganese (Mn
2+
) fed in ratios of 5:1:0.002 mM (UMG cocktail) for two CHO-K1SV cell lines expressing two separate IgGs under GS 
expression system 
22
 Face-centred DOE design for main-effects modeling of UMG cocktail developed by Gramer et al. cocktail, tested on two CHO-K1SV cell lines stably expressing 




Table 18 – Comparison of glycoform shifts and differences between reported experiments for the supplementation of the acetylated amine sugar acetyl-mannosamine 
(ManNAc), and the nucleoside cytidine (Cyt), towards expanding intracellular nucleotide-sugar pools of CMP-NeuAc in cultured mammalian cells and affecting N-
linked glycoforms of recombinant glycoproteins. N-linked glycoforms of recombinant glycoproteins. Glycoform shifts are reported as %-shifts in indices of 
mannosylation (MI), antennarity (AI), fucosylation (FI), galactosylation (GI), and sialylation (SI) (as per Equations 1-5, Figure 31) relative to reported control culture 
glycoforms. Experimental differences reported include: Supplementation cocktails and concentrations with multiple bullet-points representing separate flask or 
bioreactor conditions; The cell line utilized and the lineage of that cell line where reported; The protein being expressed and whether it is a mutant variant or fusion; 
The bioprocess scale, time of supplementation, and time of harvest; The amount of glutamine (Gln) utilized in the growth medium. 





Control Glycoform Affected Glycoform 
























IgG  1L -Bioreactor, 
fedbatch 
 Addition 48h 
 Harvest 336h 
8 5.6 38 93.4 13.8 0.5 5.2 38 94.1 11.9 0.6  Speculation that 
increases in CMP-
NeuAc lead to 














IgG  500mL Flasks 
 Addition 48h 
 Harvest 96h 
0.4 
(GS) 
12.8 34.9 100 16 0 11.2 35.5 100 14.5 0  44x CMP-NeuAc 
 No improvement to 
sialylation 








TIMP-1  Flasks 
 1000mL 
 Addition 24h 

































 -22% Neu5Gc 
content in NS0 
cultures 
 +1% shifts in %-
sialylation 
 12x increase in CMP-
SA (CHO) 
 30x increase in CMP-
SA (NS0) 






FII  Flasks 
 Addition 48h 
 Harvest 144h 























(Lee et al., 
2017) 
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Control Glycoform Affected Glycoform 

























IFN-γ  100mL Flasks 
 Addition 0h 
 Harvest 96h 
-     - -    - -  27x increase CMP-
SA 
 +15% complete 
sialylation 




ManNAc fed at 2mM 
& 20mM 
respectively 





 0.5mM Cyt RH N/A  3mL Culture 
dish 
 Addition 16h 
 Harvest 24h 
2.4    - -    - -  3.0x CTP 
 3.2x UDP-HexNAc 











 2L Fed-batch 
bioreactor 
 Addition 120h 
 Harvest 288h 
GS 3.9 38 66 46 28 - - - - 28  Statistically 
insignificant sialic-
acid content increase 
(terminal galactose 
determined to be 
limiting) 








NCAM  6 & 24-well 
plates 
 Addition 12-18h 
 Harvest 128h 
6    - -    - -  +10-20% 
polysialylation in 
CHO 










IFN-γ  Flasks (n=1) 
 1000mL 
 Addition 48h 
 Harvest 96h 















 30-120x increase in 
CMP-SA 
 +32-36% sialylation -
/+ Cyt 
 +26-52% higher 
specific productivity 
(N. S. C. 
Wong et al., 
2010) 
 
